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ABSTRACT 
 
N-TERMINAL PROTEIN MODIFICATION BY AMINOACYL TRANSFERASE:  
ENZYMOLOGY AND APPLICATIONS. 
Anne M. Wagner 
E. James Petersson 
 
Protein modification is an important tool for understanding how a protein moves, 
folds, and operates in its cellular environment.  We aim for a minimalist approach to 
protein modification in order to learn more about the protein while not perturbing its 
native state.  Our method for ligation of small molecules to proteins has high N-terminal 
specificity and creates natural amide bond linkages under mild conditions.  We utilized E. 
coli aminoacyl L/F transferase (AaT) in our ligation reaction to recognize a small 
synthetic substrate analog, which mimics aminoacylated tRNA, and can be chemically 
synthesized in only three steps.  We have studied the mechanism of AaT in order better 
utilize unnatural substrates and expand the scope of aminoacyl donors and N-terminal 
acceptors.  Using AaT, we can enzymatically attach a wide range of synthetic moieties to 
the N-termini of peptides and proteins, including natural and unnatural amino acids with 
reactive azido groups, fluorescent labels, protected disulfides, and photoinducible 
crosslinkers.  This method introduces new opportunities for protein semi-synthesis, which 
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we have applied in two model systems, α-synuclein and calmodulin, and contributes as an 
effective method to label proteins for biophysical research. 
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CHAPTER 1 
 
INTRODUCTION TO LEUCYL/PHENYLALANYL AMINOACYL TRANSFERASE AND 
CURRENT N-TERMINAL MODIFICATION METHODS 
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Section 1.1 – Introduction to Protein Engineering 
 If DNA is considered the “blueprint” of life, then an enzyme would aptly be 
described as the machine of life.  Enzymes access a countless number of reactions to 
maintain cell function, and their biological activities have evolved to incredible levels of 
complexity over 4 billion years.1   Natural products can be accessed through enzymatic 
reactivity that is mostly unavailable to synthetic chemists on the timescale and yield of 
the enzyme.2  Learning more about the structure and function of enzyme molecular 
machines gives us insight into how enzymes can access their reactive abilities.  One way 
to learn more about enzymes is through the process of protein engineering (Figure 1-1).  
By making primary sequence changes to an enzyme, you can change its original 
function.3  However, haphazard mutational changes without thought of the molecular 
effects of the change are unlikely to be beneficial to enzymatic catalysis; evolution is 
successful because it is possible to select for very rare enhancements of function.4  There 
are several methods that can be used to enhance the effectiveness of primary sequence 
mutations: rational design, computer-aided design, directed evolution, and protein semi-
synthesis.5  All of the aforementioned techniques can attain the engineered product, a 
new and improved protein, with a variety of possible alterations such as improved 
enzyme activity, altered specificity for a substrate or product, or enzyme regulation; they 
can also be used as a tool to understand inherent protein characteristics that remain 
mysterious, such as protein folding mechanisms.6  The desired ultimate change in the 
protein is directly linked to the first step in changing the protein sequence.  You can take 
protein engineering one step further by putting in an unnatural amino acid into the protein 
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in order to give it entirely new functionality that is unavailable with the 20 naturally 
occurring amino acids.  In this introduction, I will review current methods of protein 
modification and delve into the heart of my thesis research with a background and history 
of leucyl/phenylalanyl aminoacyl transferase, which the Petersson group has utilized as 
an N-terminally modifying enzyme that can contribute to the field of protein engineering. 
 
Figure 1-1.  Protein Engineering Pathway 
This flow chart describes modes of protein engineering and their respective outcomes adapted 
from Foo et al.7 
 
Section 1.2 – Current Methods of Protein Modification 
1.2.1 – Introduction to Amide Bond-Forming Ligation Techniques 
 Modifications of proteins in a site-selective manner can introduce a chemical 
consequence from which one can infer information about protein structure and function.  
Standard manipulations of protein structure include molecular biology techniques such 
amino acid mutagenesis.8  However, these modifications are limited to natural amino 
acids, ribosomal synthesis, and uncontrolled posttranslational modifications.9  One 
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current method for adding a synthetic group to a protein is solid-phase peptide synthesis 
(SPPS), which generates peptides in vitro (Figure 1-2).  This method allows for 
sequence-specific addition of natural and unnatural amino acids.  However, there are 
some limitations to this method; SPPS requires lengthy synthetic steps, the use of 
protecting groups, and undesirable peptide byproducts due to incomplete reactions.10  The 
accumulation of peptide byproducts limits the number of amino acids that can be 
synthesized directly on solid phase with an upper limit at ~ 50 amino acids.9  Despite its 
limitations, SPPS was and continues to be an advantageous method, and proteins, such 
as, RNAseA, have been fully synthesized by this method.11  Through the use of SPPS, 
unnatural amino acids and backbone alterations, such as a thioamide, can be incorporated 
easily into peptides.12 
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Figure 1-2.  Mechanism of SPPS Amino Acid Activation and Amide Bond Formation 
(1) DCC deprotonates (often with added base) the unprotected carboxylic acid of an N-terminal 
Fmoc-protected amino acid.  (2) Negatively charged oxygen from the carboxylic acid attacks the 
central carbon of DCC, forming an activated amino acid.  (3) The activated amino acid can now 
be attacked by an N-terminal amino acid that is resin bound.  (4) The tetrahedral intermediate 
collapses to form a peptide bond.  Steps 1-4 are repeated until desired length of peptide is 
reached.  Peptide synthesis is completed with deprotection of all the amino acid protecting groups 
and cleavage from the solid-phase resin.  R1 and R2 are protected amino acid sidechains.13-14 
 
1.2.2 – Native Chemical Ligation 
One technique that has expanded upon SPPS and can circumvent the limitation of 
peptide length is native chemical ligation (NCL). (Figure 1-3)  NCL utilizes the reaction 
of a cysteine and thioester to generate an amide bond in aqueous conditions with near-
physiological pH.  Kent et al. used NCL between two large SPPS fragments, 51 and 48 
amino acids in length, to create the create the monomer of the HIV-1 protease, one 
peptide containing a C-terminal thioester and the other fragment with an N-terminal 
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cysteine.15  This ligation strategy was a breakthrough into studying larger proteins and 
without the need of amino acid protecting groups.16  Two key aspects of NCL are its 
regioselectivity and chemoselectivity.  In the presence of an exogenous thiol catalyst, 
NCL is regioselective because the thiol(ate)-thioester exchange is reversible.9, 17  The 
NCL reaction demonstrates chemoselectivity because the reaction will only occur at a 
peptide or protein terminus and not at internal residues.18  Thioesters have unique 
chemical properties in comparison to oxoesters, which contribute to their efficacy in 
NCL.  Thioesters are more stable than oxoesters to hydroxide-catalyzed hydrolysis, but 
conversely, are also more reactive than oxoesters to thiolysis and aminolysis.9  Thus, the 
thioester yields itself well to working with proteins and peptides in the NCL reaction 
because under physiological pH, the thioester will react readily with cysteine but not 
hydrolyze under these conditions.9  In addition to its mild conditions, racemization does 
not occur at either the N or C-terminal residues of the connecting peptides.  The 
aforementioned attributes of the NCL reaction make it a very powerful tool for protein 
engineering. 
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Figure 1-3.  NCL Mechanism 
(1) In the first step, the cysteine thiol attacks the c-terminal thioester carbonyl group. (2 and 3) A 
transthioesterification reaction occurs, forming a tetrahedral intermediate that collapses with 
expulsion of the SR leaving group.  (4) An S to N acyl shift occurs, which is an irreversible 
reaction, forming the final product, peptide 1 and 2 ligated together via a peptide bond, 
highlighted in yellow. 
 
1.2.3 – Expressed Protein Ligation 
The NCL reaction has opened up the ability to synthetically create proteins that 
are not limited by the 50 amino acid restriction of length and can produce protein in near 
quantitative yield.9  Additionally, Muir and coworkers have improved upon the NCL 
reaction through the use of inteins to make recombinant proteins that are functionalized 
with a C-terminal thioester with a method termed expressed protein ligation (EPL).  EPL 
is a semi-synthetic technique that utilizes a recombinant protein with a fused intein, 
which can be thiolysed to form a C-terminal thioester in situ and then ligated with the N-
terminal cysteine of a synthetic peptide or recombinant protein.19  An intein is a protein 
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sequence within a precursor protein that is self-excised during the maturation process of a 
protein; the protein segments that are rejoined after intein excision are called exteins 
(Figure 1-4).20-22  To make inteins a more useful tool for semi-synthesis, Muir and 
coworkers have made several modifications to native intein splicing.  As seen in Figure 
1-5, the EPL reaction and intein excision mechanism begin the same way, with an S-to-N 
acyl shift.  However, for EPL, the intein has been mutated, preventing the continuation of 
the splicing mechanism, and the exogenous thiol, such as sodium 2-
mercaptoethanesulfonate (MESNA), attacks the carbonyl of the transient thioester formed 
from the acyl shift in excision of the intein.  An additional mutation at N454A prevents the 
intein from excising itself from its C-terminus.  The C-terminus is fused to a chitin 
binding domain (CBD) or a His tag, which is used to purify out the thiolysed intein from 
the reaction.  Then, with the addition of a C-terminal cysteine-bearing peptide or 
recombinant protein, the NCL reaction can proceed.  EPL’s exploitation of intein 
thiolysis allowed for the formation of C-terminal thioesters in situ on a recombinant 
protein.  This procedure was a significant advancement in protein semi-synthesis because 
the protein fragments did not need to be synthesized using SPPS, and thus much larger 
fragments could be generated. 
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Figure 1-4.  Mechanism of Intein Excision 
(1) The protein splicing mechanism begins with an N-to-X acyl shift.  X can be either an oxygen or 
sulfur atom.  Now the N-extein has moved to the Cys/Ser residue.  (2) Transthioesterification 
reaction occurs between a conserved Cys/Ser/Thr residue at the C-terminus cleavage site of the 
intein.  (3) A conserved asparagine excises the intein from the two exteins. (4) The mechanism 
ends with a final X-to-N acyl shift, forming an amide bond.23 
 
 
Figure 1-5.  EPL Mechanism 
(1) N-to-S acyl shift.  (2) Transthioesterification resulting in intein thiolysis.  (3) A thioester is 
formed from excision of the intein and can now perform NCL.23  The R group of RSH can be 
either alkyl, phenyl, benzyl, or CH2CH2SO3 (MESNA).19  CBD = chitin binding domain. 
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1.2.4 – Traceless Staudinger Ligation 
While NCL and EPL have helped to advance protein semi-synthesis, both 
reactions require a cysteine residue at the ligation site.  This amino acid requirement can 
be a hindrance because the natural occurrence of cysteine in proteins is very low at less 
than 2 % with tryptophan being the least abundant.9, 24  The low abundance of natural 
cysteine limits the opportunities for ligation sites that maintain original primary sequence.  
Additionally, cysteine mutagenesis can be detrimental to protein structure and function 
due to its nucleophilic and oxidative reactivities.24  One strategy that circumvents the 
need for a cysteine residue is the traceless Staudinger ligation (TSL); this ligation 
reaction does not have any inherent residue restrictions at the ligation site (Figure 1-6).  
The TSL reaction scheme begins with transthioesterification between a phosphinothiol 
and a thioester-bearing peptide.25  Now the first peptide is ready for reaction with the 
second peptide, which bears an N-terminal α-azido acid.  The phosphorous and azide 
react to form an iminophosphorane, which can undergo subsequent rearrangements.24  
The negatively-charged nitrogen of the iminophosphorane will attack the carbonyl carbon 
of the thioester and form an amidophosphonium salt, which upon hydrolysis, yields the 
ligated peptide product and phosphine oxide byproduct.16, 24-25  The original ligation was 
done in the presence of DMF, and since then a variety of phosphinothiol coupling 
reagents have been synthesized that have a range of ligation efficiencies and water 
solubilities.26  The TSL reaction using water soluble phosphinothiols has been shown to 
be compatible with EPL so that C-terminal fragments can be prepared from expressed 
proteins.26  Additionally, the TSL reaction has been modified by Bertozzi et al. through 
metabolic labeling using biotinylated water soluble phosphinothiol and metabolically-
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incorporated azido-bearing sugars.27-28  The TSL reaction has some limitations; in protein 
semi-synthesis the incorporation of the azido group still must be synthetically 
incorporated, and in addition, the phosphine can oxidize in the presence of air.  Steric 
bulk at the ligating residues can also slow the reaction.  The TSL reaction, even with 
these limitations, offers an alternate route for protein semi-synthesis at amino acids other 
than cysteine.27 
 
Figure 1-6.  Traceless Staudinger Ligation Reaction 
(1) Transthioesterification.  (2) Formation of iminophosphorane.  (3) Formation of 
amidophosphonium salt.  (4) Hydrolysis of amidophosphonium salt forms amide bond.15-16, 25 
 
1.2.5 – KAHA Ligation:  α-Ketoacid–hydroxylamine amide-forming ligation reaction 
 Another ligating reaction, recently developed by Bode et al., is a chemoselective 
amide ligation occurring via decarboxylative condensation between an N-
alkylhydroxylamine and α-ketoacid named the KAHA ligation.  KAHA ligations are 
successful under two conditions, Type I and Type II, which differ by hydroxylamine 
substitution and solvent conditions (Figure 1-7).  Type II O-substituted hydroxylamines 
have faster reaction kinetics in aqueous conditions, and Type I unsubstituted 
hydroxylamines are much slower and are superior in organic solvents.29  Additionally, 
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Type II ligations require a lower hydroxylamine concentration for a successful ligation.  
The Bode group has investigated the KAHA ligation over several years and have 
proposed several mechanisms.29-30  Most recently in 2011, Pusterla et al. elucidated the 
mechanism for Type I KAHA ligations by using 18O labeling to determine which 
intermediates were involved in producing the final amide product (Figure 1-8).  In this 
mechanism, formation of a nitrone is required, as opposed to being a non-productive 
byproduct as they initially proposed in their 2006 mechanism.  They also speculated that 
the Type II ligation could follow direct oxidative decarboxylation as described in their 
initial 2006 mechanism or through an oxaziridine intermediate.29-30  These ligations can 
be performed in conditions that maintain protein folding and stability; however, 
currently, successful ligations have only been performed on the peptide scale. 
 
Figure 1-7.  KAHA Ligation Types Depending on O-Substitution 
Type I ligations use unsubstituted hydroxylamines and Type II ligations use substituted 
hydroxylamines.29 
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Figure 1-8.  Bode Mechanism Proposal for Type I KAHA Ligation 
It is proposed that the ligation proceeds through an alpha-lactone and oxaziridine intermediate. 
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1.2.6 – Reverse Proteolysis - Subtiligase 
Reverse proteolysis is another option for protein ligation.  Proteases have two 
possible reaction outcomes of the acyl intermediate, amide bond formation and 
proteolytic cleavage, which is the primary reaction.31  One protease in particular, 
subtilisin, has been mutated to favor amide bond formation.  In its wild type form, 
subtilisin has a kcat that is approximately 109 greater than spontaneous amide cleavage.  
However, upon mutation of two residues, S221C and P225A, a high efficiency protein 
ligase was created, called subtiligase (Figure 1-9).  The S221C residue mutation is one of 
the catalytic triad amino acids and the cysteine mutation creates steric crowding during 
the formation of the oxyanion transition state required for cleavage, therefore, pushing 
the reaction towards ligation.  Additionally, it is suspected that the S221C mutation slows 
hydrolysis and aids in bond formation.  The P225A mutation aids in opening the active site 
to fit the S221C mutation.  This double mutant has a greater than 107 reduction in amidase 
activity and a 500 fold increase in peptide bond formation preference over hydrolysis.  
Subtiligase is useful because it can catalyze peptide bond formation under protein-
friendly conditions, but this reaction requires high concentrations of protein to reverse the 
reaction equilibrium.32 
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Figure 1-9.  Subtiligase Reaction and Catalytic Triad in Wild Type Subtilisin 
(A) The mutant subtilisin, subtiligase, prefers amide bond formation over lysis.  (B) Catalytic triad 
is shown as sticks (S221 (in cyan), H64, D32) in WT subtilisin.  (C) P225 is also shown in stick form in 
cyan to highlight that the mutation to Ala makes room in the enzyme active site.16, 31  (PDB ID:  
2SBT)33 
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1.2.7 – Non-amide Bond Forming Ligations and N-Terminal Modifications 
Forming unnatural linkages provides options at the ligation site other than amide 
bonds (Figure 1-10).  One ligation reaction that has been used in vitro and in vivo is click 
chemistry.  Click reactions have a broad definition of being high yielding, selective, and 
kinetically favorable.34  The standard click reaction developed by Sharpless and Meldal is 
a CuI-catalyzed reaction between an azido group and an alkyne, which forms a triazole 
ring.35-36  The triazole is very stable and only 1.5 angstroms longer than an amide.16  
Click reactions can also be accelerated without the use of copper by using strained 
cyclooctynes developed by Carolyn Bertozzi (SPAAC reaction), which are more 
biocompatible reagents and have been used in live cell imaging.37  Another option for 
peptide modification is the PLP-mediated biomimetic transamination, which is special for 
its chemoselectivity toward the N-terminus.38  This reaction introduces a ketone or 
aldehyde at the α-amine of the N-terminus, and upon reacting with a substituted (R'-) 
hydroxylamine, forms an N-terminal oxime or hydrazine.  The R' group of the 
hydroxylamine can effectively label the N-terminus with new functionality.  This reaction 
can be done under reasonably mild aqueous conditions at pH 6.5.  However, the reaction 
is incompatible with N-terminal serine, threonine, cysteine and tryptophan residues due 
to additional side reactions.38 
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Figure 1-10.  Alternate Non-Amide Bond Forming Reactions: Click Reaction, SPAAC, and 
Biomimetic Transamination 
 
All of the aforementioned ligation and protein modification techniques have their 
respective strengths and weaknesses.  There is a need for amide bond-forming reactions 
that allow for more flexibility at the ligation site, yet can still be easily performed at pH 7 
in aqueous solution.  To develop such an ideal reaction, we have investigated enzymatic 
catalysis by E. coli aminoacyl transferase (AaT).  AaT catalyzes the formation of amide 
bonds using aminoacyl-tRNA as its substrate and transfers the amino acid onto 
positively-charged N-termini, i.e. Lys or Arg, of proteins independently of the 
ribosome.39  In the following sections, I will discuss the biological basis for L/F 
transferase function and current research on the AaT active site. 
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Section 1.3 – AaT and the N-end Protein Degradation Pathway 
1.3.1 – Prokaryotic N-End Pathway 
 AaT is the primary initiating enzyme in the N-end protein degradation pathway in 
E. coli.40  The N-end pathway regulates protein half-life through the use of destabilizing 
amino acids, called degrons, to signal proteolytic machinery to degrade the “destabilized” 
protein.40  This protein degradation pathway exists in both prokaryotes and eukaryotes.  I 
will first discuss the role of AaT in the prokaryotic N-end pathway and then briefly 
discuss the similar pathway that exists in eukaryotes. 
 The purpose of protein degradation pathways in living organism is multifold:  the 
regulation of short-lived signaling proteins and elimination of abnormal proteins that 
could be cell toxic.41  The first degron (secondary destabilizing residue) in the N-end 
pathway in E. coli is lysine or arginine exposure of the N-terminus of a protein; these 
residues indicate metabolic instability.42  An N-terminal lysine or arginine makes the 
protein a substrate for AaT, which is involved in the first step of the N-end pathway 
(Figure 1-11 and 1-12).39  AaT specifically recognizes the positively charged N-terminal 
Lys or Arg with a negatively charged pocket within its active site.43  AaT transfers 
leucine or phenylalanine (primary destabilizing residue) via a leucyl- or phenyalanyl-
tRNA substrate to the protein N-terminus, making the second degron signal, N-terminal 
(L/F)(K/R).42-43  An “adapter protein,” ClpS, recognizes the second degron signal and 
brings the protein to the proteolysis machinery complex, ClpAP.40, 44  According to Erbse 
et al., ClpS has some affinity for the individual destabilizing residues, but ClpS has a 
higher affinity for the N-terminal sequence (L/F)(K/R), which correlated well with their 
in vivo degradation studies.  Using a β-galatosidase-based assay, they found that F/L-R- 
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β-galatosidase was degraded faster than L-β-galatosidase.44  The ClpS protein brings the 
two degron-tagged protein to the protease machine, ClpAP, a complex of two proteins 
ClpA and ClpP.  ClpA is an AAA+ protein (ATPases associated with various cellular 
activities).45  AAA+ proteins include a large group of proteins that have wide-ranging 
function, but have a connective structural element: an ATP-binding domain that is 200 to 
250 amino acids in length.45  AAA+ proteins couple the energy provided by their ATPase 
to an additional protein or macromolecule; in context of the ClpAP complex, ClpA is the 
“gate keeper” for proteins to access ClpP.45-46  ClpS has an additional function in the E. 
coli N-end pathway; ClpS inhibits degradation of non-N-end rule proteins.39  Upon 
binding of the degron-tagged protein, ClpA unfolds the protein via ATP hydrolysis, and 
passes it through a pore to ClpP, which processively degrades the protein into 7 to 10 
residue peptide fragments without a significant degree of sequence specificity.39, 47-49  
Upon degradation, the peptide fragments can now be used in an amino acid “pool” for 
reuse in new protein synthesis.41 
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Figure 1-11.  N-End pathway in E. coli 
Adapted from Mogk et al.39 
 
An additional transferase called Bpt that transfers only leucine has been identified 
in the N-end pathway of Vibrio vulnificus.  V. vulnificus is prokaryotic pathogen found in 
marine environments, particularly shellfish.50  Bpt has no sequence similarity to AaT but 
is a sequelog of Ate1, an arginyl transferase involved in the N-end protein degradation 
pathway in eukaryotes.47  Bpt ligates leucine to the N-terminus of proteins bearing an N-
terminal aspartate or glutamate (Figure 1-12).  Additionally, V. vulnificus also has an AaT 
gene that is encoded in the genome directly adjacent to Bpt under the control of the same 
operon.  Graciet et al. tested whether deletion of one of the transferase genes affected the 
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other gene’s expression, and determined that each transferase could work 
independently.50  According to coimmunoprecipitation tests and E. coli cAMP two hybrid 
analysis, Graciet et al. determined that it was unlikely that the two transferases interacted; 
however, the tandem gene of AaT-Bpt was found to be conserved within 
proteobacteria.50-51  While key active site residues have been identified, the crystal 
structure has yet to be determined and more information is needed to understand the 
reason for transferase duplicity in V. vulnificus. 
 
Figure 1-12.  N-End Pathway N-degrons in Prokaryotes 
Adapted from Varshavsky et al.47  
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two complexes, 19S and 20S.47  The 19S complex has 6 AAA+ proteins that are involved 
in the process of unfolding and passing the protein substrate to the 20S complex, which is 
the proteolytic core.39  The origins of the ubiquitilation systems in the N-end pathway are 
still unclear, but the processive proteolysis found both in prokaryotes and eukaryotes 
likely links them by a common ancestor.50 
 
Figure 1-13.  N-End Pathway N-degrons in Eukaryotes 
Adapted from Varshavsky et al.47 
 
 
Figure 1-14.  N-End Pathway in Eukaryotes 
Adapted from Varshavsky et al.47 
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Section 1.4 – History of AaT and Its Active Site Chemistry 
1.4.1 – History of AaT 
 The natural formation of amino acid peptide bonds can occur through a variety of 
mechanisms in both eukaryotes and prokaryotes with two well-studied processes being 
ribosomal protein synthesis and protein modification via aminoacyl-tRNA transferases.  
The first observation of transferase activity, discovered by Kaji et al. in 1965, was found 
thorough incorporation of radiolabeled leucine and phenylalanine in cell extracts of E. 
coli.53  Five years later, the enzyme responsible for the amino acid transfer, AaT, was 
first extracted from E. coli and purified by Leibowitz and Soffer.54  The unique 
characteristic of E. coli AaT was its ability to transfer amino acids onto proteins with 
equal preference for both leucine and phenylalanine.54  They also determined several 
requirements of AaT function: optimal activity at pH 8, requirement of a monovalent 
cation source, 0.15 M KCl to achieve maximal kinetic function, enzymatic inhibition by 
divalent cations and the antibiotic puromycin, and complete independence of the 
ribosome, magnesium ions, and GTP.54  In 1973, Soffer et al. found the protein acceptors 
of the AaT reaction to be N-terminal lysine or arginine, with stereoselectivity for the L-
isomer and some loss of peptide substrate binding according to the penultimate N-
terminal residue, in particular, glutamate.55  In 1991, Tobias et al. determined that the 
physiological role of AaT was its involvement in the N-end rule in bacteria, but a crystal 
structure was yet to be determined until 2006 by Suto et al.42, 56  According to the crystal 
structure at 2.4 angstrom resolution, AaT forms two distinct domains, an N-terminal 
domain and a C-terminal domain (Figure 1-15).56  The crystal structure was solved with 
puromycin, a known inhibitor of AaT, bound in its active site, which is a cleft formed 
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between the N- and C-terminal domains.56  The structural fold of the C-terminal domain 
is similar to enzymes in the FemABX family.  The FemABX family of enzymes contain a 
GNAT fold and their active sites catalyze the binding of an amino acid, using aminoacyl 
tRNA, to a peptidoglycan precursor, which is involved in cell wall development.56-57  
Despite the similarity in aminoacylation reactions, the FemABX enzymes hold no 
significant primary sequence similarities to AaT.56 
 
Figure 1-15.  Crystal Structure of AaT at 2.4 Å 
The N-terminal domain consists of amino acids 3-62 (four β-strands, β1–4, and one α-helix, α1) 
and the C-terminal domain consists of amino acids 63-232 eight β-strands, β5–12, and six α-
helices, α2–7).  The chains that make up the active site of AaT are from both the N and C 
terminal domains (β9, α5, and β10 of the C-terminal domain and β3 from the N-terminal domain).  
PDB ID – 2DPT.56 
 
1.4.2 – AaT Active Site Chemistry 
AaT naturally transfers three amino acids, leucine and phenylalanine, which are 
involved in the N-end pathway, and methionine at a lower efficiency.58  Using the crystal 
structure and amino acid mutagenesis, amino acid residues in the binding cleft, M144, 
F153, L170, F173, and I185, were found to interact with the hydrophobic portion of 
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puromycin, which could indicate the leucyl/phenylalanyl binding site of the aminoacyl 
tRNA.56  Suto et al. proposed that the active site discriminates against β-branched 
residues such as isoleucine due to the close proximity (≤ 4 Å) of Met158 and the amide 
bond of Gly155 and Glu156 (Figure 1-16).  Additionally, they proposed a tRNA docking 
model with AaT proposing that the tRNA 3' end likely adopts a bent conformation that 
mediates amino acid binding in the hydrophobic pocket of AaT.56  
 
Figure 1-16.  Amino Acids Involved in Puromycin Binding in AaT 
The aminoacyl moiety (Cα, Cβ, Cγ) is stacked between residues Met158 and the peptide bond 
linking Gly155 and Glu156.  The Hydrophobic pocket: Met144, Phe153, Leu170, Phe173, Ile185. Pm = 
puromycin. Reprinted with permission from (Kyoko Suto, Yoshihiro Shimizu, Kazunori Watanabe, 
Takuya Ueda, Shuya Fukai, Osamu Nureki, Kozo Tomita. The EMBO Journal. 2006, Vol. 25, No. 
24, 15139–15147.).  Copyright (2006) Nature Publishing Group. 
 
More information about the reaction mechanism was elucidated in 2007 by the 
same group using crystal structures bound separately to minimized AaT substrates, 
phenylalanyl adenosine and peptide product, FRYLG.  Watanabe et al. determined that 
Q188, acting as a general base, follows a mechanism similar to the reverse reaction of a 
serine protease (Figure 1-17).43  However, the mechanism was challenged by Fung et al. 
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in 2011, and through the use of highly sensitive MALDI analysis, it was determined that 
none of the active site residues are actually catalytic; instead, the active site simply 
allows for “substrate-assisted catalysis” of the substrates, in which the α-amine of the 
protein substrate undergoes nucleophilic attack on the ester carbonyl bond of the 
aminoacyl L-tRNALeu or Phe-tRNAPhe.  Currently, the proposed mechanism by Fung et 
al. seems more likely to be correct because the supposed catalytic residue of the 
Watanabe et al. proposed mechanism, Q188, can be mutated to an alanine and still retain 
enzymatic activity; however, neither mechanism has been fully confirmed or disproved.43, 
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Figure 1-17.  Phe-A Bound to the Active Site of AaT 
Q188 is labeled to show its close proximity to the Phe-A substrate, 2.9 Å.  PDB – 2Z3K43 
 
  
Q188 
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Section 1.5 – Minimization of AaT Substrates 
The selection of the correct amino acids in ribosomal protein synthesis is 
complex, with a variety of checks and balances throughout the process.60  Gromadski et 
al. determined that the ribosome exhibited a greater than 450 fold selectivity for cognate 
aminoacyl tRNA anticodons versus a single mismatch at the anticodon.60  Effraim et al. 
tested the ribosomal acceptance of combinations of Ala, Phe, and Lys tRNAs and found 
that misacylation does not effect the yield of dipeptide formation when only misacylated 
tRNA is supplied; however, when in competition with correctly acylated tRNA, the 
ribosome shows a clear discrimination against misacylation.61  Similarly, AaT has been 
shown to use misacylated tRNA as well as minimized tRNA mimics (Figure 1-18).62-63  
The ability of AaT to use misacylated non-cognate tRNA indicated that amino acid 
identity was less selective than previously expected.64  Abramochkin et al. determined 
that the aminoacyl-tRNA anticodon is not a transferase recognition determinant.64  Also, 
mutations in the anticodon and extra arm of the tRNALeu substrate did not substantially 
alter transfer.64  They did not find stringent conservation of nucleotide sequences between 
L/F transferase tRNAs, but charged tRNA with a GC stem was a poor substrate.64  
Connor et al. used mutant aminoacyl tRNA synthetases to transfer unnatural amino acids 
to the N-termini of peptides using AaT.65  Taki et al. also minimized the aminoacyl tRNA 
substrate and demonstrated that truncated aminoacyl tRNAs from 20 bases down to 
dinucleotides could be utilized as an AaT substrates.63  The greatest minimization of the 
AaT aminoacyl tRNA substrate was reduction to phenylalanyl adenosine (Phe-A), which 
was used as a substrate analog for analysis of substrate binding in crystal structures.43  
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Watanabe et al. found that in the presence of an accepter peptide AaT could use Phe-A as 
a substrate, forming approximately 1 % N-terminally phenylalanine-ligated product.43  
These findings have shown that AaT can have amino acid promiscuity in its active site 
while maintaining ligation efficiency for a variety of tRNA lengths. 
 
Figure 1-18.  Minimized Substrates 
Aminoacyl tRNA, specifically L/F, is the natural substrate for AaT.  Dinucleotides (Xaa = amino 
acid) and phenylalanyl adenosine have also been shown to be AaT substrates. 
 
Section 1.6 – Summary 
Protein modification is an important tool for understanding how a protein moves, 
folds, and operates in its cellular environment.  However, many current N-terminal 
modifications and ligation techniques can perturb protein structure from its natural state 
through cysteine mutagenesis and unnatural amide backbone linkages.  In our work, we 
aim to learn more about the protein structure and function with minimal perturbation 
from its natural state.  Our new method of protein modification ligates small molecules 
onto proteins with N-terminal specificity and creates natural amide bonds at ligation sites.  
AaT-mediated ligations recognize a small synthetic aminoacyl-tRNA analog, aminoacyl 
adenosine, which can be chemically synthesized in only three steps.66  Using AaT, we 
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can enzymatically attach a wide range of synthetic moieties to the N-termini of peptides 
and proteins, including natural and unnatural amino acids with reactive azido groups, 
fluorescent labels, protected disulfides, and photoinducible crosslinkers.  This method 
introduces new opportunities for protein semi-synthesis and contributes an effective 
method to label proteins for biophysical research, which we have demonstrated in two 
model proteins, α-synuclein and calmodulin.  We have also explored other aminoacyl 
transferase options, Bpt from V. vulnificus and Ate1, a mammalian arginyl transferase. 
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CHAPTER 2 
 
N-TERMINAL PROTEIN MODIFICATION USING SIMPLE AMINOACYL 
TRANSFERASE SUBSTRATES 
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Reprinted (adapted) with permission from (Anne M. Wagner, Mark W. Fegley, John B. 
Warner, Christina L. J. Grindley, Nicholas P. Marotta, and E. James Petersson. J. Am. 
Chem. Soc. 2011, 133, 15139–15147.).  Copyright (2011) American Chemical Society. 
 
Section 2.1 - Introduction 
The conjugation of synthetic molecules to proteins contributes to biomedical 
research by enabling the immobilization of proteins on surfaces, modifications with 
chromophores to make in vitro sensors, or tagging with in vivo imaging agents.67-71 In 
most cases, the formation of well-defined conjugates is valuable, if not essential.  The 
protein termini are attractive targets for conjugation, because in many cases appending 
synthetic molecules at the termini will have minimal undesired effects on protein folding 
and function.72-92  This is particularly applicable in cases where the terminus is relatively 
unstructured.  As part of our research on minimalist labeling strategies for biophysical 
studies, we sought a method for N-terminal modification that could be carried out easily 
under conditions that maintain folding without substantial prior protein manipulation.12 
Selective N-terminal modification has been achieved by a variety of chemical and 
enzymatic methods, each with benefits and drawbacks.  Small molecule strategies permit 
the attachment of a variety of molecules, but they are subject to side reactions and 
incomplete specificity for the N-terminus and may need to be carried out in organic 
solvent mixtures.38, 82, 93-101  Reverse proteolysis methods can be used to modify the N-
terminus under conditions that do not require protein unfolding, but the reaction can be 
difficult to drive to completion without high protein concentrations.23, 32, 102-113  Several 
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other chemoenzymatic methods are valuable in functioning under benign conditions but 
have moderate-sized target sequences that must be appended to the protein.114-121  Here, 
we describe a minimal system for N-terminal protein labeling that utilizes only adenosine 
esters of natural or unnatural amino acids and a single, readily available enzyme.  This 
process gives high yields of modified proteins under nondenaturing conditions and 
requires only a single basic amino acid for specific recognition. 
Aminoacyl tRNA transferases (AaTs) are members of a growing class of enzymes 
that use aminoacyl tRNAs in secondary metabolism.122  The E. coli AaT catalyzes the 
transfer of Leu, Phe, or Met from an aminoacyl tRNA to a protein bearing an N-terminal 
Arg or Lys.43, 56, 123  The addition of Leu or Phe targets that protein for degradation by 
ClpA as part of the N-end rule pathway.39-40, 42, 124  Kaji et al. first observed AaT 
aminoacylation activity in crude E. coli preparations.53, 123, 125  Soffer and Leibowitz 
subsequently reconstituted the purified enzyme and characterized its specificity or both 
the RNA and amino acid components of the donor molecule, demonstrating its first use in 
transferring an unnatural amino acid, p-fluorophenylalanine (Figure 2-1, Top).126-127 
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Figure 2-1.  Transferase-Mediated N-terminal Protein Modification 
(Top) Fully enzymatic methods use aminoacyl tRNA synthetase (aaRS), tRNA, aminoacyl 
transferase (AaT), amino acid, and ATP.  (Bottom) Chemoenzymatic methods use only a 
synthetic nucleic acid donor and transferase.  In this work, an aminoacyl mononucleoside (Rn =H) 
was used. 
 
Recently, purified AaT has been used to modify proteins in vitro with a variety of 
unnatural amino acids charged onto tRNAs, either by chemical semi-synthesis or the use 
of a mutant aminoacyl tRNA synthetase (aaRS).62-63, 85, 128-129  Abramochkin and Shrader 
discovered that AaT was tolerant of variation in the acceptor stem (aminoacylation site) 
of the tRNA, and Sisido and coworkers have shown that much shorter oligonucleotides 
(Figure 2-1, bottom, Rn = 1 - 21 nucleotides) can act as donors.63-64, 130  As part of their 
structural characterization of AaT, Tomita and co-workers found that AaT could bind 
phenylalanyl adenosine and transfer Phe to peptides in trace amounts.43  However, the 
use of adenosine mononucleoside as a donor substrate for AaT has not, to our knowledge, 
been further explored. 
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We have found that a variety of hydrophobic amino acids can be transferred from 
adenosine donors with high yields at relatively low protein concentrations (Figure 2-1, 
bottom, Rn = H).  These donors can be synthesized from commercially available active 
esters of the amino acids.  Reduction of the two step synthetase/AaT reaction sequence to 
the one step AaT-only sequence allows us to explore the substrate specificity of AaT 
without limitation by the specificity of the synthetase in the first step.  While this is also 
possible with Sisido’s pdCpA dinucleotide donors, the shorter synthesis of the simple 
adenosine donors (1 - 2 steps vs. 7 steps) makes this exploration easier.  We have 
characterized the substrate scope of the wild type AaT enzyme using a reporter peptide, 
determined the kinetic parameters for the adenosyl substrates, and demonstrated the 
efficient modification of a full-sized protein, 23 kDa α-casein. 
 
Section 2.2 - Results and Discussion 
The synthesis of adenosyl donor compounds, shown in Scheme 2-1, can be 
carried out on any amino acid with appropriate acid-labile protecting groups (e.g., N-
Boc).  This synthesis is not limited to α-amino acids, and our donor synthesis has also 
enabled us to test the transfer of analogs such as α-azidophenylalanine (N3f, 4g).  
Conversion to the cyanomethyl ester (1a - h) is typically high-yielding, although yields 
for the subsequent acylation of 5′-O-dimethoxytrityl-adenosine ((DMT)-A) varied 
between 60 and 90 %.  Acylation yields generally decreased with side chain bulk; 
derivatives such as N-1,8-naphthyldiaminopropionic acid coupled poorly (data not 
shown).  Uncatalyzed reactions took 1 - 5 days, but in all cases, addition of 
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tetrabutylammonium acetate increased reaction rates. 
 
 
Scheme 2-1.  Synthesis of Adenosyl Donors and Use in AaT-Catalyzed Protein 
Modifications 
Donor synthetic intermediates: 1a, 2a, 3a X = NHBoc, Z = Ph; 1b, 3b X = NHBoc, Z = i-Pr; 1c, 3c 
X = NHBoc, Z = p-azidophenyl; 1d, 3d X = NHBoc, Z = 2-naphthyl; 1e, 3e X = NHMeBoc, Z = Ph; 
1f, 3f X = NHAc, Z = Ph; 1 g, 3 g X=N3, Z = Ph; 1 h, 3 h X = NHBoc, Z = 7-Methoxycoumarinyl; 1i, 
3i X = NHMeBoc, Z = p-benzoylphenyl 
 
The Phe donor 4a was synthesized from both the cyanomethyl ester (1a) and N-
hydroxysuccinimidyl (OSu) ester (2a).  All other adenosyl donors were synthesized from 
the cyanomethyl ester (1b - h).  After trifluoroacetic acid (TFA) deprotection and CH2Cl2 
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washing (or Et2O precipitation) to remove DMT byproducts, the compounds could be 
taken on directly to AaT enzymatic reactions (contaminants were limited to incompletely 
deprotected compounds which are not transferred by AaT).  However, in most cases the 
deprotected adenosyl donor was purified by HPLC, and higher transfer yields were 
generally observed with these purified donors. 
Transfer extent was evaluated by HPLC analysis of reactions with adenosyl 
donor, AaT, and an aminocoumarin-labeled reporter peptide used previously by Tirrell 
and co-workers (LysAlaAcm, Scheme 2-1).65  Monitoring LysAlaAcm acylation in crude 
reaction mixtures using absorbance at 325 nm conveniently eliminates background due to 
other proteins and nucleic acids, although some unnatural amino acids such as 
napthylalanine (Nap) and methoxycoumarinylalanine (Mcm) also absorb in this range.  
Example HPLC chromatograms from Phe ligations are shown in Figure 2-2.  LysAlaAcm 
starting material eluted at 11.8 min (Figure 2-2A); hydrophobic products eluted at 12 to 
15 min (PheLysAlaAcm 5a elutes at 13.0 min in Figure 2-2B, NapLysAlaAcm 5d elutes 
at 14.1 min in Figure 2-2D). 
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Figure 2-2.  Reversed-Phase HPLC Analysis of Transferase Reactions 
Top: AaT-mediated transfer of Phe from adenosyl donor 4a to LysAlaAcm reporter peptide.  
HPLC chromatograms obtained after (A) 0 h or (B) 4 h show conversion of LysAlaAcm (11.8 min 
retention time) to PheLysAlaAcm (13.0 min retention time).  Conversion after one addition of 
donor 4a is 92 % (B).  A second addition of 1 mM 4a drives the reaction to completion with a 
small amount of double Phe addition (C).  Bottom: HPLC analysis of transfer of Nap from 
adenosyl donor 4d to LysAlaAcm after (D) 4 h shows conversion to NapLysAlaAcm (14.1 min 
retention time).  Product identities confirmed by observation of indicated masses by MALDI MS. 
 
To evaluate substrate scope, reactions were analyzed after 4 h, when transfer 
should be complete for the fully enzymatic reaction with Phe tRNA synthetase.65  Phe 
(4a) and Leu (4b) were transferred efficiently (Table 2-1).  Our PheLysAlaAcm yields 
from donor 4a were comparable to yields from Phe-pdCpA, the dinucleotide used by 
Sisido.  Transfer yields for other substrates varied with side chain size, where Mcm (4h) 
is too large and benzoylphenylalanine (Bzf, 4i) is a poor substrate (see Table 2-1).  Sisido 
has shown that AaT mutants can use substrates with larger side chains; we are currently 
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exploring some of these mutations.63  While transfer yields after 4 h varied, most 
reactions could be driven to completion by a bolus of donor molecule (Figure 2-2C). 
 
Table 2-1.  N-Terminal Modification of Reporter Peptide After Single Addition of Adenosyl 
Donor 
Donor Additivesa Yield (%)b 
4a (Phe)  92.7 ± 5.2 
Phe-pdCpA  95.2 ± 4.3 
4a (Phe) 1 mM ATP 86.1 ± 0.8 
4a (Phe) 5 mM ATP 79.1 ± 0.4 
4a (Phe) 5 mM AMP 88.2 ± 0.8 
4a (Phe) 5 mM A 93.1 ± 1.1 
4a (Phe) 1 mM pdCpA 90.4 ± 0.9 
4b (Leu)  80.4 ± 0.9 
4c (Azf)  78.5 ± 5.2 
4d (Nap)  95.4 ± 0.4 
4d (Nap) 100 µM PheLysAlaAcm 93.8 ± 0.3 
4e (Mef)  0.6 ± 0.1 
4f (Acf)  5f not observed 
4g (N3f)  5g not observedc 
4h (Mcm)  5h not observed 
4i (Bzf)  9.2 ± 0.3 
 
a Standard AaT-catalyzed transfer conditions with or without potential inhibitor added. b Yield 
determined by integration of HPLC chromatogram peak areas at 325 nm, described in Materials 
and Methods.  Standard deviations are reported for an average of at least 6 experiments with at 
least 2 different AaT preparations.  c HPLC and MALDI MS analysis indicate that the observed 
product is 5a not 5g. 
 
One of the advantages of adenosyl donors over in situ tRNA aminoacylation with 
a tRNA synthetase is that we are not limited by the substrate specificity of the synthetase.  
In particular, nonamino acid substrates can be attached to adenosyl donors to assess their 
transferability by AaT.  N-Methyl phenylalanine (Mef, 4e) can be transferred, albeit with 
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low yield.  We have also tested N-acetyl phenylalanine (Acf, 4f) and α-
azidophenylalanine (4g) and found them to be poor substrates.  In some experiments, 
substantial conversion of LysAlaAcm was found when incubated with 4g, but MALDI 
MS analysis has shown the product to be 5a, presumably obtained by transfer of Phe after 
prior reduction (i.e., Phe donor 4a is formed from 4g under the reaction conditions).  
Steps taken to alter the concentration of β-mercaptoethanol reductant did not improve the 
yield of 5g (data not shown).  We believe that disproportionation of the azide is 
incomplete, but that AaT is selective for the α-amine substrate (Phe-A, 4a), so far more 
5a than 5g is formed.  This may be due to an important interaction of the α-amine with 
Q188, which also acts as a catalytic base to deprotonate the peptide substrate for amide 
bond formation.  The Q188/α-amine interaction was defined by the structural and 
enzymological work of Watanabe and co-workers.43  We note that the preference of AaT 
for unmodified N-termini was previously documented with full-length tRNA by Soffer 
and Leibowitz.127 
To better understand limitations on the yield from AaT reactions, we assessed the 
possibilities of inhibition by hydrolyzed substrate or aminoacylated product.  Since the 
acyl adenosine donor substrate is not regenerated during the reaction (unlike the 
aaRS/tRNA/AaT reaction), we hypothesized that the adenosine byproduct might inhibit 
further acylation by binding to AaT.  To investigate this possibility, we added adenosine 
to the reaction at varying concentrations and monitored the reaction timecourse by 
fluorescence spectroscopy and by HPLC.  Addition from the Phe donor 4a was not 
inhibited by the addition of 5 mM concentrations of adenosine (Table 2-1).  A 
40 
 
comparison of adenosine compounds, including pdCpA, the dinucleotide donor used by 
Sisido, showed that only adenosine triphosphate (ATP) inhibited the reaction. 
We were also able to monitor product formation in real time based on partial 
quenching of coumarin fluorescence upon addition of Nap to the LysAlaAcm peptide to 
form 5d.  The fluorescence intensity at 390 nm of NapLysAlaAcm is 28 % of the 
fluorescence of LysAlaAcm, and the overall fluorescence of mixtures of the two peptides 
can be used to determine the proportions of each peptide if the total concentration is 
known.  Intensity was used to monitor NapLysAlaAcm formation in real time, and HPLC 
injection of the reaction end points were used to confirm the final product distribution.  
We found that exogenous adenosine did not significantly inhibit the reaction, even at 
concentrations up to 1 mM (Figure 2-3A). 
 
 
Figure 2-3.  Kinetic Analysis of AaT Reactions 
(A) Real time monitoring of Nap transfer to LysAlaAcm from 4d by quenching of Acm 
fluorescence.  No significant inhibition is observed in the presence of 1 mM adenosine.  (B) 
Saturation curve used to determine Michaelis-Menten kinetic parameters for LysAlaAcm 
modification by Phe donor 4a. 
 
We also assessed the possibility of product inhibition by the aminoacylated 
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LysAlaAcm product.  In our standard 4 h transfer assay, addition of 100 µM (1 equiv.) 
PheLysAlaAcm did not significantly inhibit production of NapLysAlaAcm (5d) when 
Nap-A (4d) was used as a donor (Table 2-1).  MALDI MS analysis and differences in 
HPLC retention time allowed us to easily distinguish LysAlaAcm and PheLysAlaAcm 
from NapLysAlaAcm (Figure 2-2).  Finally, we investigated the question of whether 
donor hydrolysis slowed reaction rates after 30 - 60 min.  Analysis of mock reactions 
lacking transferase or LysAlaAcm indicates that donor hydrolysis may contribute 
significantly to slowing reactions, which is why a donor bolus can be used to drive the 
reaction to completion (see Materials and Methods section). 
To characterize the enzymatic activity of AaT toward our acyl adenosyl 
substrates, we used our HPLC assay to determine initial reaction rates to be fit to a 
standard Michaelis-Menten kinetic model.  Equations describing this kinetic analysis are 
included in the Supporting Information.  Since adenosine does not inhibit the enzyme, by 
keeping LysAlaAcm concentrations high (100 µM), we measured the rate of transfer as a 
function of the concentration of Phe donor 4a and fit this to a single-substrate kinetic 
model to determine a kcat of 1.68 ± 0.09 × 10–1 s–1 and a KM of 1.24 ± 0.23 × 10–4 M.  The 
enzyme efficiency (kcat/KM = 1.35 ± 103 M–1 s–1) is relatively low.131  While KM is higher 
for Phe-A than what Shrader reported for aminoacyl tRNALeu-4 (0.3 µM), the kcat is 
comparable (0.13 × 10–1 s–1).64  Since it is trivial to run our reactions at donor 
concentrations well above KM, the lower apparent affinity for our substrates should not 
affect the utility of the reaction.  We note that the binding affinity, which gives a KM of 
124 µM for 4a must arise primarily from Phe binding interactions since the KI for 
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adenosine inhibition is greater than 5 mM. 
It is possible that larger protein substrates are modified with different efficiencies 
than peptide substrates.63-64, 127  To address this question and to demonstrate the utility of 
our method in tagging full-sized proteins with useful fluorophores or affinity purification 
tags, we modified the milk protein α-casein (bearing a native N-terminal Arg after 
proteolysis of a leader sequence).132  First, modification using Phe donor 4a was assessed 
by Edman degradation, where successful, quantitative addition of Phe was observed. 
In a more complex set of experiments, we first modified α-casein with Azf using 
donor 4c and then used a Cu-catalyzed Huisgen cycloaddition (“click” reaction) to 
append a fluorescein label (Figure 2-4A).133-136  Prior to fluorescent-labeling, the initial 
transfer of Azf was analyzed by trypsin digest and MALDI MS of α-casein (Figure 2-
4C).  The N-terminal peptide ArgProLys disappeared from the mass spectrum following 
modification and a peptide corresponding to AzfArgProLys was observed (also a mass 
corresponding to AzfArgProLys after loss of N2 during ionization; N2 loss was also 
observed for AzfLysAlaAcm).  Complete conversion of α-casein was observed in 
MALDI MS due to double addition of 4c to drive the reaction. 
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Figure 2-4.  AaT-Catalyzed Modification and “Click” Reaction of α-Casein N-terminus 
(A) α-Casein modification scheme.  (B) PAGE gel analysis of α-casein modification. Lanes (left to 
right): (1) molecular weight (MW) markers (Masses in kDa: 17, 25, 30, 46, 58, 80, 175); (2) α-
casein; (3) α-casein mixed with fluorescein alkyne (FlAlk); (4) α-casein mixed with FlAlk, CuSO4, 
THPTA, and sodium ascorbate; (5) α- casein mixed with Azf-A (4c) and AaT; (6) α-casein mixed 
with 4c and AaT, then FlAlk; (7) α-casein mixed with 4c and AaT, then propargylamine (Alk), 
CuSO4, Tris-(3-hydroxypropyltriazolylmethyl) amine (THPTA), and sodium ascorbate; (8) α-
casein mixed with 4c and AaT, then FlAlk, CuSO4, THPTA, and sodium ascorbate;( 9) MW 
markers; and (10) cell lysate labeling, α-casein reaction carried out using conditions of lane 8 with 
unpurifed AaT in cleared E. coli lysate.  (C) MALDI MS analysis of trypsinized N-terminal 
fragment of α-casein with or without modification by Azf using AaT and 4c (double addition). 	  
After AaT-catalyzed modification of α-casein with Azf, residual 4c was removed 
by dialysis, AaT (His10-tagged) was removed by treatment with Ni beads, and the azide-
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bearing protein was reacted with fluoroescein alkyne (FlAlk) in the presence of Cu(I).  
The results of this labeling experiment, as well as appropriate control reactions, are 
shown in Figure 2-4B.  One can see that fluorescent α-casein is only observed under the 
proper conditions (Lane 8), where both the chemoenzymatic labeling by AaT with 4c and 
the subsequent click reaction are successful. Finally, we carried out a similar labeling 
experiment in crude E. coli lysate with unpurified AaT.  Azf transfer was successful, as 
shown by the observation of fluorescence after labeling with FlAlk.  Control reactions 
(shown in Supporting Information) show no observable labeling of any protein, implying 
that endogenous levels of proteins terminating in Arg or Lys are too low to be observed 
here. 
Substantial recent effort has been devoted to developing methods for labeling 
proteins under conditions that maintain protein folding and activity.16, 137-138  E. coli 
aminoacyl tRNA transferase can work under these conditions and specifically modifies 
the N-terminus, a useful point for conjugation.  However, certain aspects of its native 
mechanism are nonideal for its use as a preparative tool (i.e., a multistep, multienzyme 
reaction sequence).  The work of Leibowitz, Shrader, and Sisido showed that E. coli 
aminoacyl tRNA transferase can modify the N-terminus of a protein ending in Arg or Lys 
with amino acids from an aminoacyl oligonucleotide donor.63-64, 127  Watanabe et al. 
crystallized AaT with Phe-A bound and showed that Phe could be transferred from Phe-A 
to the N-terminus of the peptide RYLGYL in trace amounts.  These two results provide 
crucial precedent for our own work, in which we show that AaT can efficiently use a 
variety of easily synthesized acyl adenosine substrates.  Enzymological analysis 
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demonstrates that AaT is able to use the Xaa-A substrates with turnover numbers 
comparable to full-length aminoacyl tRNAs.  Furthermore, we have shown that neither 
the adenosine reaction byproduct nor aminoacylated protein product (at least in the case 
of our reporter peptide) appreciably inhibit the reaction.  In fact, the major obstacle to 
efficient transfer is donor hydrolysis, but this can be overcome by a second addition of 
donor molecule since the KI for inhibition by adenosine is greater than 5 mM. 
Our AaT-only reaction sequence allows us to explore the compatibility of Phe 
analogs lacking a primary α-amine with transfer by AaT.  The wild type transferase 
seems to have a strong preference for the α-amine, as only N-methylphenylalanine was 
transferred.  In contrast, the side chain pocket is quite permissive: we have observed the 
transfer of bicyclic amino acid side chains and Sisido has reported mutants capable of 
transferring tricyclic amino acids.63  We are currently investigating the transfer of larger 
side chains such as benzophenone, biotin, and fluorescein derivatives. 
Our reaction conditions and yields compare favorably to two well-established 
methods in the field.  Subtiligase (reverse proteolysis) reactions can be carried out in a 
few hours, but rarely go to completion.108-109, 113  The pryidoxyl-5-phosphate (PLP) 
transamination reactions of Francis and co-workers can require elevated temperatures to 
achieve high yields and are subject to a number of side reactions.100-101  AaT transfer 
reactions are highly specific (no Lys side chain modifications were observed in our work 
or the work of others) and can be driven to completion by subsequent repeated additions 
of donor.  Our discovery of efficient transfer from simple adenosyl donors removes the 
limitations imposed by the selectivity of synthetases on the range of molecules that can 
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be AaT substrates without restricting reaction scale by necessitating the synthesis of 
oligonucleotide donors.  Our yields are comparable to those obtained with pdCpA donors, 
but pdCpA synthesis requires 6 steps, and overall yields are typically 25 %.  We see our 
methods as complementary to the fully enzymatic synthetase-based methods (Figure 2-1, 
Top).  Fully enzymatic methods do not require prior synthesis and aminoacyl tRNAs are 
efficient substrates for AaT.  On the other hand, our methods can be easily scaled up to 
modify larger quantities of protein since they do not require the use of purified tRNA. 
We have shown that our method can be used to transfer reactive handles to the N-
terminus under “protein friendly” (pH ∼7, high salt, 37 °C) conditions and that the 
labeled protein product can be easily purified afterward.  Given the previous success of 
Sisido and co-workers, we expect that further mutation of AaT will allow us to transfer 
larger side chains that may permit direct transfer of fluorescent probes or affinity tags.  
We also hope to use the available crystal structures to redesign AaT to act on other N-
terminal sequences through a combination of rational design and selection.  Finally, our 
demonstration that AaT can modify α-casein in crude lysates, coupled with the cell-
permeability of our moderately polar donors raises the exciting possibility of using AaT 
as part of an in vivo labeling strategy. 
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Section 2.3 – Materials and Methods 
2.3.1 – Materials 
General Information.  Chloroacetonitrile, N,N-diisopropylethylamine (DIPEA), 
5′-O-(4,4′-Dimethoxytrityl) adenosine ((DMT)-A), tetrabutylammonium acetate 
(TBAAc), trifluoroacetic acid (TFA), and triisopropyl silane (TIPSH) were purchased 
from Sigma-Aldrich (St. Louis, MO).  Note: (DMT)-A production was discontinued by 
Sigma-Aldrich, after which it was purchased as a custom order from ChemGenes 
Corporation (Wilmington, MA) and was additionally synthesized in-house following the 
protocol outlined by Ogilvie et al.139  N-Boc-L-phenylalanine-O-succinimide (Boc-Phe-
OSu) and Lysylalanylaminomethylcoumarin (LysAlaAcm) were purchased from Bachem 
(Torrence, CA).  N-Boc-L-phenylalanine (Boc-Phe-OH) and all solvents were purchased 
from Fisher Scientific (Pittsburgh, PA).  All deuterated solvents were purchased from 
Cambridge Isotopes Laboratories, Inc. (Andover, MA).  E. coli BL21(DE3) cells were 
purchased from Stratagene (La Jolla, CA).  The pEG6 plasmid, containing His10-tagged 
E. coli AaT, was a gift from Alexander Varshavsky (California Institute of Technology).  
Sequencing-grade trypsin was purchased from Promega (Madison, WI).  All other 
reagents were purchased from Fisher Scientific (Pittsburgh, PA).  N-Boc-L-leucine (Boc-
Leu-OH), N-Boc-L-p-azidophenylalanine (Boc-Azf-OH), N-Boc-L-naphthylalanine 
(Boc-Nap-OH), N-Boc-, N-Me-L-phenylalanine (Boc-Mef-OH), N-Acetyl-L-
phenylalanine (Acf-OH), and N-Fmoc-methoxycoumarinylalanine (Fmoc-Mcm-OH) 
were purchased from Bachem (Torrence, CA).  All solvents were purchased from Fisher 
Scientific (Pittsburgh, PA).  QuikChange® site-directed mutagenesis kits were purchased 
from Stratagene (La Jolla, CA).  DNA oligomers were purchased from Integrated DNA 
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Technologies, Inc (Coralville, IA).  Bradford reagent assay kits were purchased from 
BioRAD (Hercules, CA). Protease inhibitor cocktail was purchased from Sigma-Aldrich 
(St. Louis, MO).  All other reagents were purchased from Fisher Scientific (Pittsburgh, 
PA).  Infrared spectra were recorded on a Nicolet 6700 FT-IR instrument.  Milli-Q 
filtered (18 MΩ) water was used for all aqueous solutions (Millipore; Billerica, MA).  
Matrix-assisted laser desorption ionization (MALDI) mass spectra were collected using a 
Bruker Ultraflex III MALDI-TOF-TOF mass spectrometer (Billerica, MA).  UV 
absorbance spectra were obtained with a Hewlett-Packard 8452A diode array 
spectrophotometer (currently Agilent Technologies; Santa Clara, CA).  Donor molecule 
purification was conducted on a BioCad Sprint FPLC (GMI Inc.; Ramsey, MN; originally 
from Perseptive Biosystems) with a Waters Sunfire Prep C18-prep OBD column, 5 µm, 
17 - 150 mm (Milford, MA).  Analytical HPLC assays were performed on an Agilent 
1100 HPLC using a Waters Symmetry Shield C18 column.  NMR spectra, 1H and 13C, 
were collected with a Bruker DRX 500 MHz instrument.  “Low resolution” electrospray 
ionization (ESI) mass spectra (LRMS) were obtained on a Waters Acquity Ultra 
Performance LC connected to a single quadrupole detector (SQD) mass spectrometer.  
“High resolution” ESI mass spectra (HRMS) were obtained on a Waters LCT Premier 
XE LC/MS.  DNA sequencing was performed at the University of Pennsylvania DNA 
sequencing facility.  Fluorescence spectra were collected with a Varian Cary Eclipse 
fluorescence spectrophotometer fitted with a Peltier multicell holder (currently Agilent 
Technologies). 
 
49 
 
2.3.2 – Donor (4a) Synthesis 
The synthesis of Phe donor 4a is given as a general procedure, starting from 
commercially available Boc-Phe-OH or Boc-Phe-OSu.  The carboxy-terminus of the 
amino acid was activated as a cyanomethyl ester using chloroacetonitrile to give 1a.  
Next, the protected amino acid was attached to one of the available hydroxyls (2′ OH or 
3′ OH) of (DMT)-A without preference.  The resulting protected adenylate (3a) was 
deprotected using a 50/50 mixture of TFA and THF with TIPSH present as a scavenger.  
The final product, deprotected adenylate (4a), was purified on C18 reverse-phase HPLC 
column. 
 
(S)-Cyanomethyl 2-((tert-butoxycarbonyl)amino)-3-phenylpropanoate (Boc-Phe-
OCH2CN, 1a). 
Boc-Phe-OH (2.01 g, 7.57 mmol) was dissolved in 10 mL tetrahydrofuran under 
ambient conditions.  Ten equivalents of chloroacetonitrile (4.78 mL, 75.4 mmol) and 1.1 
equiv. of DIPEA (8.30 mmol, 1.45 mL) were added to the reaction mixture and allowed 
to stir overnight.  1a was purified on silica gel (20 % EtOAc in hexanes) to give 2.474 g 
(100 %) of a pale-yellow oil after evaporation.  Rf 0.4 in 20 % EtOAc in hexanes; 1H 
NMR (500 MHz, CDCl3) δ 7.26 (t, J = 7.0 Hz, 2H), 7.20 (t, J = 7.1 Hz, 1H), 7.11 (d, J = 
7.3 Hz, 2H), 5.11 (d, J = 7.8 Hz, 1H), 4.69 - 4.57 (m, 3H), 3.09 - 2.98 (m, 2H), 1.36 (s, 
9H); 13C NMR (125 MHz, CDCl3) δ 170.8, 155.1, 135.4, 129.2, 128.7, 127.3, 114.0, 
80.9, 80.2, 54.4, 48.8, 37.8, 28.2; HRMS (ESI) calcd m/z for C16H20N2O4Na [M + Na]+ 
327.132, found 327.133. 
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(S)-(2R,3R,4R,5R)-2-(6-Amino-9H-purin-9-yl)-5-((bis(4-methoxyphenyl)( 
phenyl)methoxy) methyl)-4-hydroxytetrahydrofuran-3-yl 2-((tert-
butoxycarbonyl)amino)-3-phenylpropanoate (Boc-Phe-(DMT)-A, 3a). 
(DMT)-A (25 mg, 44 µmol) was dissolved in 5 mL of tetrahydrofuran (dried with 
4 Å molecular sieves) in an oven-dried 4 dram reaction vessel.  Twenty equivalents of 1a 
(272 mg, 0.895 mmol) were added to the reaction mixture.  TBAAc (4.9 mg, 16 µmol), 
the reaction catalyst, was added last to the reaction mixture.  In reproductions of this 
reaction, TBAAc additions varied according to reaction progress.  The reaction stirred 
under argon overnight at room temperature for 1 - 4 days.  After evaporation of solvent, 
the product was purified on silica gel (gradient solvent system: 20 – 0 % petroleum ether 
in EtOAc, 5 % methanol in EtOAc) to give 27 mg (75 %) of a pale-yellow foam after 
evaporation.  Rf 0.5 in 5 % methanol in EtOAc.  1H NMR (500 MHz, THF-d8) δ 8.08 (s, 
1H), 8.00 (s, 1H), 7.44 (d, J = 3.68Hz, 2H), 7.32 (d, J = 8.85 Hz, 4H), 7.20 (dd, J = 
8.33Hz, J = 6.66, 2H), 7.13 (t, J = 7.25Hz, 1H), 7.21 - 7.10 (m, 4H), 6.77 (d, J = 4.30 Hz, 
2H), 6.75 (d, J = 4.29 Hz, 2H), 5.92 (d, J = 4.87 Hz, 1H), 5.49 (t, J = 4.34 Hz, 1H), 5.13 
(t, J = 5.54 Hz, 1H), 4.51 - 4.47 (m, 1H), 4.14 (t, J = 4.07Hz, 1H), 3.71 (s, 6H) (S), 3.42 - 
3.32 (m, 2H), 3.12 - 2.96 (m, 3H), 1.37 (s, 9H); 13C NMR (125 MHz, THF-d8) δ 172.2, 
159.9, 157.6, 156.7, 153.8, 146.3, 138.3, 146.3, 138.3, 1367.0, 136.9, 131.2, 131.1, 130.3, 
129.3, 129.2, 129.1, 128.6, 128.5, 127.5, 114.0, 113.9, 89.7, 87.5, 82.5, 79.7, 75.1, 73.5, 
64.7, 56.4, 55.5, 38.9, 30.6, 28.8; LRMS (ESI) calcd m/z for C45H48N6O9H (M + H)+ 
816.9, C45H48N6O9Na (M + Na)+ 839.3, found 817.3, 839.3. 
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 (S)-(2R,3R,4R,5R)-2-(6-Amino-9H-purin-9-yl)-5-((bis(4-methoxyphenyl)( 
phenyl)methoxy) methyl)-4-hydroxytetrahydrofuran-3-yl 2-((tert-
butoxycarbonyl)amino)-3-phenylpropanoate (3a) from 2a. 
(DMT)-A (26 mg, 45 µmol) was dissolved in 5 mL of tetrahydrofuran (dried with 
4 Å molecular sieves) in an oven-dried 4-dram reaction vessel.  Twenty equivalents of 2a 
(321 mg, 0.885 mmol) were added to the reaction mixture.  TBAAc (19 mg, 64 µmol), 
the reaction catalyst, was added last to the reaction mixture in two separate additions, 6 
mg, at the beginning of the reaction, and 13 mg after the first 24 h of reaction.  The 
reaction stirred under argon overnight at room temperature for 2 days.  After evaporation 
of solvent, the product was purified on silica gel (gradient solvent system: 20 – 0 % 
petroleum ether in EtOAc, 5 % methanol in EtOAc) to give 19.1 mg (52.1 %) of a pale-
yellow foam after evaporation.  LRMS (ESI) calcd m/z for C45H48N6O9H(M+H)+ 816.9, 
C45H48N6O9Na (M + Na)+ 839.3, found 817.4, 839.4. 
 
(S)-(2R,3R,4R,5R)-2-(6-Amino-9H-purin-9-yl)-4-hydroxy-5-
(hydroxymethyl)tetrahydrofuran-3-yl 2-amino-3-phenylpropanoate (Phe-A, 4a). 
3a (50 mg) was dissolved in 1 mL of THF and 1 mL trifluoroacetic acid (TFA) 
and reacted overnight with four equiv. of TIPSH.  Upon addition of TFA, the reaction 
turned a bright-orange color and at the completion of the reaction, the color had become a 
dark brown.  The reaction mixture was reduced to dryness by rotary evaporation and 
extracted using 1 mL dichloromethane and 1 mL water twice with a 1 mL water final 
back-extraction against the dichloromethane layer.  The water-soluble layer containing 4a 
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was then HPLC-purified on a C18-prep column using an increasing acetonitrile gradient 
(Gradient 2: 1 – 100 % acetonitrile with water and 0.1 % TFA, 1 % per min) to remove 
any protected material.  Prep. HPLC purified to give 13.6 mg (53.5 %) of a white solid 
after evaporation.  MALDI MS calcd m/z for C19H22N6O5H (M + H)+ 415.4, 
C19H22N6O5Na (M + Na)+ 437.4, found 415.0, 437.0. 
 
2.3.3 – Donor (4b-i) Synthesis 
As described above, the carboxy-terminus of the amino acid (or analog) was 
activated as a cyanomethyl ester using chloroacetonitrile to give 1b-i.  Next, the protected 
amino acid was attached to one of the available hydroxyls (2′ OH or 3′ OH) of DMT-A 
without preference.  The resulting protected adenylate (3b-i) was deprotected using a 
50/50 solvent mixture of trifluoroacetic acid and THF (1 mL) or neat TFA (1 mL) with 
TIPSH present as a scavenger, stirred for 24 h, concentrated under reduced pressure, 
extracted using DCM and water as mentioned in the main text, and HPLC purified.  The 
final product, deprotected adenylate (4b-i), was purified via C18 column purification 
using an HPLC. 
 
(S)-cyanomethyl 2-((tert-butoxycarbonyl)amino)-4-methylpentanoate (Boc-Leu- 
OCH2CN, 1b). 
Chloroacetonitrile (5 mL) and DIPEA (160 mg, 0.21 mL, 1.2 mmol) were added 
to Boc-Leu-OH (252 mg, 1.09 mmol) and stirred for 12 h.  The solvent was removed 
under reduced pressure and SiO2 flash chromatography (20 % ethyl acetate in hexanes) 
afforded 284 mg of a pale yellow oil in 96 % yield.  Rf 0.5 in 20 % ethyl acetate in 
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hexanes; 1H NMR (500 MHz, CDCl3): δ 5.00 (d, J = 7.7 Hz, 1H), 4.80 – 4.65 (m, 2H), 
4.30 – 4.29 (m, 1H), 1.70 – 1.65 (m, 1H), 1.60 – 1.47 (m, 2H), 1.39 (s, 9H), 0.91 – 0.89 
(m, 6H); 13C NMR (125 MHz, CDCl3): δ172.2, 155.5, 114.21, 80.3, 53.2, 52.0, 41.0, 
28.3, 24.8, 22.8, 21.7; HRMS (ESI) m/z calcd for C13H22N2O4Na [M + Na]+ 293.147, 
found 293.151. 
 
(S)-cyanomethyl 3-(4-azidophenyl)-2-((tert-butoxycarbonyl)amino)propanoate (Boc-
Azf-OCH2CN, 1c). 
Chloroacetonitrile (5 mL) and DIPEA (99 mg, 0.13 mL, 0.76 mmol) were added 
to Boc-Azf-OH (212 mg, 0.691 mmol) and stirred for 12 h.  The solvent was removed 
under reduced pressure and SiO2 flash chromatography (30 % ethyl acetate in hexanes) 
afforded 230 mg of a pale yellow oil in 96 % yield.  Rf 0.5 in 30 % ethyl acetate in 
hexanes; 1H NMR (500 MHz, CDCl3): δ 7.13 (d, J = 8.3 Hz, 2H), 6.97 (d, J = 8.4 Hz, 
2H), 5.00 (d, J = 7.7 Hz, 1H), 4.80 – 4.65 (m, 2H), 4.62 – 4.58 (m, 1H), 3.12 – 3.01 (m, 
2H), 1.40 (s, 9H); 13C NMR (125 MHz, CDCl3): δ 170.7, 155.1, 139.4, 132.0, 130.7, 
119.5, 114.0, 80.7, 54.4, 49.0, 37.5, 28.3; HRMS (ESI) m/z calcd for C16H19N5O4Na [M 
+ Na]+ 368.133, found 368.135. 
 
(S)-cyanomethyl 2-((tert-butoxycarbonyl)amino)-3-(naphthalen-2-yl)propanoate 
(Boc-Nap-OCH2CN, 1d). 
Chloroacetonitrile (2.5 mL) and DIPEA (25 mg, 33 µL, 0.19 mmol) were added 
to Boc-NapAla-OH (54.8 mg, 0.174 mmol) and stirred for 12 h.  The solvent was 
54 
 
removed under reduced pressure and SiO2 flash chromatography (30 % ethyl acetate in 
hexanes) afforded 61 mg of a pale yellow solid in 99 % yield.  Rf 0.5 in 30 % ethyl 
acetate in hexanes; 1H NMR (500 MHz, CDCl3): δ 7.83-7.81 (m, 3H), 7.62 (s, 1H), 7.51 
– 7.46 (m, 2H), 7.29 (dd, J = 8.4, 1.5 Hz, 1H), 5.00 (d, J = 7.4 Hz, 1H), 4.79 – 4.64 (m, 
3H), 3.31 (dd, J = 14.1, 5.9 Hz), 3.25 (dd, J = 14.0, 6.5 Hz, 1H), 1.41 (s, 9H); 13C NMR 
(125 MHz, CDCl3): δ 170.9, 155.2, 133.6, 132.8, 132.8, 128.8, 128.3, 127.8, 127.2, 
126.5, 126.2, 114.0, 80.7, 54.5, 49.0, 38.2, 28.4; HRMS (ESI) m/z calcd for 
C20H22N2O4Na [M + Na]+ 377.147, found 377.149. 
 
(S)-cyanomethyl 2-((tert-butoxycarbonyl)(methyl)amino)-3-phenylpropanoate (Boc-
Mef-OCH2CN, 1e). 
Chloroacetonitrile (1.1 mL) and DIPEA (258 mg, 0.341 mL, 1.99 mmol) were 
added to Boc-MePhe-OH (497 mg, 1.78 mmol) in tetrahydrofuran (5 mL) and stirred for 
12 h.  The solvent was removed under reduced pressure and SiO2 flash chromatography 
(20 – 35 % ethyl acetate in hexanes) afforded 505 mg of a pale yellow oil in 89 % yield.  
Rf 0.3 in 20 % ethyl acetate in hexanes; 1H NMR (500 MHz, CDCl3): δ 7.28 – 7.25 (m, 
2H), 7.20 – 7.16 (m, 3H), 4.72 – 4.68 (m, 2H), 4.53 – 4.52 (m, 1H), 3.27 (m, 1H), 3.11 – 
3.02 (m, 1H), 2.67 (d, J = 17 Hz, 3H), 1.36 (d, J = 12 Hz, 9H); 13C NMR (125 MHz, 
CDCl3): δ 169.9, 155.5, 136.8, 128.9, 128.6, 128.4, 126.8, 126.7, 114.2, 80.8, 61.5, 48.7, 
35.4, 33.0, 28.1; HRMS (ESI) m/z calcd for C17H22N2O4Na [M + Na]+ 341.147, found 
341.149. 
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(S)-cyanomethyl 2-acetamido-3-phenylpropanoate (Acf-OCH2CN, 1f). 
Chloroacetonitrile (2 mL) and DIPEA (630 mg, 0.841 mL, 4.87 mmol) were 
added to N-Ac-Phe-OH (501 mg, 2.42 mmol) and stirred for 12 h.  The solvent was 
removed under reduced pressure and SiO2 flash chromatography (50 % ethyl acetate in 
hexanes) afforded (535 mg) of a pale yellow oil in 90 % yield.  Rf 0.2 in 50 % ethyl 
acetate in hexanes; 1H NMR (500 MHz, CDCl3): δ 7.26 (t, J = 7 Hz, 2H), 7.22 (t, J = 2.3 
Hz, 1H), 7.07 (d, J = 7.1 Hz, 2H), 6.02 (d, J = 7.4 Hz, 1H), 4.83 (dd, J = 14.0, 6.5 Hz, 
1H), 4.66 (dd, J = 15.7, 4.7 Hz, 2H), 3.10 – 3.01 (m, 2H), 1.91 (s, 3H); 13C NMR (125 
MHz, CDCl3): δ 170.6, 170.1, 135.2, 129.3, 139.0, 127.7, 114.0, 53.6, 53.2, 49.0, 37.7, 
23.0; HRMS (ESI) m/z calcd for C13H14N2O3Na [M + Na]+ 269.090, found 269.091. 
 
(S)-cyanomethyl 2-azido-3-phenylpropanoate (Boc-N3f-OCH2CN, 1g). 
Chloroacetonitrile (1 mL) and DIPEA (310 mg, 0.411 mL, 2.41 mmol) were 
added to 2-azido-3-phenylpropanoate and stirred for 12 h.  The solvent was removed 
under reduced pressure and SiO2 flash chromatography (40 – 50 % ethyl acetate in 
hexanes) afforded (250 mg) of a white solid in 50 % yield.  Rf 0.5 in 50 % ethyl acetate in 
hexanes; 1H NMR (500 MHz, CDCl3) δ 7.37 (t, J = 7.6 Hz, 2H), 7.32-7.29 (m, 1H), 7.25 
(t, J = 7.6 Hz, 2H), 4.77 (t, J = 1.0 Hz, 1H), 4.18 (dd, J = 6.2, 1.8 Hz, 1H), 3.21 (dd, J = 
14.0, 5.8 Hz, 1H), 3.08 (dd, J = 13.9, 8.4 Hz, 1H); 13C NMR (125 MHz, CDCl3) δ 168.8, 
135.1, 129.3, 129.1, 127.8, 113.7, 62.9, 49.3, 37.7; HRMS (ESI) m/z calcd for 
C11H10N4O2Na [M + Na]+ 253.070, found 253.071. 
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(S)-cyanomethyl 2-((tert-butoxycarbonyl)amino)-3-(7-methoxy-2-oxo-2H-chromen-
4-yl) propanoate (Boc-Mcm-OCH2CN, 1h). 
A solution of 20 % piperidine in tetrahydrofuran (4 mL) was added to Fmoc-
Mcm-OH (200 mg, 0.439 mmol) and was stirred for 15 minutes.  The solvent was 
removed under reduced pressure and ethyl acetate (10 mL) and 2M sodium hydroxide 
was added until pH > 8 followed by addition of Boc anhydride (110 mg, 0.526 mmol) to 
the white residue and stirred overnight.  The organic layer was extracted and washed with 
saturated sodium bicarbonate (2 x 10 mL) and all aqueous fractions were combined and 
acidified with 1 M sodium bisulfate until pH < 2.  The aqueous layer was then extracted 
with ethyl acetate (3 x 10 mL), dried with magnesium sulfate, and concentrated under 
reduced pressure.  Chloroacetonitrile (1 mL) and DIPEA (62 mg, 82 µL, 0.48 mmol) 
were added to the white residue and stirred for 12 h.  The solvent was removed under 
reduced pressure and SiO2 flash chromatography (50 % - 65 % ethyl acetate in hexanes) 
afforded 56 mg of a pale yellow oil in 35 % yield.  Rf 0.4 in 50 % ethyl acetate in 
hexanes; 1H NMR (500 MHz, CDCl3) δ 7.37 (d, J = 8.7 Hz, 1H), 6.90 (dd, J = 8.9, 2.4 
Hz, 1H), 6.85 (d, J = 2.1 Hz, 1H), 6.12 (s, 1H), 5.16 (d, J = 7.7 Hz, 1H), 4.79 (d, J = 4.2 
Hz, 2H), 4.69-4.68 (m, 1H), 3.88 (s, 3H), 3.32 (dd, J = 14.1, 5.2 Hz, 1H), 3.12 (dd, J = 
13.9, 8.4 Hz, 1H), 1.41 (s, 9H); 13C NMR (125 MHz, CDCl3) δ 170.0, 163.2, 160.8, 
155.9, 155.1, 150.5, 125.3, 113.7, 113.3, 113.0, 112.3, 101.6, 81.3, 56.0, 52.8, 49.5, 34.6, 
28.4; HRMS (ESI) m/z calcd for C20H22N2O7Na [M + Na]+ 425.133, found 425.133. 
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(S)-cyanomethyl 3-(4-benzoylphenyl)-2-((tert-butoxycarbonyl)amino)propanoate 
(Boc-Bzf-OCH2CN, 1h). 
Chloroacetonitrile (1 mL) and DIPEA (20 mg, 34 µL, 0.21 mmol) were added to 
Boc-p-benzoylphenylalanine (61 mg, 0.19 mmol).  The reaction was stirred for 18 h, then 
concentrated under reduced pressure.  SiO2 flash chromatography (40 % ethyl acetate in 
hexanes) afforded 70 mg of a pale yellow oil in 93 % yield.  Rf 0.5 in 50 % ethyl acetate 
in hexanes.  1H NMR (500 MHz, CDCl3) δ 7.79 (dd, J = 7.1, 4.9 Hz, 4H), 7.59 (t, J = 7.6 
Hz, 1H), 7.48 (t, J = 7.6 Hz, 2H), 7.29 (d, J = 8.0 Hz, 2H), 5.00 (d, J = 7.4 Hz, 1H), 4.83 
(d, J = 15.7 Hz, 1H), 4.72 – 4.69 (m, 2H), 3.25 (dd, J = 13.7, 5.8 Hz, 1H), 3.16 (dd, J = 
13.1, 6.5 Hz, 1H), 1.43 (s, 9H); 13C NMR (125 MHz, CDCl3) δ 196.4, 170.6, 155.1, 
140.3, 137.6, 136.9, 132.7, 130.8, 130.2, 129.4, 128.5, 113.9; HRMS (ESI) m/z calcd for 
C23H24N2NaO5 [M + Na]+ 431.158, found 431.158. 
 
(S)-(2R,3R,4R,5R)-2-(6-amino-9H-purin-9-yl)-5-((bis(4-methoxyphenyl)(phenyl) 
methoxy)methyl)-4-hydroxytetrahydrofuran-3-yl 2-((tert-butoxycarbonyl)amino)-4- 
methylpentanoate (Boc-Leu-(DMT)-A, 3b). 
Tetrahydrofuran (5 mL) was added to Boc-Leu-OCH2CN 1b (226 mg, 0.837 
mmol), (DMT)-A (120 mg, 0.211 mmol), and TBAAc (15 mg, catalyst) and stirred for 24 
h.  The solvent was removed under reduced pressure and chromatography (80 – 100 % 
ethyl acetate in petroleum ether, 5 % methanol in ethyl acetate), afforded 122 mg of a 
white solid in 74 % yield.  Rf 0.5 in 5 % methanol in ethyl acetate; 1H and 13C NMR for 
3b shown below; LRMS (ESI) m/z calcd for C42H50N6O9Na (M + Na)+ 805.4, found 
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805.3. 
 
 (S)-(2R,3R,4R,5R)-2-(6-amino-9H-purin-9-yl)-5-((bis(4-
methoxyphenyl)(phenyl)methoxy)methyl)-4-hydroxytetrahydrofuran-3-yl 3-(4-
azidophenyl)-2-((tert-butoxycarbonyl)amino)propanoate (Boc-Azf-(DMT)-A, 3c). 
Tetrahydrofuran (5 mL) was added to Boc-Azf-OCH2CN 1c (101 mg, 0.290 
mmol), (DMT)-A (43 mg, 75 µmol), and TBAAc (2 mg, catalyst) and stirred for 24 h.  
Solvent was removed under vacuum and preparative TLC (100 % ethyl acetate), afforded 
44 mg of white solid in 69 % yield.  Rf 0.3 - 0.5 in ethyl acetate; 1H and 13C NMR for 3c 
shown below; LRMS (ESI) m/z calcd for C42H47N9O9Na (M + Na)+ 880.3, found 880.4. 
 
(S)-(2R,3R,4R,5R)-2-(6-amino-9H-purin-9-yl)-5-((bis(4-methoxyphenyl)(phenyl) 
methoxy) methyl)-4-hydroxytetrahydrofuran-3-yl 2-((tert-butoxycarbonyl)amino)-3- 
(naphthalen-2-yl)propanoate (Boc-Nap-(DMT)-A, 3d). 
Tetrahydrofuran (5 mL) was added to Boc-Nap-OCH2CN 1d (58 mg, 0.16 mmol), 
(DMT)-A (26 mg, 46 µmol), and TBAAc (6.4 mg, catalyst) and stirred for 24 h.  The 
solvent was removed under reduced pressure and preparative TLC (5 % methanol in ethyl 
acetate), afforded 36 mg of a white solid in 91 % yield.  Rf 0.3 - 0.5 in 5 % methanol in 
ethyl acetate; 1H and 13C NMR for 3d shown below; LRMS (ESI) m/z calcd for 
C49H50N6O9Na (M + Na)+ 889.9, found 889.4. 
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 (S)-(2R,3R,4R,5R)-2-(6-amino-9H-purin-9-yl)-5-((bis(4-methoxyphenyl)(phenyl) 
methoxy) methyl)-4-hydroxytetrahydrofuran-3-yl 2-((tert-
butoxycarbonyl)(methyl)amino)-3-phenylpropanoate (Boc-Mef-(DMT)-A, 3e). 
Tetrahydrofuran (3.5 mL) and DIPEA (44 mg, 60 µL, 0.35 mmol) were added to 
Boc-Mef-OCH2CN 1e (110 mg, 0.347 mmol), (DMT)-A (50 mg, 89 µmol), and TBAAc 
(3 mg, catalyst) and stirred for 12 h.  The solvent was removed under reduced pressure 
and SiO2 flash chromatography (50 – 100 % ethyl acetate in hexanes), afforded 10 mg of 
a white solid in 14 % yield.  Rf 0.4 - 0.5 in ethyl acetate; 1H and 13C NMR for 3e shown 
below; LRMS (ESI) m/z calcd for C46H50N6NaO9 (M + Na)+ 853.4, found 853.5. 
 
(S)-(2R,3R,4R,5R)-2-(6-amino-9H-purin-9-yl)-5-((bis(4-methoxyphenyl)(phenyl) 
methoxy)methyl)-4-hydroxytetrahydrofuran-3-yl 2-acetamido-3-phenylpropanoate 
(Acf-(DMT)-A, 3f). 
Tetrahydrofuran (5 mL) and DIPEA (250 mg, 0.30 mL, 1.9 mmol) were added to 
Boc-Acf-OCH2CN 1f (400 mg, 1.93 mmol), (DMT)-A (73 mg, 0.13 mmol) and TBAAc 
(5 mg, catalyst) and stirred for 12 h.  The solvent was removed under reduced pressure 
and SiO2 flash chromatography (5 % methanol in ethyl acetate), afforded 75 mg of a clear 
solid that was mix of DMTA and product.  Subsequent HPLC analysis suggests 
approximately 38 % of this mixture was product.  Rf 0.1 - 0.25 % methanol in ethyl 
acetate; 1H and 13C NMR for 3f shown below; LRMS (ESI) m/z calcd for C42H43N6O8 (M 
+ H)+ 759.3 C42H42N6NaO8 (M + Na)+ 781.3, found 759.3, 781.4. 
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(S)-(2R,3R,4R,5R)-2-(6-amino-9H-purin-9-yl)-5-((bis(4-
methoxyphenyl)(phenyl)methoxy)methyl)-4-hydroxytetrahydrofuran-3-yl 2-azido-3-
phenylpropanoate (Boc-N3f-(DMT)-A, 3g). 
Tetrahydrofuran (3.5 mL) and DIPEA (44 mg, 60 µL, 0.35 mmol) were added to 
Boc-N3f-OCH2CN 1g (80 mg, 0.35 mmol), (DMT)-A (50 mg, 89 µmol), and TBAC (3 
mg, catalyst) and stirred for 12 h.  The solvent was removed under reduced pressure and 
purification by silica flash chromatography (75 – 100 % ethyl acetate in hexanes), 
afforded 53 mg of a white solid in 80 % yield.  Rf 0.3 - 0.5 in ethyl acetate; 1H and 13C 
NMR for 3g shown below; LRMS (ESI) m/z calcd for C40H39N8O7 (M + H)+ 743.3, 
C40H39N8O7Na (M + Na)+ 765.3, found 743.4, 765.4; FTIR (Film) vmax 3334, 3179, 
3063, 3032, 2953, 2934, 2837, 2112 (-N3), 1757, 1644, 1606, 1508, 1252, 1177 cm-1. 
 
(S)-(2R,3R,4R,5R)-2-(6-amino-9H-purin-9-yl)-5-((bis(4-methoxyphenyl)(phenyl) 
methoxy) methyl)-4-hydroxytetrahydrofuran-3-yl 2-((tert-butoxycarbonyl)amino)-3-
(7-methoxy-2-oxo-2H-chromen-4-yl)propanoate (Boc-Mcm-(DMT)-A, 3h). 
Tetrahydrofuran (3.5 mL) and DIPEA (44 mg, 60 µl, 0.35 mmol) were added to 
Boc-Mcm-OCH2CN 1h (56 mg, 0.15 mmol), (DMT)-A (50 mg, 89 µmol), and TBAAc (3 
mg, catalyst) and stirred for 12 h.  The solvent was removed under reduced pressure and 
SiO2 flash chromatography (50 – 100 % ethyl acetate in hexanes), afforded 35 mg of a 
white solid in 43 % yield.  Rf 0.3 – 0.4 in ethyl acetate; 1H and 13C NMR for 3h shown 
below; LRMS (ESI) m/z calcd for C49H50N6NaO12 (M + Na)+ 937.3, found 937.4. 
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(S)-(2R,3R,4R,5R)-2-(6-amino-9H-purin-9-yl)-5-((bis(4-
methoxyphenyl)(phenyl)methoxy)methyl)-4-hydroxytetrahydrofuran-3-yl 3-(4-
benzoylphenyl)-2-((tert-butoxycarbonyl)amino)propanoate (Boc-Bzf-(DMT)-A, 3i). 
 THF (3.5 mL) and DIPEA (44 mg, 60 µL, 0.35 mmol) were added to Boc-Bzf-
OCH2CN (70 mg, 0.17 mmol), (DMT)-A (50 mg, 89 µmol) and TBAAc (5 mg, catalyst) 
and stirred for 16 h.  The solvent was removed under reduced pressure and SiO2 flash 
chromatography (75 % – 100 % ethyl acetate in hexanes) afforded 66 mg of a white solid 
in 81 % yield.  Rf 0.3 in 100 % ethyl acetate.  LRMS (ESI) m/z calcd for C52H52N6NaO10 
(M+ Na)+ 943.4, found 943.5. 
 
(S)-(2R,3R,4R,5R)-2-(6-amino-9H-purin-9-yl)-4-hydroxy-5-(hydroxymethyl) 
tetrahydrofuran-3-yl 2-amino-4-methylpentanoate (Leu-A, 4b). 
Trifluoroacetic acid (1 mL), tetrahydrofuran (1 mL) and TIPSH (99 mg, 0.13 mL, 
0.63 mmol) were added to 3b (123 mg, 0.157 mmol) following the general deprotection 
procedure.  HPLC/MALDI analysis m/z calcd C16H25N6O5 (M + H)+ 381.2; Gradient 2; 
retention time 14.9 min, found 381.1; retention time 16.6 min, found 381.1. 
 
(S)-(2R,3R,4R,5R)-2-(6-amino-9H-purin-9-yl)-4-hydroxy-5-(hydroxymethyl) 
tetrahydrofuran-3-yl 2-amino-3-(4-azidophenyl)propanoate (Azf-A, 4c).  
Trifluoroacetic acid (1 mL), tetrahydrofuran (1 mL) and TIPSH (33 mg, 42 µL, 
0.21 mmol) were added to 3c (44 mg, 52 µmol) following the general deprotection 
procedure. HPLC/MALDI analysis m/z calcd C19H22N9O5 (M + H)+ 456.2; Gradient 2; 
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retention time 19.6 min, found 456.1; retention time 21.1 min, found 456.1. 
 
(S)-(2R,3R,4R,5R)-2-(6-amino-9H-purin-9-yl)-4-hydroxy-5-(hydroxymethyl) 
tetrahydrofuran-3-yl 2-amino-3-(naphthalen-2-yl)propanoate (Nap-A, 4d). 
Trifluoroacetic acid (1 mL), tetrahydrofuran (1 mL) and TIPSH (26 mg, 0.34 mL, 
0.17 mmol) were added to 3d (36 mg, 41 µmol) following the general deprotection 
procedure. HPLC/MALDI analysis m/z calcd C23H25N6O5 (M + H)+ 465.2, 
C23H24N6O5Na (M + Na)+ 487.2; Gradient 2; retention time 21.9 min, found 464.6, 486.6; 
retention time 23.4 min, found 464.6, 486.6. 
 
(S)-(2R,3R,4R,5R)-2-(6-amino-9H-purin-9-yl)-4-hydroxy-5-(hydroxymethyl) 
tetrahydrofuran-3-yl 2-(methylamino)-3-phenylpropanoate (Mef-A, 4e). 
 Trifluoroacetic acid (1 mL), tetrahydrofuran (1 mL) and oxalic acid (2.9 mg) were 
added to 3e (31 mg, 37 µmol) following the general deprotection procedure.  No TIPSH 
was used in this reaction.  HPLC/MALDI analysis m/z calcd C20H25N6O5 (M + H)+ 
429.2, C20H24N6O5Na (M + Na)+ 451.2; Gradient 2; retention time 16.3 min, found 429.1; 
retention time 18.6 min, found 429.1, 451.1. 
 
(S)-(2R,3R,4R,5R)-2-(6-amino-9H-purin-9-yl)-4-hydroxy-5-(hydroxymethyl) 
tetrahydrofuran-3-yl 2-acetamido-3-phenylpropanoate (Acf-A, 4f). 
During HPLC analysis, 3f was directly deprotected to 4f by exposure to the 0.1 % 
TFA in the HPLC solvent and confirmed via MALDI.  HPLC/MALDI analysis m/z calcd 
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C21H25N6O6 (M + H)+ 457.2, (M + Na)+ C21H24N6NaO6 479.2; Gradient 2; retention time 
18.2 min, found 457.3, 479.3; retention time 19.5 min, found 457.3, 479.3. 
 
(S)-(2R,3R,4R,5R)-2-(6-amino-9H-purin-9-yl)-4-hydroxy-5-(hydroxymethyl) 
tetrahydrofuran-3-yl 2-azido-3-phenylpropanoate (N3f-A, 4g). 
Trifluoroacetic acid (1 mL) and TIPSH (21 mg, 30 µl, 0.13 mmol) were added to 
3g (25 mg, 33 µmol) following the general deprotection procedure.  HPLC/MALDI 
analysis m/z calcd C19H21N8O5 (M + H)+ 441.2, C19H20N8NaO8 (M + Na)+ 463.1; 
Gradient 2; retention time 24.5 min, found 440.9, 462.9; retention time 24.7 min, found 
440.9, 462.9. 
 
(S)-(2R,3R,4R,5R)-2-(6-amino-9H-purin-9-yl)-4-hydroxy-5-(hydroxymethyl) 
tetrahydrofuran-3-yl 2-amino-3-(7-methoxy-2-oxo-2H-chromen-4-yl)propanoate 
(Mcm-A, 4h). 
Trifluoroacetic acid (1 mL), tetrahydrofuran (1 mL) and oxalic acid (3.9 mg) were 
added to 3e (31 mg, 37 µmol) following the general deprotection procedure, except was 
worked up in water only and water-soluble portion was HPLC purified.  No TIPSH was 
used in this reaction.  HPLC/MALDI analysis m/z calcd C23H25N6O8 (M + H)+ 513.2, 
C23H24N6O8Na (M + Na)+ 535.2; Gradient 2; retention time 19.9 min, found 513.1, 535.1; 
retention time 20.9 min, found 513.1, 535.1. 
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(S)-(2R,3R,4R,5R)-2-(6-amino-9H-purin-9-yl)-4-hydroxy-5-(hydroxymethyl) 
tetrahydrofuran-3-yl 2-amino-3-(4-benzoylphenyl)propanoate (Bzf-A, 4i). 
TFA (1 mL) and TIPSH (40 mg, 50 µL, 0.26 mmol) were added to DMT-A 
benzoylphenylalanine (59 mg, 64 µmol) according the general deprotection procedure.  
HPLC/MALDI analysis m/z calcd C26H27N6O6 (M + H)+ 419.2, C26H26N6NaO6 (M + 
Na)+ 441.2; Gradient 2, retention time 19.7 min found 519.1, 541.1. 
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Figure 2-5.  1H and 13C NMR Characterization of Boc-Leu-(DMT)-A (3b) 
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Figure 2-6.  1H and 13C NMR Characterization of Boc-Azf-(DMT)-A (3c) 
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Figure 2-7.  1H and 13C NMR Characterization of Boc-Nap-(DMT)-A (3d) 
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Figure 2-8.  1H and 13C NMR Characterization of Boc-Mef-(DMT)-A (3e) 
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Figure 2-9.  1H and 13C NMR Characterization of Boc-Acf-(DMT)-A (3f) 
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Figure 2-10.  1H and 13C NMR Characterization of Boc-N3f-(DMT)-A (3g) 
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Figure 2-11.  1H and 13C NMR Characterization of Boc-Mcm-(DMT)-A (3h) 
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Figure 2-12.  1H and 13C NMR Characterization of Boc-Bzf-(DMT)-A (3i) 
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2.3.4 – HPLC Analysis of Donor Deprotection 
Trifluoroacetic acid (1 mL) and TIPSH (10 mg, 13 µl, 65 µmol) were added to 3a 
(10 mg, 13 µmol) and stirred for 12 h.  Solvent was removed under reduced pressure 
followed by precipitation with diethyl ether.  HPLC analysis of the deprotection reaction 
is shown in Figure 2-13.  The assignment of the 2' and 3' acetylated forms of Phe-A is 
based on the known thermodynamic preference for 3' acylation of adenosine.140  The 
HPLC method (Solvents A and B defined in main text) had the following solvent gradient 
(Gradient 3): 0 min 2 % B, 60 min 100 % B, 65 min 1 % B.  Monitored at 215 nm and 
260 nm. 
 
Figure 2-13.  HPLC Analysis of Donor 4a Purity After TFA Deprotection 
 
2.3.5 – HPLC Analysis of Donor Hydrolysis 
 The amino acid analog donor (4a–h) was suspected to be hydrolytically unstable 
and was tested in mock LysAlaAcm reactions without enzyme present and then analyzed 
by HPLC.  The mock LysAlaAcm reactions were performed as described in section 2.3.7; 
however, the AaT solution was replaced with water.  Phe-A solutions were analyzed at 30 
min, 1 h, and 4 h.  Immediately following the reaction, the sample was diluted to 1200 µL 
and injected onto the C18 HPLC column using Gradient 1.  As seen in Figure 2-14, Phe-
A is completely hydrolyzed after 4 h.  Additionally, 1 mM A and 1 mM Phe were 
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injected on the HPLC to serve as standards to verify retention times.  Note: The relative 
concentrations of 2' and 3' Phe-A would be different in an actual reaction where the 3' 
Phe-A is preferentially consumed by AaT in the transfer reaction.43  The change in 2':3' 
ratio between 0 h and 30 min probably reflects the higher pH of the 30 min data.140 
 
Figure 2-14.  HPLC Analysis of Donor 4a Hydrolysis in Mock Transferase Reactions 
Slight differences in retention time were observed, compound identities confirmed by MALDI MS. 
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2.3.6 – Aminoacyl Transferase Expression and Purification 
E. coli AaT was expressed from the pEG6 plasmid in E. coli BL21-Gold (DE3) 
cells using a procedure adapted from Graciet et al (Figure 2-15).50  E. coli were grown in 
a primary culture of 5 mL LB at 37 °C to OD600 of 0.5 and then were rediluted into a 
secondary culture of 500 mL LB and grown to OD600 of 0.6.  AaT expression was 
induced using 0.1 mM isopropyl β-D-thiogalactoside and cells were grown at 25 °C for 
~16 h.  Cells were pelleted at 6,000 RPM using a GS3 rotor and Sorvall RC-5 centrifuge.  
Cell pellets were resuspended in the Ni-NTA binding buffer (50 mM Tris, 10 mM 
imidazole, 300 mM KCl, and 5 mM β-mercaptoethanol, pH 8.0) and included protease 
inhibitor cocktail, 1 mM PMSF, and 10 units/mL DNAse1–Grade II.  Following 
resuspension, the cells were lysed using sonication.  Soluble proteins were collected via 
centrifugation at 13, 200 RPM for 15 min.  Collected soluble protein was gently shaken 
for 1 h at ambient temperature with Ni-NTA resin.  The resin was prepared by rinsing 
with Ni-NTA binding buffer and then washed with four volumes of Ni-NTA wash buffer 
(50 mM Tris, 50 mM imidazole, 300 mM KCl, and 5 mM β-mercaptoethanol, pH 8.0).  
The proteins were eluted with elution buffer (50 mM Tris, 250 mM imidazole, 300 mM 
KCl, and 5 mM β-mercaptoethanol, pH 8.0).  Pure elution fractions of E. coli AaT were 
dialyzed overnight in transferase buffer (50 mM Tris, 30 % glycerol, 120 mM 
(NH4)2SO4, 5 mM β-mercaptoethanol, pH 8.0) at 4 °C.  The dialyzed enzymes were 
stored at – 80°C.  Protein concentrations were determined using the Bradford assay and a 
bovine serum albumin standard curve according to the manufacturer’s instructions.141 
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Figure 2-15.  SDS PAGE Gel Analysis of AaT Expression and Purification 
Lanes (left to right): 1) Molecular weight markers (Masses in kDa: 16, 25, 32, 47, 80, 100, 210); 2) 
Pre-induction; 3) Post-induction; 4) Crude cell lysate; 5) Supernatant after centrifugation; 6) Ni-
NTA column flow-through; 7) Column wash 1; 8) Column wash 3; 9) Elution fraction 1; 10) 
Combined elution fractions 3-5 after overnight dialysis. 
 
2.3.7 – LysAlaAcm Ligation Assay 
Each ligation reaction, 125 µL total volume, contained the following reagents: 
aminoacyl adenosine donor (1 mM), recombinant His10-tagged E. coli aminoacyl 
transferase (2.26 µM), and LysAlaAcm (100 µM) in the AaT Ligation Buffer (50 mM 
HEPES pH 8.0, 150 mM KCl, 10 mM MgCl2).  The reaction mixtures were incubated at 
37 °C for four hours and quenched with 1 % acetic acid.  The proteins were extracted 
from the reactions via acetone precipitation.  The reactions were precipitated using 4X 
reaction volume of acetone and cooled at -20 °C for 1 h.  Next, the reactions were 
centrifuged at 13, 200 rpm at 4 °C for 20 min to separate the reaction from precipitated 
protein.  The supernatant was transferred to fresh 1.5 mL centrifuge tubes and allowed for 
acetone evaporation overnight at room temperature.  After acetone evaporation, the 
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supernatant was dried in a Speedvac (Savant, Thermo Scientific, Fisher Inc.) for 30 min 
to remove residual acetone.  The resulting reaction volume was dissolved up to 1.2 mL 
using Milli-Q water and analyzed by HPLC (gradient below) to determine ligation yield 
by integration of separated peak intensities monitored at 325 nm.  Collected HPLC 
fractions were characterized through MALDI MS analysis.  Reactions were performed 
with 6 trials on at least two protein preparations for all successful reactions, 3 trials for 
failed reactions.  Reactions using Phe-pdCpA as donor were carried out in an identical 
fashion.142 
 
2.3.8 – AaT Ligation Reaction Analysis by HPLC 
All HPLC analyses of LysAlaAcm ligations were monitored as described in the 
main text (Gradient 1).  Peptide retention times monitored at 325 nm (Acm absorption) 
and MALDI MS analyses confirming peptide identity are in Table 2-2. 
 
Table 2-2.  HPLC Analysis of LysAlaAcm Transfer Reactions 
Product Peptide Retention Time (min) 
M+H+ 
Calc’d Obs. 
LysAlaAcm 11.8 375.2 374.9 
PheLysAlaAcm 13.0 522.3 522.1 
LeuLysAlaAcm 12.7 488.3 487.3 
AzfLysAlaAcm 13.6 563.3 (- N2 537.3) 563.3 (- N2 537.3) 
NapLysAlaAcm 14.1 572.3 572.1 
MefLysAlaAcm 13.1 536.3 536.3 
AcfLysAlaAcm NA NA NA 
N3fLysAlaAcm NA NA NA 
McmLysAlaAcm NA NA NA 
BzfLysAlaAcm 14.6 626.3 626.1 
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2.3.9 – A/AMP/ATP/pdCpA Inhibition Studies 
Each ligation reaction was performed as described above. The addition of four 
types of adenosyl compounds (adenosine, AMP, ATP, or pdCpA) were monitored 
individually in ligation reactions with Phe donor 4a.  Adenosyl compound concentrations 
tested were 1 mM, 2.5 mM, and 5 mM HPLC analysis was used to determine inhibition 
of ligation by integration of HPLC reagent and product peaks.  The LysAlaAcm ligation 
assay was used to analyze the kinetics of AaT with substrate 4a.  The ligation assay was 
modified for ease of analysis as follows: the total reaction volume was scaled up to 590 
µL and all reagents were maintained at the same concentrations as mentioned above.  
Five concentrations of 4a were monitored for a total reaction time of 30 min, with 
concentrations ranging from 0.05 to 1 mM.  Each 30 min kinetic experiment was done in 
triplicate with a total of fourteen 40 µL aliquots for all substrate concentrations.  The 
synthesis of pdCpA was carried out essentially as previously described. 
 
2.3.10 – AaT Ligation Reaction Analysis by HPLC 
All HPLC analyses of LysAlaAcm ligations were monitored on an Agilent HPLC 
using a Waters C18 column (Milford, MA).  The solvents used for peptide purification 
were the following: 0.1 % trifluoroacetic acid in water (Solvent A) and 0.1 % 
trifluoroacetic acid in acetonitrile (Solvent B).  The HPLC method had the following 
solvent gradient (Gradient 1): 0 min 1 % B, 5 min 1 % B, 10 min 30 % B, 15 min 40 % 
B, 20 min 100 % B, 25 min 100 % B, 27 min 1 % B, 30 min 1 % B.  Peptides were 
monitored at two absorption wavelengths during HPLC analysis, 215 nm for peptide 
absorption, and 325 nm for Acm absorption.  MALDI MS analyses confirmed identity of 
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peptide, Xaa-A donor, and ligated products. 
 
2.3.11 – Fluorometric Analysis of Transferase Experiments 
Real time fluorescent monitoring of Nap addition to LysAlaAcm was carried out 
using reaction solutions prepared on the 500 µL scale in stirred quartz cuvettes with 1.00 
cm path lengths.  Reagent concentrations were as described above, except that donor 4d 
was withheld until the cuvette was placed in the fluorometer and temperature 
equilibrated.  Reactions were then initiated by addition of 20 µL of 25 mM Nap-A (4d) 
stock or water (for negative controls).  Fluorescence emission at 390 nm was monitored 
after excitation at 325 nm.  Prior calibration had shown that NapLysAlaAcm (5d) 
concentrations could be estimated from fluorescence intensity readings (F5d) using the 
equation [5d] = (1 – (F5d/ FControl))1.39[LysAlaAcm], where FControl is the fluorescence 
reading of the reaction with water added instead of 4d.  Measurements were taken on the 
Cary Eclipse fluorometer in the “Kinetics” mode at 37 °C, acquiring data every 15 s.  The 
excitation and emission slit widths were 5 nm and the averaging time was 1 s. 
 
2.3.12 – Calibration of NapLysAlaAcm Fluorometric Transfer Analysis 
In order to monitor conversion of LysAlaAcm to NapLysAlaAcm (5d) in real 
time, we designed a fluorometric assay based on intramolecular quenching of 
aminocoumarin fluorescence by the naphthyl ring.  Equimolar solutions of LysAlaAcm 
and NapLysAlaAcm, as well as mixtures of the two solutions, were prepared and their 
fluorescence compared (Figure 2-16A).  The fluorescence emission of NapLysAlaAcm at 
390 nm (λex = 325 nm) was 72 % lower than LysAlaAcm, and no non-linear effects were 
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exhibited in the mixtures (Figure 2-16B).  Therefore, the mole fraction of 
NapLysAlaAcm could be linearly related to the measured fluorescence of a reaction 
solution (F5d), and the concentration of 5d determined as (1 - 
(F5d/FControl))•1.39•[LysAlaAcm], where FControl is the fluorescence reading of the reaction 
with water added instead of donor 4d.  This calibration was used to determine the time-
dependent concentration of the NapLysAlaAcm product as described in the main text. 
 
Figure 2-16.  Fluorescence Emission of NapLysAlaAcm Solutions 
(A) Fluorescence emission of mixtures of LysAlaAcm and NapLysAlaAcm (5d); χ5d = 0.00 (red), 
0.10 (orange), 0.20 (light green), 0.25 (green), 0.33 (light blue), 0.50 (blue), 1.00 (purple)(B) 
Linear fit of normalized fluorescence vs. mole fraction NapLysAlaAcm (y = 1 – 0.72x, R = 0.999) 
 
2.3.13 – Michaelis-Menten Kinetic Analysis of Phe Transfer 
The reaction scheme for the catalysis of N-terminal aminoacylation by AaT is 
shown in Equation S1.  Previously, it has been shown that the sequential bisubstrate AaT 
reaction can be treated as pseudo-first order when carried out with saturating 
concentrations of one substrate (acceptor peptide).64  Therefore, we characterized the 
reaction in terms of the Michaelis-Menten kinetic scheme in Equation S2. 
81 
 
 
To determine initial velocities, we fit the primary kinetic data to the hyperbolic Equation 
S3, which, though phenomenological, produces a high quality fit (R > 0.99 for all 5 data 
sets).  Data from the first two minutes were fit to a linear expression (Eqn. S4).  We 
employ a non-zero intercept for improved quality of fit; this can be justified in terms of a 
rapid burst phase not captured in the 1 min resolution of this assay.  Note that this burst 
phase seems to be extremely rapid, even the 15 s intervals of our direct fluorometric 
assay are not sufficient to capture this phase (See Figure 3-3A).  The results of these 
linear fits are shown in Figure 2-17. 
 
The initial velocities were then plotted as a function of Phe-A donor concentration and fit 
to Equation S5 to obtain kcat and KM values, where KM = (k-1 + kcat)/k1 (See Figure 3-3B). 
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Figure 2-17.  Phe Transfer Reaction Kinetics 
Product concentration as a function of time determined by integration of HPLC traces.  Data are 
an average of 3 trials.  Bars indicate standard error.  Black lines indicate best fit to early 
timepoints using Eqn. S4.  Bottom Right: Fits to kinetic data according to Eqn. S4. 
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2.3.14 – α-Casein N-Terminal Modification 
α-Casein (4.8 mg) was modified with Azf-A (4c) in a reaction volume of 1 mL in 
modified AaT buffer (50 mM HEPES pH 8.0, 150 mM KCl, 10 mM MgCl2) and AaT 
(0.05 mg).  The reaction mixture was incubated at 37 °C for 12 h, AaT was removed 
using Ni2+ resin (Ni-NTA Superflow, Qiagen), and then buffer exchanged four times into 
phosphate buffered saline (PBS, 12 mM NaH2PO4, 50 mM NaCl, 4.7 mM KCl, pH 8.0) 
by Spectra/Por 1 dialysis tubing (Spectrum Laboratories; Rancho Dominguez, CA).  Azf-
modified α-casein was used directly after buffer exchange into PBS.  Aliquots (1 nmol) 
of α-casein were diluted into PBS (22 µL) containing either fluorescein-alkyne (FlAlk, 91 
µM) or propargylamine (Alk, 227 µM) for copper-catalyzed azide-alkyne cycloaddition 
(CuAAC).  The CuAAC reaction was initiated by addition of CuSO4 (100 µM), tris-(3-
hydroxypropyltriazolylmethyl) amine (THPTA, 500 µM), and sodium ascorbate (5 mM).  
For control reactions, equivalent volumes were replaced with either PBS or water.  The 
reaction mixtures were incubated at 4 °C for 2 h.  Reactions were boiled with gel loading 
dye LDS (Pierce; Rockford, IL) for 10 min at 95 °C and analyzed by SDS-PAGE.  
Fluorescence images were obtained with a Geldoc (BioRAD; Hercules, CA) using an 
excitation wavelength of 302 nm for detection of fluorescein.  α-Casein was also directly 
visualized by Coomassie Brilliant Blue staining.  Section 2.3.14 was performed by John 
Warner. 
 
2.3.15 - Edman Degradation Analysis of α-Casein Modification 
Phe was ligated to α-casein using 4a as described in the main text with the 
following modifications.  The substrate (1 mM) was 10 times more concentrated, and the 
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total volume was 4 times greater.  This reaction was run overnight; at the 4 h timepoint, 
an additional 50 µL dose of 25 mM 4a donor was added to the reaction.  The His10-
tagged AaT was separated from the reaction via nickel bead purification: 100 µL Ni-NTA 
resin was added at a ratio of 25 µL per 12.5 µM AaT, the beads were shaken with the 
reaction for 2 hours, then separated via centrifugation at 13, 200 RPM for 2 min.  The 
supernatant was removed, diluted to 1 mL with Milli-Q water, and dialyzed against 1X 
PBS (Hyclone, Fisher) overnight at 4 °C to remove any residual 4a.  The protein was 
electroblotted onto PVDF membrane and sent to Johns Hopkins University Synthesis and 
Sequencing Facility (Baltimore, MD) for Edman Degradation analysis (Figure 2-18). 
 
Figure 2-18.  Edman Degradation Analysis of α-Casein Modification 
Top: Unmodified α-casein.  R peak area is 196 counts of total, F peak area is 44 counts.  Bottom: 
Phe-modified α-casein.  F peak area is 97 counts.  R peak area is 53 counts. 
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2.3.16 – Tryptic Digest Analysis of α-Casein Modification 
α-Casein-Azf (33 µg), or α-casein (33 µg), was digested with sequencing grade 
modified Trypsin (0.6 µg) in 27 µL of 25 mM ammonium bicarbonate pH 7.5 (freshly 
prepared).  Digestions were carried out at 37 °C for 14 h.  Trypsin digest aliquots (1 µL) 
were combined with α-cyano-4-hydroxycinnamic acid (1 µL of a saturated solution in 1:1 
H2O/CH3CN with 1 % TFA) and analyzed by MALDI MS.  Section 2.3.16 was 
performed by John Warner. 
 
2.3.17 – α-Casein Labeling in Cleared Cell Lysate 
AaT was expressed in E. coli BL21-Gold (DE3) cells as previously described.  A 
cleared cell lysate was obtained by centrifugation following cell lysis using sonication.  
Proteins were modified in a final reaction volume of 110 µL with Azf-A (4c, 3 mM) 
using AaT (25 µL) from cleared lysate in AaT buffer (50mM HEPES pH 8.0, 150mM 
KCl, 10mM MgCl2).  α-Casein (0.012 mg or 0.12 mg) was added to the reaction and 
incubated at 37 °C for 2 h, after 1 h, an additional 0.3 µmole of 4c was added.  For 
control reactions, equivalent volumes were replaced with water.  Excess 4c was removed 
by buffer exchange four times against phosphate buffered saline (PBS, 12mM NaH2PO4, 
50mM NaCl, 4.7mM KCl, pH 8.0) by Spectra/Por 1 dialysis tubing.  Aliquots (18 µL) of 
4c modified lysates were diluted to a final volume of 22 µL using PBS containing FlAlk 
(182 µM) for copper catalyzed “click” reactions.  The “click” reaction was initiated by 
addition of CuSO4 (100 µM), THPTA (500 µM), and sodium ascorbate (5 mM).  The 
reaction mixtures analyzed by PAGE gel using Coomassie staining and fluorescence as 
above (Figure 2-19).  Section 2.3.17 was performed by John Warner. 
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Figure 2-19.  SDS PAGE Gel Analysis of α-Casein Modification in Cleared E. coli lysate 
Left: Coomassie stained gel.  Right: Fluorescence image from 302 nm excitation.  Lanes (left to 
right): 1) Molecular weight markers (Masses in kDa: 17, 25, 30, 46, 58, 80, 175); 2) Cleared 
lysate reacted with FlAlk; 3) Cleared lysate modified with 4c then reacted with FlAlk; 4) Cleared 
lysate with α-casein (0.012 mg) modified with 4c then reacted with FlAlk; 5) Cleared lysate with α-
casein (0.12 mg) modified with 4c then reacted with FlAlk; 6) Molecular weight markers. 
 
2.3.18 –  “Click” Reagent Synthesis 
Fluorescein 5- and 6-proparglyamide (Fluorescein-alkyne, FlAlk) was synthesized 
as previously described (Figure 2-20).134  Briefly, propargylamine (8.7 µL, 136 µmol) 
was added to a solution of 5- and 6-Carboxyfluorescein N-hydroxysuccinimide ester (32 
mg, 68 µmol) in tetrahydrofuran (5 mL).  The reaction was stirred continuously and 
monitored by TLC.  Solvent was removed by under reduced pressure.  Purification by 
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silica chromatography (Rf = 0.3, 20 % MeOH in CH2Cl2) afforded fluorescein-alkyne as 
a red-orange solid.  Tris-(3-hydroxypropyltriazolylmethyl)amine (THPTA) was also 
synthesized as previously described (Figure 2-20).143  Briefly, to a solution of 3-bromo-
propanol (2 g, 14.4 mmol) in dichloromethane (10 mL) was added Ac2O (2.94 g, 28.8 
mmol) and NEt3 (2.91 g, 28.8 mmol).  The reaction was stirred continuously and 
monitored by TLC.  An aqueous solution of NaHCO3 was added and the phases were 
separated.  The organic layer was washed once more with NaHCO3 and twice with brine.  
Solvent was removed under reduced pressure and 3-bromopropyl acetate was afforded as 
a colorless oil.  To a solution of 3-bromopropyl acetate (1.0 g, 6.0 mmol) in water (10 
mL) was added sodium azide (780 mg, 12.1 mmol).  The solution was stirred at 90 °C 
overnight.  The solution was extracted three times with 15 mL CH2Cl2 and dried with 
MgSO4.  Solvent was removed under reduced pressure to afford 3-azidopropyl acetate as 
a pale yellow oil.  To a solution of tripropargylamine (12.3 mg, 0.941 mmol) in 
tetrahydrofuran (6.5 mL) was added 3-azidopropyl acetate (0.672 g, 4.71 mmol) and 
Cu(I) acetate (5.8 mg, 5 mol %).  The solution was refluxed overnight under inert 
atmosphere.  Solvent was removed under reduced pressure.  Silica chromatography 
purification (Rf = 0.5, 5-10 % MeOH in CH2Cl2) afforded acetyl-protected THPTA as a 
yellow oil.  A solution of acetyl-protected THPTA (397 mg, 0.711 mmol) in 2.0 M 
ammonia in MeOH (10 mL) was continuously stirred overnight at 40 °C.  Solvent was 
removed under reduced pressure.  The solid was washed and filtered four times with 
acetonitrile and dried under reduced pressure to afford THPTA as a white solid.  For both 
FlAlk (25 % overall yield) and THPTA (98 % overall yield), intermediate and product 
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identities were confirmed by comparison of 1H NMR and LRMS (ESI) MS data to 
previous reports.134, 143  Section 2.3.18 was performed by John Warner. 
 
Figure 2-20.  Click Chemistry Reagents 
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CHAPTER 3 
 
NATIVE CHEMICAL LIGATIONS IN PEPTIDES AND PROTEINS USING 
PROTECTED DISULFIDE AMINOACYL TRANSFERASE ANALOGS 
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Reprinted (adapted) with permission from (Tomohiro Tanaka, Anne M. Wagner, John B. 
Warner, Yanxin J. Wang, E. James Petersson. Angew. Chem. Int. Ed. 2013, 125, 6330–
6333.).  Copyright (2013).  John Wiley and Sons. 
 
Section 3.1 - Introduction 
Protein engineering is an expansive field that has a wide-ranging definition from 
designing and creating new proteins to altering proteins to have a desired function.16  
Despite the breadth of the field, there is an overarching goal to analyze and understand 
protein structure and function.  One recent method has revolutionized the field of protein 
synthesis, native chemical ligation (NCL).  NCL component groups include a C-terminal 
peptidyl thioester and a N-terminal cysteine peptide that react to form an amide bond 
while retaining the cysteine residue at the ligation site.9  In order to minimize the need for 
peptide synthesis, the NCL reaction can be used with expressed protein fragments and is 
termed expressed protein ligation (EPL).144  The EPL reaction can be implemented in two 
methods that vary in the degree of chemical synthesis required.  One method expresses an 
N-terminal cysteine protein fragment in E. coli cells and utilizes chemical synthesis to 
create a small thioester-bearing peptide for the ligation reaction.  Another method, 
pioneered by Muir, expresses both protein fragment domains: an N-terminal cysteine-
bearing protein fragment and a fused intein at the C-terminus.  Under reducing 
conditions, the intein can be self-excised and form a C-terminal thioester in situ.  Both 
methods, NCL and EPL, have helped to make protein synthesis an efficient process. 
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The major limitation to NCL and EPL is the need of a cysteine at the ligation site.  
Since cysteine is coded by only two codons, it will be theoretically underrepresented in 
proteins at a random occurrence of 3.3 % composition in proteins.145  The percent 
composition of cysteine in proteins is actually lower than the random value, depending on 
species, 2.3 % in mammals and 0.5 % in some archeabacteria.145  One way to bypass the 
constraint of low cysteine abundance in proteins is amino acid mutagenesis.  However, 
mutagenesis to a cysteine can be disruptive to protein structure and activity.  Therefore, 
several groups have developed methods to erase or mask the ligation site to a different 
residue.  Several methods include alkylation of cysteine to form an amino acid analog or 
desulfurization of cysteine to form alanine.146-148  Other strategies, such as one developed 
by Danishefsky, desulfurize synthetic cysteine analogs to a variety of other amino acids 
such as valine and lysine.149-155  Post-ligation reactions, demonstrated by Dawson and 
Muir, utilize nitrobenzyl cysteine surrogates at ligations, which can be removed via 
photolysis.156-157  Other ligations methods create cysteine-less sites such as “traceless” 
Staudinger ligations and Bode’s ketoacid/alkoxyamine ligation.30, 158-159  Additionally, 
homocysteine (Hcs) can be used as a cysteine surrogate for ligation and then converted to 
methionine by selective methylation.160-163  All of the aforementioned strategies to mask 
the ligation site have one common link, the requirement of at least one synthetically 
incorporated reactive ligation group. 
We have developed and demonstrated a method that utilizes an enzyme, 
aminoacyl transferase (AaT) from E. coli, to specifically functionalize the N-termini of 
peptides and proteins with a wide variety of natural and unnatural residues.  Recently we 
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have developed aminoacyl donors that can transfer ligation handles such as Hcs, which 
were not previously accessible in expressed proteins.  The natural function of AaT is to 
transfer phenylalanine, leucine, and at a lesser efficiency, methionine from an aminoacyl 
tRNA (Xaa-tRNA) to the N-terminus of a protein.40, 123  In previous work, we have 
successfully demonstrated that AaT can transfer amino acids with large phenylalanine-
like side chains such as benzoylphenylalanine and naphthylalanine.66  We applied a 
similar strategy to a variety of methionine-like analogs and determined their efficiency as 
AaT substrates to be used to functionalize proteins with erasable Cys analogs for ligation.  
The applicability of AaT transfer is far reaching since it recognizes N-terminal Arg and 
Lys residues without influence by adjacent amino acids; both arginine and lysine are 
significantly more abundant than cysteine at 5.5 % and 6.4 %, respectively.40, 127, 145  We 
have demonstrated that AaT can transfer disulfide-protected Hcs and Cys to the N-
terminus of a protein via amide bond formation and in conditions that maintain protein 
stability and functionality.  Additionally, following reduction and ligation, Hcs can be 
effectively and selectively masked to become Met by alkylation (Figure 3-1).  We have 
validated the utility of this approach in two ways: by synthesizing α-synuclein (αS), a 
protein whose aggregation contributes to Parkinson’s disease pathology, and through a 
multi-step semi-synthesis of the well-characterized calcium-binding protein calmodulin 
(CaM), to demonstrate the ability to selectively incorporate an unnatural site in the 
middle of a protein while retaining the original primary sequence in the rest of a Cys-less 
protein.164-165  This N-terminal modification technique will expand the utility of current 
NCL methods. 
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Figure 3-1.  Expressed Protein Ligation at Methionine 
An expressed protein bearing an N-terminal Arg or Lys (green) is functionalized with a protected 
Hcs analog from an aminoacyl adenosine donor, under catalysis by AaT transferase.  A synthetic 
peptide thioester (red) is ligated to the modified protein under reducing conditions that allow 
deprotection of Hcs.  After ligation, Hcs is converted to Met via methylation. 
 
Section 3.2 - Results and Discussion 
Methionine is the only sulfur-containing amino acid that is naturally transferred 
by AaT in E. coli.  Although methionine is not a substrate for NCL, Hcs and other thiol-
or selenol-containing Cys analogs can be used in ligation .  Therefore, we investigated the 
possibilities of AaT ligation of Hcs and Cys (as a test for various Cys analogs such as 
selenocysteine) in the form of adenosyl analogs, which bypass the restrictive selectivity 
of an aminoacyl synthetase.  Previous studies had shown that Cys-tRNA is not a substrate 
for AaT and our own preliminary experiments showed that Hcs was not transferred (data 
not shown).58, 127 Therefore, we prepared Hcs analogs masked as aliphatic or aromatic 
disulfides in order to mimic the endogenous AaT substrates: Met, Leu, and Phe.  
Disulfide protecting groups (MeS, i-PrS, t-BuS, PhS, and CF3CH2S) were used so that 
they could be removed in situ under the reducing conditions of the subsequent NCL 
reaction. 
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3.2.1 - Disulfide Aminoacyl Adenosyl Donor Synthesis. 
All of the aminoacyl donors for AaT were created using a similar synthetic 
protocol.  For the synthesis of S-protected 3'-adenosyl homocysteine, the reaction 
sequence began with Boc-protection of the exposed amino groups of homocystine to 
form homodisulfide 1.  The second step involved disulfide exchange with a thiol 
containing the desired aliphatic or aromatic protecting group to form heterodisulfides 2a-
e.  Next, the carboxylic acid group was activated in the form of a cyanomethyl ester (3a-
e).  In the following step, the activated carbonyl will allow for nucelophilic attack of the 
2' or 3' hydroxyls of 5'-O-dimethoxytrityladenosine (DMT-A) to form protected 
aminoacyl adenosines 4a-e.  The last step of the synthetic route was deprotection of all 
protecting groups (Boc and DMT) with 50 % trifluoroacetic acid and 50 % 
tetrahydrofuran yielding the aminoacyl adenosyl analogs 5a-e, denoted Xaa-A (Scheme 
3-1).  Overall yields of products 4a-e from homocystine were ~ 40 %.  To ensure high 
purity of final product and removal of deprotection side products, the final step was 
purified by HPLC.  The syntheses of Cys analogs were carried out in a similar fashion 
(Scheme 3-2). 
 
95 
 
 
Scheme 3-1.  Synthesis of Homocysteine (Hcs) Analogs 
All homocysteine (Hcs) analogs began with the starting material homocystine, (Hcs)2.  The R-
groups for each letter is as follows: 2a-5a R = methyl, 2b-5b R = isopropyl, 2c-5c R = tertbutyl, 
2d-5d R = phenyl, and 2e-5e R = trifluoroethyl.  Reactions and conditions for step (A) 2.5 
equivalents of (Boc)2O, 4 equivalents of NaOH, 50/50 dioxane/water, (B) excess RSH (R = 
protecting group), I2, 50/50 THF/water, (C) 1.1 equivalents of DIPEA, ClCH2CN, (D) 2 – 4 
equivalents of cyanomethylester, 1 equivalent of DMT-A, catalytic equivalent of TBAC, THF, (E) 4 
equivalents TIPSH, 50/50 TFA/THF.  Yields can be found in section 3.3 Supplementary Materials 
and Methods.  Boc = tert-butyloxycarbonyl, DIPEA = N-diisopropylethylamine, THF = 
tetrahydrofuran, (DMT)-A = 5′-O-dimethoxytrityl adenosine, NBu4Ac = N,N,N,N-
tetrabutylammonium acetate, TFA = trifluoroacetic acid, TIPSH = triisopropylsilane. 
 
 
H2N
S
S
H2N
OH
O
OH
O
(Hcs)2                                                1                                                   2 a-e
N
H
S
S
H2N
OH
O
OH
O
Boc N
H
S
S
R
OH
O
Boc
N
H
S
S
R
O
O
Boc
N
N
N
N
NH2
N
O
OHO
ODMT
O
N
H
S
S
R
Boc
TFA
N
N
N
NH2
N
O
OHO
HO
O
H2N
S
S
R
Xaa-A
(Boc)2O RSH
ClCH2CN
A                                                       B
(DMT)-A
 5 a-e                                              4 a-e
C
3 a-e
DE
96 
 
 
Scheme 3-2.  Synthesis of Cysteine (Cys) Analogs 
All Reagents and conditions: a) NaSMe, I2, 1:1 H2O/THF, 0 °C; b) ClCH2CN, DIPEA, THF; c) 
(DMT)-A, NBu4Ac, THF; d) TFA, TIPSH, THF.  The R-groups for each letter is as follows: 7a-10a 
R = methyl, 7b-10b R = isopropyl, 7c-10c R = tertbutyl, 7d-10d R = phenyl, and 7e-10e R = 
trifluoroethyl.  Reactions and conditions for step (A) excess RSH (R = protecting group), I2, 50/50 
THF/water, (B) 1.1 equivalents of DIPEA, ClCH2CN, (C) 2 – 4 equivalents of cyanomethylester, 1 
equivalent of DMT-A, catalytic equivalent of TBAC, THF, (D) 4 equivalents TIPSH, 50/50 
TFA/THF.  Yields can be found in section 3.3 Supplementary Materials and Methods.  Some 
analogs were commercially-bought as the Boc-protected amino acid, including Cys-S-t-butyl 
(Csb) and Cys-benzyl (Cbz).  All cysteine disulfide cyanomethylesters were synthesized by Dr. 
Tomohiro Tanaka except for Csb and Cbz, which were synthesized by Anne Wagner and Jose 
Villegas.  The rest of the synthetic pathway was completed by Anne Wagner. 
 
3.2.2 - LysAlaAcm Model Ligations with Disulfide Analogs 
 As in Chapter 2, we used LysAlaAcm as a model peptide to test the feasibility of 
disulfide analogs as aminoacyl-tRNA substrate mimics for AaT.  All reactions were kept 
standardized, as discussed in Chapter 2, with one additional change: all reactions had a 
total of 4 doses of 1 mM Xaa-A added at t = 0 h, 1h, 2h, and 3 h time-points of the 4 h 
reaction.  This change significantly enhanced ligation efficiency by making more analog 
available throughout the 4 h reaction to compete against analog hydrolysis.  We 
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compared yields of XaaLysAlaAcm by HPLC analysis after four hour reactions at pH 8.0 
at 37 °C (Figure 3-2).  Under these conditions, transfer of Phe is quantitative and Met 
proceeds in 75 % yield.  Once we determined that AaT could transfer sulfur-containing 
amino acids, we tested a methionine isostere, Cys-S-methyl (Csm), and it produced a 
ligation efficiency of 21 %.  While this was lower than Met, it established that we could 
transfer disulfide-protected analogs without substantial sidereactions.  Hcs donors (5a-e) 
and Cys donors (10a-10e) were tested in a similar fashion (Schemes 3-1 and 3-2).  For 
homocysteine analogs, the bulk of the protecting group was a significant factor in transfer 
efficiency: Hcm was transferred most efficiently from 5a, with somewhat lower yields 
for Hcp and Hcb.  Of the cysteine disulfide analogs, Csp had the highest transfer 
efficiency: Csp (10b) > Csb (10c) > Csm (10a).  All of the aromatic protecting groups 
(5d and 10d) prevented the ligation of their respective amino acid to LysAlaAcm, 
including Cbz, which was not a disulfide, indicating that issues with residue steric bulk, 
not reactivity of the aryl-S bond.  In order to probe active site pocket polarity, ligation 
with a trifluoroethyl protecting group (5e and 10e) was attempted without success for 
either homocysteine or cysteine disulfide analogs. 
To ensure maintenance of the disulfide-protected analogs during the transfer 
reaction, we eliminated β-mercaptoethanol (BME) from the AaT purification process and 
reaction buffer (Figure 3-3).  This small change increased the yields of HcmLysAlaAcm 
from 21 % to 37 % and CspLysAlaAcm from 64 % to 68 %.  Once Hcm was identified as 
the optimal homocysteine substrate, we assessed the possibility of generating Hcm-tRNA 
in situ using a synthetase.  Free Hcm was synthesized by TFA deprotection of Boc-Hcm.  
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Wild type E. coli MetRS and an L13G mutant (Met*RS) previously used by the Tirrell 
group were tested with Hcm, ATP, and E. coli total tRNA.166  Met*RS was more active 
than MetRS, giving full transfer at ≤ 0.1 mg/mL loading.  This is consistent with Met*RS 
structural analysis, where longer sidechains are accommodated by the expanded active 
site.166 
 
Figure 3-2.  (A) Schematic Representation of Model LysAlaAcm Peptide N-Terminal 
Ligation Reaction Using AaT.  (B) Molecular Structures of All Sulfur-Based Analogs Tested 
with AaT 
Listed below each amino acid is its percent ligation efficiency, (a) reaction in the presence of 5 
mM beta-mercaptoethanol, (b) reaction with no beta-mercaptoethanol, and (c) reaction using 
methionine L13G synthetase, free-amino acid, tRNA, and AaT.  NR = no reaction. 
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Figure 3-3.  Hcm Ligation Increased Efficiency 
(A) LysAlaAcm starting material, (B) Hcm ligation in presence of 5 mM BME using Hcm-A and 
AaT, (C) Hcm transfer using MetRS L13G mutant synthetase (Met*RS), tRNA ATP and AaT 
 
3.2.3 – Hcm/Csp and Native Chemical Ligation 
Our next step in analyzing our analogs’ applicability to semi-synthetic techniques 
was to test their efficiency in NCL reactions (Figures 3-4a, 3-4b).  First, we analyzed the 
Csp analog, which was most efficiently transferred onto our model peptide, LysAlaAcm.  
We ligated CspLysAlaAcm (12) with Ac-MetAspValPhe-SR (11), which is the four 
amino acid starting sequence of αS, and formed the NCL product (13) over a 24 h 
reaction in 100 % yield (Figure 3-5a).  We then took HcmLysAlaAcm (14) on to a model 
ligation reaction with Ac-MetAspValPhe-SR (11).  HPLC and MALDI MS analyses 
showed that disulfide cleavage was completed almost immediately and that the 
subsequent ligation reached 100 % completion after 24 h (Figure 3-5b).  After ligation, 
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the product peptide (15) was treated with 1000 equiv. MeI at pH 8.6 to form 16.  After 5 
min, 89 % conversion of Hcs5 to Met5 was observed by HPLC and MALDI MS analyses 
(See Materials and Methods).  Unreacted 15 (11 %) could be removed after disulfide 
formation.  Oxidation of Met1, was observed (4 %), but no undesired alkylation of Met or 
Lys was seen.  This is consistent with previous uses of Hcs as a ligation handle, where 
subsequent alkylation is surprisingly selective, given that the pKa of Hcs (8.9) is close to 
the pKa of Lys (9.5).167 
 
Figure 3-4a. Peptide Native Chemical Ligation and Masking Proof-of-Principle for Csp 
Compound 11 is the C-terminal thioesterified first four amino acid sequence of α-synuclein.  
Compound 12 is Csp ligated to LysAlaAcm via AaT.  Compound 13 is the NCL product.  Reaction 
Conditions: (A) 1.0 mM (12), 3.3 mM (11), 100 mM sodium phosphate dibasic, 20 mM TCEP, 0.5 
% thiophenol, 0.5 % benzylmercaptan, pH 7.2 at room temperature for 24 h, 100 % yield for 13.  
The formed amide bond is highlighted in a yellow box.  The resulting deprotected disulfide is 
highlighted in pink (Cys). 
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Figure 3-4b.  Peptide Native Chemical Ligation and Masking Proof of Principle for Hcm 
Compound 11 is the C-terminal thioesterified first four amino acid sequence of α-synuclein.  
Compound 14 is Hcm ligated to LysAlaAcm via AaT.  Compound 15 is the native chemical 
ligation product with Hcm deprotected to Hcs.  Compound 16 is the methylated masked final 
product, creating a traceless ligation site at the second methionine.  Reaction Conditions: (A) 1.0 
mM 13, 3.3 mM 11, 100 mM sodium phosphate dibasic, 20 mM TCEP, 0.5 % thiophenol, 0.5 % 
benzylmercaptan, pH 7.2 at room temperature for 24 h, 100 % yield for 15; (B) 50 mM MeI, 100 
mM sodium bicarbonate, pH 8.6 at room temperature for 5 min, 89 % yield for 16.  The formed 
amide bond is highlighted in a yellow box.  The resulting deprotected disulfide is highlighted in 
blue (Hcs).  The Hcs is selectively methylated, highlighted in the green box. 
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Figure 3-5a.  HPLC Analysis of Peptide Ligation Reactions with Csp 
(A) N-terminal Csp peptide 12 formation reaction; (B) C-terminal thioester peptide (11) NCL 
reaction with 12 after 24 h, forming product 13. 
 
 
Figure 3-5b.  HPLC Analysis of Peptide Ligation Reactions with Hcm 
(A) N-terminal Hcm peptide 14; (B) C-terminal thioester peptide 11; (C) Ligation reaction after 1 h; 
(D) Purified ligation product 15; (E) Methylation of 15 to form methionine in peptide 16.  (15)2 is a 
disulfide between the Hcs thiol of two 15 product peptides.  Peak areas indicated by red, green, 
and blue shading were integrated in Kaleidagraph to obtain methylation yields. 
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After successful completion of the model peptide ligation, we wished to test the 
Hcm transfer/ligation strategy with a full-sized protein.  One protein that we have 
previously studied, which has the requisite MetLys motif, is αS.  Several recent studies 
have shown that the N-terminal sequence of αS can have important consequences for its 
folding and self-association.168-172  However, these studies profoundly disagree on what 
those consequences are.  Therefore, the preparation of N-terminally-modified αS could be 
useful to addressing these questions and serve as a valuable demonstration of our method. 
We chose Met5Lys6 as the point of disconnection and prepared an αS6-140 plasmid 
with an N-terminal His10 tag and a Factor Xa proteolysis site.  The precursor protein, 
HisTag-αS6-140 (17), was isolated by Ni-affinity chromatography and cleaved with Factor 
Xa to yield αS6-140 (18).  We incubated 18 with AaT, Met*RS, tRNA, Hcm, and ATP.  
Transfer of Hcm was complete after 1 h, within the limits of quantitation by MALDI MS 
(Figure 3-6).  Complete transfer is extremely valuable for large proteins, since separation 
of an Hcm-modified protein such as 19 from unmodified 18 is not generally feasible.  
Modified αS 19 was isolated from AaT, Met*RS, and tRNA by boiling and FPLC 
purification.  Then 19 was incubated with thioester Ac-McmMetAspValPhe-SR (S13), 
which corresponds to αS1-4 labeled at the N-terminus with 7-methoxycoumarinylalanine 
(Mcm).  Overnight incubation at 37 °C gave 20a in high yield from 19.  No unligated 
starting materials were observed, though some oxidized 20a was observed.  Purified 20a 
was quantitatively converted to 21a by treatment with aqueous MeI, as determined by 
analyses by John Warner using Ellman’s reagent and MALDI MS (Figure 3-7).  In 
general, we expect that the NCL reaction will not be 100 % efficient, but we do not view 
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this as a severe limitation, provided that the NCL product can be purified away from the 
starting materials and methylation is quantitative and selective. 
A similar ligation was carried out with Ac-MetAspValPhe-SR (11), yielding N-
Ac-αS after methylation (21b) (Figure 3-8).  The ligation product 21b was subjected to 
trypsin digest and MALDI MS analysis to confirm that methylation occurred with high 
yield and few side reactions.  Observation of the Ac-MetAspValPheMetLys fragment 
(Ac-αS1-6) with only trace Ac-MetAspValPheHcsLys contamination confirmed that 
methylation proceeded in > 95 % yield within the limitations of quantitation by MS 
(Figure 3-6).  Furthermore, MALDI MS analysis of the rest of the tryptic fragments 
demonstrated that there were no substantial alkylation side reactions, even on His50 in the 
αS46-58 fragment (See Materials and Methods). 
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Figure 3-6.  α-Synuclein Model Ligation 
Functionalization of αS6-140 by a) cleavage of His tag at Factor Xa site, b) attachment of Hcm by 
AaT-catalyzed modification, c) ligation of an N-terminal thioester peptide (11 or S10), and d) 
conversion of Hcs to Met by methylation.  20a, 21a Xxx = AcMcm; 20b, 21b Xxx = Ac.  Top Right: 
Gel image showing product of each step, WT indicates full-length αS.  Middle Right: MALDI MS 
analysis of full length Ac-αS before (12b) and after (13b) methylation.  Bottom Right: Trypsinized 
fragment corresponding to Ac-αS1-6 (812.4 m/z) confirms successful methylation.  Asterisk 
indicates the expected mass of unmethylated Ac-αS1-6Hcs5.   
 
 
 
Figure 3-7. Edman Degradation Analysis 
Left: UV/Vis analysis of Hcs methylation using Ellman’s reagent.  Right: Fluorescence emission 
spectra of Ac-Mcm-αS6-140 (20a) and WT αS. 
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Figure 3-8.  HPLC and MALDI MS Analysis of Ligation and Methylation 
 
3.2.4 – Three-Part Native Chemical Ligation with Hcs Masking 
With αS, we have shown that we can semi-synthetically create a protein with a 
new type of ligation site, methionine.  To further demonstrate the power of our semi-
synthetic techniques, we will perform a three-part native chemical ligation.  Our goal is to 
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introduce one non-native protein element while maintaining native amide bonds at the 
connection points and retaining the correct primary sequence in the final protein product.  
As shown in Scheme 3-3, we will recombinantly express the N- and C- terminal domains 
of calmodulin and only chemically synthesize a small four amino acid middle segment, 
which contains the non-native element, either a fluorescent label, 7-methoxycoumarinyl 
alanine, or a thioamide analog of alanine, which can be used as a quencher of Tyr 
fluorescence in calmodulin.  Currently we have reached step 3A, a three-part native 
chemical ligation with homocysteine at the ligation sites, and have obtained MALDI 
confirmation of all steps prior. 
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Scheme 3-3. Three-Part Native Chemical Ligation of Calmodulin 
Reaction steps: (1A) AaT N-terminal ligation of Hcm, (1B) Native chemical ligation of middle 
peptide to C-terminus CaM domain, (1C) Deprotection of thiazolidine to expose N-terminal 
homocysteine, (2) Cleavage of intein from N-terminus CaM domain to form a thioester, (3A)  
Native chemical ligation of N-terminus and C-terminus CaM domains, (3B) Methylation of 
homocysteine residues using methyl iodide. 
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3.2.5 – Method Applications 
Application of our system to targets other than αS may require mild denaturation 
of the protein in order to access the N-terminal amino acids.  Therefore, we have tested 
AaT activity in the presence of low concentrations of denaturants and detergents.  We 
find that AaT activity has a Gdn•HCl IC50 of 0.4 M and that full activity could be 
maintained in 5 % v/v Triton X-100.  While the N-termini of some proteins may be 
buried in important structural interactions, these concentrations should allow one to 
partially unfold many proteins to access the terminus for Hcm transfer and ligation. 
While our experiments begin to remove the sequence limitations for EPL, they 
certainly do not eliminate them entirely.  Essentially, one can now use XxxMetArg or 
XxxMetLys as a disconnection point in a retrosynthetic analysis of a potential protein 
target.  The utility of our approach depends on how frequently this motif occurs.  To 
address this, Jerri Wang analyzed the protein sequences in the PDB and found that out of 
the 60,325 proteins surveyed, 5,405 possible N-terminal ligation sites (< 40 amino acids 
from the N-terminus) were identified in 5,156 unique proteins.  These numbers increased 
to 31,259 ligation sites and 20,701 proteins when we considered proteins with the ligation 
motif in the center of the protein where one might use multiple ligations to synthesize the 
full-length protein.  We chose to restrict our search to the PDB since these sequences 
represent proteins with some degree of prior characterization typical of a protein target 
chosen for synthesis via NCL. 
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3.2.6 – Future Directions 
While it is clear that many proteins could be potential synthesis targets using AaT, 
we wish to eventually make our methods as broadly useful as possible.  Therefore, it is 
worth noting that there exist other transferases with different N-terminal specificity, such 
as the Bpt transferase from V.  vulnificus, which transfers Leu to an N-terminal Asp or 
Glu.50  Our preliminary experiments indicate that Bpt can transfer Leu from small 
molecule donors in vitro, but our current yields are too low (< 10 % after 4 h) to be 
useful.  In situ aminoacylations using Hcp, Hcb, or Hcm with Bpt and either Met*RS or 
E. coli LeuRS have not produced significant transfer yields.  Efforts are underway to 
improve transfer of Hcs analogs.  We are also working to mutate AaT to alter the 
substrate specificity for both Xaa and the N-terminal residue. (See Chapter 4.) 
Prior to our work, the only way to avoid Cys at a ligation site in the expressed 
protein fragment during EPL was to desulfurize to form Ala or mask Cys by forming a 
non-native amino acid.  Here, we have shown that a protein N-terminus can be 
functionalized with Hcs under mild conditions.  After ligation, Hcs can be efficiently and 
selectively converted to Met, erasing the ligation site.  Our work begins to remove the N-
terminal Cys requirement for ligation by allowing one to use the MetArg or MetLys motif 
as a point of disconnection in protein semi-synthesis. 
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Section 3.3 – Materials and Methods 
3.3.1 – Materials 
Homocystine ((Hcs)2) was purchased from Toronto research chemical (Toronto, 
Canada).  Benzotriazol-1-yl-oxy-tris-pyrrolidinophosphonium hexafluorophosphate 
(PyBOP), Fmoc-Met-OH, Fmoc-Val-OH, Fmoc-Phe-OH, Fmoc-Asp(OtBu)-OH, Fmoc-
β-(7-methoxy-coumarin-4-yl)-Ala-OH, and 2-chlorotrityl chloride resin were purchased 
from Bachem (Torrance, CA) or EMD Chemicals (Philadelphia, PA).  Piperidine and 2-
(1Hbenzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (HBTU) were 
purchased from American Bioanalytical (Natick, MA).  Sigmacote, N,N-
diisopropylethylamine (DIPEA), thiophenol, methyl mercaptopropionate, sodium 
thiomethoxide, 2-propanthiol, 2-methyl-2-propane thiol, mercaptophenylacetic acid 
(MPAA), trifluoroacetic acid (TFA), tris(2-carboxyethyl) phosphine hydrochloride 
(TCEP), and 5,5'-dithiobis-(2-nitrobenzoic acid (DTNB) were purchased from Sigma-
Aldrich (St.  Louis, MO).  Iodine was purchased from JT Baker (Phillipsburg, NJ).  All 
deuterated solvents were purchased from Cambridge Isotopes Laboratories, Inc.  
(Andover, MA).  Ni-NTA resin was from Qiagen (Valencia, CA).  E. coli BL21(DE3) 
cells were purchased from Stratagene (La Jolla, CA).  Sequencing-grade trypsin was 
purchased from Promega (Madison, WI).  Restriction-grade Factor Xa protease was 
purchased from Novagen (San Diego, CA).  QuikChange® site-directed mutagenesis kits 
were purchased from Stratagene.  DNA oligomers were purchased from Integrated DNA 
Technologies, Inc (Coralville, IA).  Protease inhibitor cocktail was purchased from 
Sigma-Aldrich.  All other reagents were purchased from Fisher Scientific (Pittsburgh, 
PA).  Milli-Q filtered (18 MΩ) water was used for all solutions (Millipore, Billerica, 
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MA).  Matrix-assisted laser desorption/ionization (MALDI) mass spectra were collected 
with a Bruker Ultraflex III MALDI-TOFTOF mass spectrometer (Billerica, MA).  
Electrospray ionization (ESI) mass spectra were collected with a Waters LCT Premier 
XE liquid chromatograph/mass spectrometer (Milford, MA).  UV/vis absorbance spectra 
were obtained with a Hewlett-Packard 8452A diode array spectrophotometer (Agilent 
Technologies, Santa Clara, CA).  Intein plasmid pTXB1 and all restriction enzymes were 
purchased from New England Biolabs (Ipswich, MA). 
 
3.3.2 – Adenosyl Donor Synthesis 
The synthesis of (S)-(2R,3R,4R,5R)-2-(6-amino-9H-purin-9-yl)-4-hydroxy-5-
(hydroxymethyl) tetrahydrofuran-3-yl 2-amino-3-phenylpropanoate (Phe-A, Figure 3-9) 
has been reported previously.66  The other Xaa-A donors were synthesized in a similar 
fashion (Scheme 3-4). 
 
Figure 3-9.  Structure of Phenylalanyl Adenosine (Phe-A) 
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Scheme 3-4.  Synthesis of Met-A and Cbz-A Donor 
S2-S4a – R = methionine.  S2-S4b – R = Cys(Bz).  Reagents and conditions: a) ClCH2CN, 
DIPEA, THF; b) (DMT)-A, THF, RT; c) TFA, TIPSH, THF.  Cbz-A was synthesized in the same 
fashion but starting with Boc-Cys(Bz)-OH 
 
 (S)-cyanomethyl 2-((tert-butoxycarbonyl)amino)-4-(methylthio)butanoate (Boc-
Met-OCH2CN, S2a).   
Chloroacetonitrile (5 mL) and DIPEA (471 mg, 0.64 mL, 3.6 mmol) were added 
to Boc-Met-OH (826 mg, 3.3 mmol) and stirred for 14 h.  The solvent was removed 
under reduced pressure and SiO2 flash chromatography (gradient from 10 - 50 % ethyl 
acetate in hexanes) afforded 799 mg of a pale yellow oil in 83 % yield.  Rf 0.45 in 30 % 
ethyl acetate in hexanes; 1H NMR (500 MHz, CDCl3): δ = 5.19 (d, J = 8.0 Hz, 1H), 4.83 
– 4.69 (m, 2H), 4.47 – 4.46 (m, 1H), 2.59 – 2.49 (m, 2H), 2.14 – 1.96 (m, 2H), 2.08 (s, 
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3H), 1.42 (s, 9H); 13C NMR (125 MHz, CDCl3): δ = 171.3, 155.4, 114.1, 80.6, 52.5, 49.1, 
31.3, 30.0, 28.4, 15.6,14.3; HRMS (ESI) m/z calculated for C12H20N2NaO4S [M + Na]+ 
311.104, found 311.104. 
 
(S)-(2R,3R,4R,5R)-2-(6-amino-9H-purin-9-yl)-5-((bis(4-
methoxyphenyl)(phenyl)methoxy)methyl)-4-hydroxytetrahydrofuran-3-yl 2-((tert-
butoxycarbonyl)amino)-4-(methylthio) butanoate (Boc-Met-(DMT)-A, S3a). 
Tetrahydrofuran (5 mL) was added to Boc-Met-OCH2CN S2 (219.4 mg, 0.702 
mmol), (DMT)-A (179.2 mg, 0.1792 mmol), and NBu4Ac (7.4 mg) and stirred for 24 h.  
The solvent was removed under reduced pressure and chromatography (100 % Hexanes, 
50 – 100 % ethyl acetate in hexanes, 5 - 10 % methanol in ethyl acetate), afforded 92.9 
mg of an off-white solid in 64.7 % yield.  Rf 0.5 in 5 % methanol in ethyl acetate; 1H and 
13C NMR for S3a shown in Figure 3-10; LRMS (ESI) m/z calculated for C41H49N6O9S 
(M + H)+ 801.3, found 801.6. 
 
(S)-(2R,3R,4R,5R)-2-(6-amino-9H-purin-9-yl)-4-hydroxy-5-(hydroxymethyl) 
tetrahydrofuran-3-yl 2-amino-4-(methylthio)butanoate (Met-A, S4a). 
Trifluoroacetic acid (1 mL tetrahydrofuran (1 mL) and TIPSH (73.5 mg, 0.095 
mL, 0.46 mmol) were added to S3a (92.9 mg, 0.116 mmol).  Upon addition of TFA, the 
reaction turned a bright orange color and at the completion of the reaction, the color had 
become a pale yellow - orange.  The reaction mixture was reduced to dryness by rotary 
evaporation and extracted using 1 mL dichloromethane and 1 mL water twice with a final 
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1 mL water back-extraction against the dichloromethane layer.  The water-soluble layer 
containing S4a was then HPLC-purified on a C18-prep column using Gradient 1 at 11 
mL/min (Table 3-1).  HPLC/MALDI analysis m/z calculated C15H23N6O5S (M + H)+ 
399.1; retention time 21.0 min, found 399.3 retention time 22.44 min, found 399.3. 
 
(R)-cyanomethyl 3-(benzylthio)-2-((tert-butoxycarbonyl)amino)propanoate (Boc-
Cbz-OCH2CN, S2b). 
Boc-Cys(benzyl)-OH (500.0 mg, 1.681 mmol) was dissolved in 5 mL 
chloroacetonitrile (solvent) and DIPEA (0.322 mL, 1.849 mmol) were added to the 
reaction mixture and allowed to stir overnight.  The reaction mixture was concentrated 
under reduced pressure, then purified on silica gel (30 % EtOAc in hexanes) to give 
588.7 mg (~ 100 %) of the titled compound S2b.  Rf 0.4 in 30 % EtOAc in hexanes; 1H 
NMR (500 MHz, CDCl3): δ = 7.30 – 7.20 (m, 5H), 4.68 (s, 2H), 4.51 – 4.5 (d, 1H), 3.67 
(s, 2H), 2.85 – 2.75 (m, 2H). 1.40 (s, 9H); 13C NMR (125 MHz, CDCl3): δ = 170.1, 
155.2, 137.5, 129.1, 128.9, 127.7, 113.9, 80.9, 53.2, 49.3, 36.9, 33.3, 28.5.  LRMS (ESI) 
m/z calculated for C17H22N2O4SNa [M + Na]+ 373.1, found 373.2. 
 
(2R,3R,4R,5R)-2-(6-amino-9H-purin-9-yl)-5-((bis(4-
methoxyphenyl)(phenyl)methoxy)methyl)-4-hydroxytetrahydrofuran-3-yl 3-
(benzylthio)-2-((tert-butoxycarbonyl)amino)propanoate 
 (Boc-Cbz-(DMT)-A, S3b). 
Tetrahydrofuran (5 mL) was added to Boc-Cys(Bz)-OCH2CN S2b (279.4 mg, 
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0.797 mmol), (DMT)-A (113 mg, 0.199 mmol), and NBu4Ac (6.3 mg,) and stirred for 24 
h.  The solvent was removed under reduced pressure and preparative thin-layer 
chromatography (5 % methanol in ethyl acetate, eluted in 10 % methanol in chloroform), 
afforded 42.3 mg of a white solid in 24.6 % yield.  1H and 13C NMR for (Figure 3-11) 
shown below; LRMS (ESI) m/z calculated for C46H51N6O9S (M + H)+ 863.3, found 
863.5. 
 
(2R,3R,4R,5R)-2-(6-amino-9H-purin-9-yl)-4-hydroxy-5-
(hydroxymethyl)tetrahydrofuran-3-yl 2-amino-3-(benzylthio)propanoate 
 (Cbz-A, S4b). 
Trifluoroacetic acid (1 mL), tetrahydrofuran (1 mL) and TIPSH (7.8 mg, 0.01 mL, 
0.05 mmol) were added to S3b (28.5 mg, 0.0331 mmol) following the deprotection 
procedure given for S4a.  The water-soluble layer containing S3b was then HPLC-
purified on a C18-prep column using Gradient 1 at 15 mL/min (Table 3-1).  
HPLC/MALDI analysis m/z calculated C20H25N6O5S (M + H)+ 461.2; retention time 17.5 
min, found 460.5. 
 
 (R)-2-((tert-butoxycarbonyl)amino)-3-(methyldisulfanyl)propanoic acid (Boc-Csm-
OH, 7a). 
Boc-L-Cys-OH (110 mg, 0.50 mmol) was dissolved in 20 mL of 1:1 H2O/THF.  
Sodium thiomethoxide (350 mg, 5.0 mmol) was added to the solution after cooling to 0 
°C in an ice bath.  Then, a solution of iodine in 95 % EtOH was added dropwise until the 
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color of the reaction changed from colorless to brown.  The mixture was stirred for 5.5 h 
with warming to room temperature.  After removing tetrahydrofuran under reduced 
pressure, the reaction mixture was acidified by addition of 1 N HCl aq. until the pH was 2 
- 3.  The solution was extracted with EtOAc.  The organic phase was washed with 
saturated NaS2O4 aq. and brine, and dried over MgSO4.  The solvent was removed under 
reduced pressure, and then the reaction was purified on silica gel (25 % EtOAc in 
hexanes containing 1 % AcOH) to give 90.8 mg (68 %) of the titled compound 7a.  Rf 
0.37 in 33 % ethyl acetate in hexanes containing 1 % AcOH; 1H NMR (360 MHz, 
CDCl3): δ = 5.34 (s, 1H), 4.63 (s, 1H), 3.26 - 3.16 (m, 2H), 2.43 (m, 3H), 1.47 (s, 9H); 
13C NMR (90 MHz, CDCl3): δ = 175.2, 155.7, 80.9, 53.2, 39.9, 28.5, 23.3.  NMRs, 1H 
and 13C, can be found in Figure 3-12.   HRMS (ESI) m/z calculated for C9H17NNaO4S2 
[M + Na]+ 290.049, found 290.050. 
 
 (R)-cyanomethyl 2-((tert-butoxycarbonyl)amino)-3-(methyldisulfanyl)propanoate 
(Boc-Csm-OCH2CN, 8a). 
Compound 7a (106 mg, 0.397 mmol) was dissolved in 3 mL tetrahydrofuran.  50 
equiv. chloroacetonitrile (1.26 mL, 19.85 mmol) and DIPEA (67 µL, 796 µmol) were 
added to the reaction mixture and allowed to stir overnight.  The reaction mixture was 
concentrated under reduced pressure, then purified on silica gel (25 % EtOAc in hexanes) 
to give 47 mg of compound 8a (44 %).  Rf 0.33 in 25 % EtOAc in hexanes; 1H NMR (360 
MHz, CDCl3): δ = 5.34 (s, 1H), 4.87 – 4.74 (dd, J = 33.1 Hz, 2H), 4.71 (s, 1H), 3.18 - 
3.11 (m, 2H), 2.43 (m, 3H), 1.46 (s, 9H); 13C NMR (90 MHz, CDCl3): δ = 170.0, 155.2, 
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113.9, 81.0, 52.8, 49.3, 39.2, 28.5, 23.1; HRMS (ESI) m/z calculated for 
C11H18N2NaO4S2 [M + Na]+ 392.061, found 392.061. 
 
(R)-(2R,3R,4R,5R)-2-(6-amino-9H-purin-9-yl)-5-((bis(4-
methoxyphenyl)(phenyl)methoxy) methyl)-4-hydroxytetrahydrofuran-3-yl 2-((tert-
butoxycarbonyl)amino)-3-(methyldisulfanyl) propanoate (Boc-Csm-(DMT)-A, 9a). 
Tetrahydrofuran (5 mL) was added to Boc-Csm-OCH2CN 8a (123.6 mg, 0.403 
mmol), (DMT)-A (115.7 mg, 0.2031 mmol), and NBu4Ac (7.4 mg,) and stirred for 48 h.  
The solvent was removed under reduced pressure and preparative thin-layer 
chromatography (5 % methanol in ethyl acetate and eluted from silica with 10 % 
methanol in chloroform), afforded 80.8 mg of a white solid in 48.6 % yield.  Rf 0.7 in 5 % 
methanol in ethyl acetate; 1H and 13C NMR shown below in Figure 3-13; LRMS (ESI) 
m/z calculated for C40H47N6O9S2 (M + H)+ 819.3, found 819.4. 
 
(R)-(2R,3R,4R,5R)-2-(6-amino-9H-purin-9-yl)-4-hydroxy-5-
(hydroxymethyl)tetrahydrofuran-3-yl 2-amino-3-(methyldisulfanyl)propanoate 
(Csm-A, 10a). 
Trifluoroacetic acid (1mL), tetrahydrofuran (1 mL) and TIPSH (62.6 mg, 0.081 
mL, 0.40 mmol) were added to 9a (80.8 mg, 0.0987 mmol) following the deprotection 
procedure given for S4a.  The water-soluble layer containing 10a was then HPLC-
purified on a C18-prep column using Gradient 1 at 11 mL/min (Table 3-1).  
HPLC/MALDI analysis m/z calculated C14H21N6O5S2 (M + H)+ 417.1; retention time 
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21.3 min, found 416.8; retention time 23.4 min, found 416.8. 
 
 (2R,3R,4R,5R)-2-(6-amino-9H-purin-9-yl)-5-((bis(4-methoxyphenyl) 
(phenyl)methoxy)methyl)-4-hydroxytetrahydrofuran-3-yl 2-((tert-
butoxycarbonyl)amino)-3-(isopropyldisulfanyl)propanoate (Boc-Csp-(DMT)-A, 9b). 
Tetrahydrofuran (5 mL) was added to Boc-Csp-OCH2CN 8b (332.5 mg, 0.994 
mmol), (DMT)-A (141.5 mg, 0.249 mmol), and NBu4Ac (12.5 mg,) and stirred for 24 h.  
The solvent was removed under reduced pressure and flash chromatography over silica 
gel (Gradient 20 % -100 % ethyl acetate in hexanes, 5 % - 10 % methanol in ethyl 
acetate) afforded 159.3 mg of a white solid in 75.7 % yield.  Rf 0.75 in 5 % methanol in 
ethyl acetate; 1H and 13C NMR for (Figure 3-14) shown below; LRMS (ESI) m/z 
calculated for C42H51N6O9S2 (M + Na)+ 869.3, found 869.6. 
 
(2R,3R,4R,5R)-2-(6-amino-9H-purin-9-yl)-4-hydroxy-5-
(hydroxymethyl)tetrahydrofuran-3-yl 2-amino-3-(isopropyldisulfanyl)propanoate 
(Csp-A, 10b). 
Trifluoroacetic acid (1mL), tetrahydrofuran (1 mL) and TIPSH (11.9 mg, 0.154 
mL, 0.752 mmol) were added to 9b (159.3 mg, 0.188 mmol) following the deprotection 
procedure given for S4a.  The water-soluble layer containing 10b was then HPLC-
purified on a C18-prep column using Gradient 1 at 11 mL/min (Table 3-1).  
HPLC/MALDI analysis m/z calculated C16H25N6O5S2 (M + H)+ 445.1; retention time 
26.1 min, found 445.2; retention time 28.1 min, found 445.2. 
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 (R)-2-((tert-butoxycarbonyl)amino)-3-(tert-butyldisulfanyl)propanoic acid (Boc-
Csb-OH, 7c). 
Cys(S-tBu)-OH (250 mg, 1.2 mmol) was dissolved in 12 mL of 1:1 H2O/dioxane.  
Sodium hydroxide (71.6 mg, 1.8 mmol) and di-tert-butyl carbonyl anhydride (391 mg, 
1.8 mmol) were added to the solution and the mixture was stirred overnight at room 
temperature.  20 mL of MilliQ water was added to the reaction, and then the reaction 
mixture was extracted twice with ethyl acetate.  The organic layer was back extracted 
twice with saturated sodium bicarbonate solution.  The combined aqueous layers were 
acidified to a pH of 1 using 6 M HCl aq.  The solution was extracted with EtOAc three 
times.  The extract was washed with brine, and dried over MgSO4.  After filtration, 
solvent was removed to give 263.4 mg (70 %) of 7c, a white solid.  Further purification 
was not performed.  Rf 0.5 in 60 % ethyl acetate in hexanes; 1H NMR (500 MHz, CDCl3): 
4.59 - 4.47 (m, 1H), 3.23 – 3.13 (m, 2H), 1.45 (s, 9H), 1.32 (s, 9H); 13C NMR (125 MHz, 
CDCl3): δ = 175.5, 155.6, 80.8, 53.4, 48.4, 42.3, 30.0, 28.5; LRMS (ESI) m/z calculated 
for C12H23NO4S2Na (M + Na)+ 332.1, found 332.2. 
 
(R)-cyanomethyl 2-((tert-butoxycarbonyl)amino)-3-(tert-butyldisulfanyl)propanoate 
(Boc-Csb-OCH2CN, 8c). 
Compound 7c (206.7 mg, 0.668 mmol) was dissolved in 5 mL chloroacetonitrile 
(solvent) and DIPEA (0.128 mL, 0.735 mmol) were added to the reaction mixture and 
allowed to stir overnight.  The reaction mixture was concentrated under reduced pressure, 
then purified on silica gel (30 % EtOAc in hexanes) to give 140.6 mg (60 %) of the titled 
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compound 8c.  Rf 0.6 in 30 % EtOAc in hexanes; 1H NMR (500 MHz, CDCl3): δ = 4.80 
(dd, J = 12.5 Hz, 2H), 2.66 - 2.64 (m, 1H), 3.15 – 3.14 (m, 2H), 1.44 (s, 9H), 1.33 (s, 
9H); 13C NMR (125 MHz, CDCl3): δ = 169.9, 155.2, 114.0, 80.8, 53.1, 49.3, 48.8, 41.9, 
29.9, 28.4; LRMS (ESI) m/z calculated for C14H24N2O4S2Na [M + Na]+ 371.1, found 
371.2. 
 
(2R,3R,4R,5R)-2-(6-amino-9H-purin-9-yl)-5-((bis(4-methoxyphenyl)(phenyl) 
methoxy)methyl)-4-hydroxytetrahydrofuran-3-yl 2-((tert-butoxycarbonyl)amino)-3-
(tert-butyldisulfanyl)propanoate (Boc-Csb-(DMT)-A, 9c). 
Tetrahydrofuran (5 mL) was added to Boc-Csb-OCH2CN 8c (140.6 mg, 0.404 
mmol), (DMT)-A (57.5 mg, 0.101 mmol), and NBu4Ac (7.7 mg,) and stirred for 24 h.  
The solvent was removed under reduced pressure and preparative thin-layer 
chromatography (5 % methanol in ethyl acetate, eluted in 10 % methanol in chloroform), 
afforded 28.5 mg of a white solid in 30.4 % yield.  Rf 0.5 in 5 % methanol in ethyl 
acetate; 1H and 13C NMR for (Figure 3-15) shown below; LRMS (ESI) m/z calculated for 
C43H52N6O9S2Na (M + Na)+ 883.3, found 883.6. 
 
(2R,3R,4R,5R)-2-(6-amino-9H-purin-9-yl)-4-hydroxy-5-
(hydroxymethyl)tetrahydrofuran-3-yl 2-amino-3-(tert-butyldisulfanyl)propanoate 
(Csb-A, 10c). 
Trifluoroacetic acid (1mL), tetrahydrofuran (1 mL) and TIPSH (21 mg, 0.027 mL, 
0.13 mmol) were added to 9c (28.5 mg, 0.0331 mmol) following the deprotection 
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procedure given for S4a.  The water-soluble layer containing 10c was then HPLC-
purified on a C18-prep column using Gradient 1 with a flow rate of 15 mL/min (Table 3-
1).  HPLC/MALDI analysis m/z calculated C17H27N6O5S2 (M + H)+ 459.2; retention time 
20.0 min, found 459.0; retention time 22.1 min, found 459.0. 
 
 (2R,3R,4R,5R)-2-(6-amino-9H-purin-9-yl)-5-((bis(4-
methoxyphenyl)(phenyl)methoxy)methyl)-4-hydroxytetrahydrofuran-3-yl 2-((t-
butoxycarbonyl)amino)-3-(phenyldisulfanyl)propanoate 
 (Boc-Csf-(DMT)-A, 9d). 
Tetrahydrofuran (5 mL) was added to Boc-Csf-OCH2CN 8d (110.0 mg, 0.303 
mmol), (DMT)-A (85.0 mg, 0.152 mmol), and NBu4Ac (15 mg,) and stirred for 24 h.  
The solvent was removed under reduced pressure and preparative thin-layer 
chromatography (5 % methanol in ethyl acetate, eluted in 10 % methanol in chloroform), 
afforded 64.5 mg of a yellow solid in 48.3 % yield.  Rf 0.75 in 5 % methanol in ethyl 
acetate; 1H and 13C NMR for (Figure 3-16) shown below; LRMS (ESI) m/z calculated for 
C45H49N6O9S2 (M + H)+ 881.3, found 881.4. 
 
(2R,3R,4R,5R)-2-(6-amino-9H-purin-9-yl)-4-hydroxy-5-
(hydroxymethyl)tetrahydrofuran-3-yl 2-amino-3-(phenyldisulfanyl)propanoate 
 (Csf-A, 10d). 
Trifluoroacetic acid (1 mL), tetrahydrofuran (1 mL) and TIPSH (46.4 mg, 0.06 
mL, 0.29 mmol) were added to 9d (64.5 mg, 0.073 mmol) following the deprotection 
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procedure given for S4a.  The water-soluble layer containing 10d was then HPLC-
purified on a C18-prep column using Gradient 1 at 11 mL/min (Table 3-1).  
HPLC/MALDI analysis m/z calculated C19H23N6O5S2 (M + H)+ 479.1; retention time 
29.1 min, found 479.0; retention time 30.6 min, found 479.0. 
 
 (2R,3R,4R,5R)-2-(6-amino-9H-purin-9-yl)-5-((bis(4-
methoxyphenyl)(phenyl)methoxy)methyl)-4-hydroxytetrahydrofuran-3-yl 2-((tert-
butoxycarbonyl)amino)-3-((2,2,2-trifluoroethyl)disulfanyl)propanoate 
 (Boc-CsTf-(DMT)-A, 9e). 
Tetrahydrofuran (5 mL) was added to Boc-Csf-OCH2CN 8e (36.9 mg, 0.10 
mmol), (DMT)-A (40.7 mg, 0.07 mmol), and NBu4Ac (2.7 mg,) and stirred for 24 h.  The 
solvent was removed under reduced pressure and preparative thin-layer chromatography 
(5 % methanol in ethyl acetate, eluted in 10 % methanol in chloroform), afforded 18.8 mg 
of a white solid in 29.7 % yield.  Rf 0.8 in 5 % methanol in ethyl acetate; 1H and 13C 
NMR for (Figure 3-17) shown below; LRMS (ESI) m/z calculated for C41H46F3N6O9S2 
(M + H)+ 887.3, found 887.5. 
 
(2R,3R,4R,5R)-2-(6-amino-9H-purin-9-yl)-4-hydroxy-5-
(hydroxymethyl)tetrahydrofuran-3-yl 2-amino-3-((2,2,2-
trifluoroethyl)disulfanyl)propanoate (CsTf-A, 10d) 
Trifluoroacetic acid (1mL), tetrahydrofuran (1 mL) and TIPSH (13.4 mg, 0.02 
mL, 0.085 mmol) were added to 9e (18.8 mg, 0.021 mmol) following the deprotection 
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procedure given for S4a.  The water-soluble layer containing 10d was then HPLC-
purified on a C18-prep column using Gradient 1 at 11 mL/min (Table 3-1).  
HPLC/MALDI analysis m/z calculated C15H20F3N6O5S2 (M + H)+ 485.1; retention time 
25.4 min, found 485.0; retention time 27.5 min, found 485.0. 
 
 (2S,2’S)-4,4’-disulfanediylbis(2-((tert-butoxycarbonyl)amino)butanoic acid ((Boc-
Hcs)2, 1). 
L-Homocystine ((Hcs)2, 402.5 mg, 1.5 mmol) was dissolved in 15 mL of 1:1 
H2O/dioxane.  600 mL of 10 N Sodium hydroxide aq. (6 mmol) and di-tert-butyl 
carbonyl anhydride (618 mg, 3.75 mmol) were added to the solution after cooling to 0 ºC 
in the ice bath.  The mixture was stirred overnight with warming to room temperature.  
The reaction mixture was acidified by 1 N HCl aq. until reached 2 - 3.  The solution was 
extracted with EtOAc.  The extract was washed with brine, and dried over MgSO4.  After 
filtration, solvent was removed to give 572.8 mg (81 %) of 1.  Further purification was 
not performed. 
 
(S)-2-((tert-butoxycarbonyl)amino)-4-(methyldisulfanyl)butanoic acid (Boc-Hcm-
OH, 2a). 
Boc-L-Homocystine (1), 188 mg, 0.4 mmol) was dissolved in 16 mL of 1:1 
H2O/THF.  Sodium thiomethoxide (560 mg, 8.0 mmol) was added to the solution after 
cooling to 0 °C in an ice bath.  Then, a saturated solution of iodine in 95 % EtOH was 
added dropwise until the color of the reaction changed from colorless to brown.  The 
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mixture was stirred for 1.5 h with warming to room temperature.  After removing 
tetrahydrofuran under reduced pressure, the reaction mixture was acidified by addition of 
1 N HCl aq. until the pH reached 2 - 3.  The solution was extracted with EtOAc.  The 
extract was washed with saturated NaS2O4 aq. and brine, dried over MgSO4, and purified 
on silica gel (25 % EtOAc in hexanes containing 1 % AcOH) to give 179.3 mg (80 %) of 
2a.  Rf 0.4 in 33 % ethyl acetate in hexanes containing 1 % AcOH; 1H NMR (360 MHz, 
CDCl3): δ = 5.34 (s, 1H), 4.63 (s, 1H), 2.80 - 2.76 (m, 2H), 2.42 (s, 2H), 2.35 (m, 1H), 
2.09 (s, 1H), 1.46 (s, 9H); 13C NMR (90 MHz, CDCl3): δ = 176.5, 155.6, 80.6, 52.5, 33.8, 
32.8, 28.3, 23.3 (Note: A second set of concentration-dependent peaks was also observed, 
these peaks can be seen in the included 13C spectrum.  These could be reduced but not 
eliminated by diluting the sample, no evidence of dimerization is seen in the more dilute 
1H spectrum sample, Figure 3-18); HRMS (ESI) m/z calculated for C10H19NNaO4S2 [M + 
Na]+ 304.065, found 304.066. 
 
(S)-2-amino-4-(methyldisulfanyl)butanoic acid (Hcm-OH, free amino acid) 
Boc-Hcm-OH (2a), 150 mg, 0.53 mmol) was dissolved in 10 mL of 95:2.5:2.5 
TFA/H2O/TIPS.  Reaction was stirred for 2 hours.  Solvent was removed under reduced 
pressure.  Crude Hcm was extracted using excess cold diethylether.  Precipitate was 
collected via centrifugation and pellet was resuspended in water.  Crude Hcm was 
purified by HPLC (Gradient 2).  Post purification, sample concentration was determined 
by UV-Vis at 280 nm using the extinction coefficient of disulfide (ε280 = 125 M-1 cm-1).  
1H NMR (500 MHz, CDCl3): δ = 4.12 (t, J = 6.5 Hz, 1H), 2.95 (t, J = 7.5 Hz, 2H), 2.52 
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(s, 1H), 2.50 – 2.39 (m, 2H); 13C NMR (125 MHz, CDCl3): δ = 173.0, 52.7, 32.0, 29.6, 
22.1; HRMS (ESI) m/z calculated for C5H12NO2S2 [M + H]+ 182.030, found 182.031.  
NMRs can be found in Figure 3-19. 
 
(S)-2-((tert-butoxycarbonyl)amino)-4-(isopropyldisulfanyl)butanoic acid (Boc-Hcp-
OH, 2b).   
1 (234 mg, 0.5 mmol) was dissolved in 19 mL of 50 % aqueous tetrahydrofuran.  
2-propanethiol (929 µL, 10.0 mmol) and 10 N sodium hydroxide aq. (1.1 mL, 11 mmol) 
were added to the solution at 0 °C.  Then, a solution of iodine in 95 % EtOH was added 
dropwise until the color of the reaction system changed from colorless to brown.  The 
mixture was stirred for over-night with gradual warming room temperature.  After 
removing THF under reduced pressure, reaction mixture was neutralized by 1 N HCl aq. 
until pH 2 - 3.  The solution was extracted with EtOAc.  The extract was washed with 
saturated NaS2O4 aq. and brine, and dried over MgSO4.  Concentration under reduced 
pressure followed by flash chromatography over silica gel with EtOAc/Hexane/AcOH 
(75:25:1) gave 2b (170 mg, 55 % yield).  Rf 0.47 in 33 % ethyl acetate in hexanes 
containing 1 % AcOH; 1H NMR (360 MHz, CDCl3): δ = 5.05 (s, 1H), 4.40 (s, 1H), 3.07 
– 2.95 (m, 1H), 2.75 (t, J = 7.6 Hz, 2H), 2.30 (s, 1H), 2.08 (s, 1H), 1.46 (s, 9H), 1.32 - 
1.30 (dd, J = 6.8 Hz, 6H); 13C NMR (90 MHz, CDCl3): δ = 176.6, 155.8, 80.7, 52.8, 41.3, 
35.6, 32.5, 28.5, 22.8 (Note: A second set of concentration-dependent peaks was also 
observed, these peaks can be seen in the included 13C spectrum.  These could be reduced, 
but not eliminated by diluting the sample, no evidence of dimerization is seen in the more 
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dilute 1H spectrum sample, Figure 3-21); HRMS (ESI) m/z calculated for 
C12H23NNaO4S2 [M + Na]+ 332.096, found 332.097. 
 
(S)-2-((tert-butoxycarbonyl)amino)-4-(tert-butyldisulfanyl)butanoic acid (Boc-Hcb-
OH, 2c). 
1 (56.4 mg, 0.12 mmol) was dissolved in H2O/THF (50 % v/v, 19 mL).  To the 
solution was added 2-methyl-2-propanethiol (270 µL, 2.4 mmol) and 5 N sodium 
hydroxide aq. (528 µL, 2.64 mmol) after cooling to 0 °C in an ice bath.  Then, a solution 
of iodine in 95 % EtOH was added dropwise until the color of the reaction changed from 
colorless to brown.  The mixture was stirred overnight with warming to room 
temperature.  After removing THF under reduced pressure, the reaction mixture was 
acidified by addition of 1 N HCl aq. until the pH reached 2 - 3.  The solution was 
extracted with EtOAc.  The extract was washed with saturated NaS2O4 aq. and brine, and 
dried over MgSO4.  Concentration under reduced pressure followed by flash 
chromatography over silica gel with EtOAc/Hexane/AcOH (75:25:1) gave 2c (78.4 mg, 
quant.  yield).  Rf 0.5 in 33 % ethyl acetate in hexanes containing 1 % AcOH; 1H NMR 
(360 MHz, CDCl3): δ = 5.05 (s, 1H), 4.39 (s, 1H), 2.78 - 2.74 (m, 2H), 2.30 (s, 1H), 2.10 
(s, 1H), 1.46 (s, 9H), 1.33 (s, 9H); 13C NMR (90 MHz, CDCl3): δ = 176.2, 155.7, 114.0, 
80.4, 60.7, 52.8, 48.0, 33.6, 31.9, 28.5, 23.3 (Note: A second set of concentration-
dependent peaks was also observed; these peaks can be seen in the included 13C 
spectrum.  These could be reduced, but not eliminated by diluting the sample, no 
evidence of dimerization is seen in the more dilute 1H spectrum sample, Figure 3-23); 
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HRMS (ESI) m/z calculated for C13H24NO4S2 [M + H]+ 322.115, found 322.115. 
 
(S)-2-((tert-butoxycarbonyl)amino)-4-(phenyldisulfanyl)butanoic acid (Boc-Hcf-OH, 
2d). 
1 (234 mg, 0.5 mmol) was dissolved in H2O/THF (50 % v/v, 19 mL).  To the 
solution was added thiophenol (600 µL, 5.9 mmol) and 10 N sodium hydroxide aq. (700 
µL, 7 mmol) after cooling to 0 °C in an ice bath.  Then, a solution of iodine in 95 % 
EtOH was added dropwise until the color of the reaction changed from colorless to 
brown.  The mixture was stirred overnight with warming to room temperature.  After 
removing THF under reduced pressure, the reaction mixture was acidified by addition of 
1 N HCl aq. until the pH reached 2 - 3.  The solution was extracted with EtOAc.  The 
extract was washed with saturated NaS2O4 aq. and brine, and dried over MgSO4.  
Concentration under reduced pressure followed by flash chromatography over silica gel 
with EtOAc/Hexane/AcOH (80:20:1) gave 2d (166 mg, 44 %).  Rf 0.47 in 33 % ethyl 
acetate in hexanes containing 1 % AcOH 1H NMR (360 MHz, CDCl3): δ = 7.52-7.50 (m, 
2H), 7.32-7.28 (m, 2H), 7.23-7.21 (m, 1H), 4.98 (s, 1H), 4.36 (s, 1H), 2.80 - 2.76 (m, 
2H), 2.35-2.29 (m, 1H), 2.08-2.00 (m, 1H), 1.42 (s, 9H); 13C NMR (90 MHz, CDCl3): δ = 
176.5, 155.8, 137.2, 129.3,128.2, 127.3, 80.8, 52.7, 34.6, 32.1, 28.5 (Note: A second set 
of concentration-dependent peaks was also observed, these peaks can be seen in the 
included 13C spectrum.  These could be reduced, but not eliminated by diluting the 
sample, no evidence of dimerization is seen in the more dilute 1H spectrum sample, 
Figure 3-25); HRMS (ESI) m/z calculated for C15H21NNaO4S2 [M + Na]+ 366.080, found 
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366.081. 
 
(S)-cyanomethyl 2-((tert-butoxycarbonyl)amino)-4-(methyldisulfanyl)butanoate 
(Boc-Hcm-OCH2CN, 3a). 
Compound 2a (367 mg, 1.3 mmol) was dissolved in 4 mL tetrahydrofuran.  50 
equiv. chloroacetonitrile (4.1 mL, 65.2 mmol) and DIPEA (453 mL, 2.6 mmol) were 
added to the reaction mixture and allowed to stir overnight.  The reaction mixture was 
concentrated under reduced pressure, then purified on silica gel (25 % EtOAc in hexanes) 
to give 307.5 mg (74 %) of the titled compound 3a.  Rf 0.33 in 25 % EtOAc in hexanes; 
1H NMR (360 MHz, CDCl3): δ = 5.02 (s, 1H), 4.73 (dd, J = 31.3 Hz, 2H), 4.49 (s, 1H), 
2.77 - 2.73 (m, 2H), 2.37 - 2.27 (m, 1H), 2.13 - 2.02 (m, 1H), 1.46 (s, 9H); 13C NMR (90 
MHz, CDCl3): δ = 171.2, 155.4, 114.03, 80.9, 52.5, 49.2, 33.6, 31.9, 28.5, 23.3; HRMS 
(ESI) m/z calculated for C12H20N2NaO4S2 [M + Na]+ 343.076, found 343.076. 
 
(S)-cyanomethyl 2-((tert-butoxycarbonyl)amino)-4-(isopropyldisulfanyl)butanoate 
(Boc-Hcp-OCH2CN, 3b). 
Compound 2b (100 mg, 324 µmol) was dissolved in 1 mL tetrahydrofuran.  50 
equiv. chloroacetonitrile (1.08 mL, 16.2 mmol) and DIPEA (113 uL, 647 µmol) were 
added to the reaction mixture and allowed to stir overnight.  The reaction mixture was 
concentrated under reduced pressure, then purified on silica gel (25 % EtOAc in hexanes) 
to give 95.1 mg (84 %) of 3b.  Rf 0.43 in 25 % EtOAc in hexanes; 1H NMR (360 MHz, 
CDCl3): δ = 5.01 (s, 1H), 4.85 - 4.73 (m, 2H), 4.46 (s, 1H), 3.03 - 2.99 (m, 1H), 2.72 (t, 
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2H), 2.30 - 2.27 (m, 1H), 2.09 - 2.03 (m, 1H), 1.45 (s, 9H), 1.33 - 1.31 (m, 4H); 13C NMR 
(90 MHz, CDCl3): δ = 171.2, 155.4, 114.0, 80.8, 52.5, 49.2, 41.3, 35.2, 31.9, 28.4, 22.8, 
22.8; HRMS (ESI) m/z calculated for C14H24N2NaO4S2 [M +Na]+ 371.107, found 
371.108. 
 
(S)-cyanomethyl 2-((tert-butoxycarbonyl)amino)-4-(tert-butyldisulfanyl)butanoate 
Boc-Hcb-OCH2CN, 3c). 
Compound 2c (100 mg, 309 µmol) was dissolved in 1 mL tetrahydrofuran.  50 
equiv. chloroacetonitrile (977 µL, 15.5 mmol) and DIPEA (108 uL, 618 µmol) were 
added to the reaction mixture and allowed to stir overnight.  The reaction mixture was 
concentrated under reduced pressure, then purified on silica gel (25 % EtOAc in hexanes) 
to give 106.3 mg (95 %) of compound 3c.  Rf 0.47 in 25 % EtOAc in hexanes; 1H NMR 
(360 MHz, CDCl3): δ = 5.00 (s, 1H), 4.73 (dd, J = 25.2 Hz, 2H), 4.46 (s, 1H), 2.74 (t, 
2H), 2.33 - 2.24 (m, 1H), 2.11 - 2.00 (m, 1H), 1.45 (s, 9H), 1.34 (s, 9H); 13C NMR (90 
MHz, CDCl3): δ = 171.2, 155.4, 114.1, 80.8, 52.6, 49.2, 48.3, 35.9, 31.9, 30.1, 28.5; 
HRMS (ESI) m/z calculated for C15H26N2NaO4S2 [M + Na]+ 385.123, found 385.124. 
 
(S)-cyanomethyl 2-((tert-butoxycarbonyl)amino)-4-(phenyldisulfanyl)butanoate 
(Boc-Hcf-OCH2CN, 3d). 
Compound 2d (100 mg, 291 µmol) was dissolved in 1 mL tetrahydrofuran.  50 
equiv. chloroacetonitrile (921 µL, 14.6 mmol) and DIPEA (101.5 uL, 583 µmol) were 
added to the reaction mixture and allowed to stir overnight.  The reaction mixture was 
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concentrated under reduced pressure, then purified on silica gel (25 % EtOAc in hexanes) 
to give 103.8 mg (93 %) of compound 3d.  Rf 0.37 in 25 % EtOAc in hexanes; 1H NMR 
(360 MHz, CDCl3): δ = 7.53-7.50 (m, 2H), 7.34-7.30 (m, 2H), 7.25-7.21 (m, 1H), 4.91 (s, 
1H), 4.73 (dd, J = 25.2 Hz, 2H), 4.41 (s, 1H), 2.79-2.74 (m, 2H), 2.30 - 2.22 (m, 1H), 
2.07 - 2.01 (m, 1H), 1.42 (s, 9H); 13C NMR (90 MHz, CDCl3): δ = 171.1, 155.4, 137.0, 
129.4, 128.3, 127.5, 114.0, 80.9, 52.4, 49.2, 34.5, 31.5, 28.5; HRMS (ESI) m/z calculated 
for C17H21N2O4S2 [M + H]+ 381.094, found 381.094. 
 
(S)-(2R,3R,4R,5R)-2-(6-amino-9H-purin-9-yl)-5-((bis(4-
methoxyphenyl)(phenyl)methoxy) methyl)-4-hydroxytetrahydrofuran-3-yl 2-((tert-
butoxycarbonyl)amino)-4-(methyldisulfanyl) butanoate (Boc-Hcm-(DMT)-A, 4a). 
Tetrahydrofuran (5 mL) was added to Boc-Hcm-OCH2CN 3a (80 mg, 0.250 
mmol), (DMT)-A (71.3 mg, 0.125 mmol), and NBu4Ac (5 mg) and stirred for 24 h.  The 
solvent was removed under reduced pressure and preparative thin-layer chromatography 
(5 % methanol in ethyl acetate and eluted from silica with 10 % methanol in chloroform), 
afforded 67.4 mg of a white solid in 64.7 % yield.  Rf 0.75 in 5 % methanol in ethyl 
acetate; 1H and 13C NMR for 4a shown below in Figure 3-20; LRMS (ESI) m/z 
calculated for C41H49N6O9S2 (M + H)+ 833.3, found 833.4. 
 
(S)-(2R,3R,4R,5R)-2-(6-amino-9H-purin-9-yl)-5-((bis(4-
methoxyphenyl)(phenyl)methoxy) methyl)-4-hydroxytetrahydrofuran-3-yl 2-((tert-
butoxycarbonyl)amino)-4-(isopropyldisulfanyl) butanoate (Boc-Hcp-(DMT)-A, 4b). 
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Tetrahydrofuran (5 mL) was added to Boc-Hcp-OCH2CN 3b (74.5 mg, 0.214 
mmol), (DMT)-A (61.2 mg, 0.107 mmol), and NBu4Ac (4 mg) and stirred for 24 h.  The 
solvent was removed under reduced pressure and chromatography (100 % hexanes, 20 – 
100 % ethyl acetate in hexanes, 2.5 - 10 % methanol in ethyl acetate), afforded 38.0 mg 
of a white solid in 41.1 % yield.  Rf 0.75 in 5 % methanol in ethyl acetate; 1H and 13C 
NMR for 4b shown below, Figure 3-22; LRMS (ESI) m/z calculated for C43H53N6O9S2 
(M + H)+ 861.3, found 861.5. 
 
(S)-(2R,3R,4R,5R)-2-(6-amino-9H-purin-9-yl)-5-((bis(4-
methoxyphenyl)(phenyl)methoxy)methyl)-4-hydroxytetrahydrofuran-3-yl 2-((tert-
butoxycarbonyl)amino)-4-(tert-butyldisulfanyl)butanoate (Boc-Hcb-(DMT)-A, 4c). 
Tetrahydrofuran (5 mL) was added to Boc-Hcb-OCH2CN 3c (95.3 mg, 0.263 
mmol), (DMT)-A (76.6 mg, 0.1316 mmol), and NBu4Ac (11.4 mg) and stirred for 24 h.  
The solvent was removed under reduced pressure and preparative thin layer 
chromatography (5 % methanol in ethyl acetate and eluted from silica with 10 % 
methanol in dichloromethane), afforded 94.6 mg of a white solid in 39.9 % yield.  Rf 0.75 
in 5 % methanol in ethyl acetate; 1H and 13C NMR for 4c shown below, Figure 3-24; 
LRMS (ESI) m/z calculated for C44H55N6O9S2 (M + H)+ 875.3, found 875.5. 
 
(S)-(2R,3R,4R,5R)-2-(6-amino-9H-purin-9-yl)-5-((bis(4-
methoxyphenyl)(phenyl)methoxy)methyl)-4-hydroxytetrahydrofuran-3-yl 2-((tert-
butoxycarbonyl)amino)-4-(phenyldisulfanyl)butanoate (Boc-Hcf-(DMT)-A, 4d). 
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Tetrahydrofuran (5 mL) was added to Boc-Hcf-OCH2CN 3d (103.8 mg, 0.272 
mmol), (DMT)-A (78.3 mg, 0.137 mmol), and NBu4Ac (13.5 mg) and stirred for 24 h.  
The solvent was removed under reduced pressure and preparative thin layer 
chromatography (5 % methanol in ethyl acetate and eluted from silica with 10 % 
methanol in dichloromethane), afforded 91.5 mg of a white solid in 74.6 % yield.  Rf 0.75 
in 5 % methanol in ethyl acetate; 1H and 13C NMR for 4d shown below, Figure 3-26; 
LRMS (ESI) m/z calculated for C46H51N6O9S2 (M + H)+ 895.3, found 895.5. 
 
(2R,3R,4R,5R)-2-(6-amino-9H-purin-9-yl)-5-((bis(4-
methoxyphenyl)(phenyl)methoxy)methyl)-4-hydroxytetrahydrofuran-3-yl 2-((tert-
butoxycarbonyl)amino)-4-((2,2,2-trifluoroethyl)disulfanyl)butanoate (Boc-HcTf-
(DMT)-A, 4e). 
Tetrahydrofuran (5 mL) was added to Boc-HcTf-OCH2CN 3e (76.1 mg, 0.196 
mmol), (DMT)-A (75.9 mg, 0.133 mmol), and NBu4Ac (4.7 mg) and stirred for 24 h.  
The solvent was removed under reduced pressure and preparative thin layer 
chromatography (5 % methanol in ethyl acetate and eluted from silica with 10 % 
methanol in chloroform), afforded 94.9 mg of a white solid in 79.1 % yield.  Rf 0.75 in 5 
% methanol in ethyl acetate; 1H and 13C NMR for 4e shown below, Figure 3-27; LRMS 
(ESI) m/z calculated for C42H48F3N6O9S2 (M + H)+ 901.3, found 901.5. 
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(S)-(2R,3R,4R,5R)-2-(6-amino-9H-purin-9-yl)-4-hydroxy-5-
(hydroxymethyl)tetrahydrofuran-3-yl 2-amino-4-(methyldisulfanyl)butanoate 
(Hcm-A, 5a). 
Trifluoroacetic acid (1 mL), tetrahydrofuran (1 mL) and TIPSH (51.3 mg, 0.066 
mL, 0.32 mmol) were added to 4a (67.4 mg, 0.081 mmol) following the deprotection 
procedure given for S4a.  HPLC/MALDI analysis m/z calculated C15H23N6O5S2 (M + 
H)+ 431.1; Gradient 1, 11 mL/min (Table 3-1); retention time 24.7 min, found 430.7; 
retention time 26.3 min, found 430.7. 
 
(S)-(2R,3R,4R,5R)-2-(6-amino-9H-purin-9-yl)-4-hydroxy-5-
(hydroxymethyl)tetrahydrofuran-3-yl 2-amino-4-(isopropyldisulfanyl)butanoate 
(Hcp-A, 5b). 
Trifluoroacetic acid (1 mL), tetrahydrofuran (1 mL) and TIPSH (29 mg, 0.036 
mL, 0.18 mmol) were added to 4b (38 mg, 0.0441 mmol) following the deprotection 
procedure given for S4a.  HPLC/MALDI analysis m/z calculated C17H27N6O5S2 (M + 
H)+ 459.1; Gradient 1, 11 mL/min (Table 3-1); retention time 29.3 min, found 458.9; 
retention time 30.8 min, found 458.9. 
 
(S)-(2R,3R,4R,5R)-2-(6-amino-9H-purin-9-yl)-4-hydroxy-5-
(hydroxymethyl)tetrahydrofuran-3-yl 2-amino-4-(tert-butyldisulfanyl)butanoate 
(Hcb-A, 5c). 
Trifluoroacetic acid (1 mL), tetrahydrofuran (1 mL) and TIPSH (68 mg, 0.089 
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mL, 0.43 mmol) were added to 4c (94.6 mg, 0.108 mmol) following the deprotection 
procedure given for S4a.  HPLC/MALDI analysis m/z calculated C18H29N6O5S2 (M + 
H)+ 473.2; Gradient 1, 11 mL/min (Table 3-1); retention time 31.3 min, found 472.8; 
retention time 32.8 min, found 472.8. 
 
(S)-(2R,3R,4R,5R)-2-(6-amino-9H-purin-9-yl)-4-hydroxy-5-(hydroxymethyl)-
tetrahydrofuran-3-yl 2-amino-4-(phenyldisulfanyl)butanoate (Hcf-A, 5d). 
Trifluoroacetic acid (1 mL), tetrahydrofuran (1 mL) and TIPSH (65 mg, 0.084 
mL, 0.409 mmol) were added to 4d (91.5 mg, 0.1022 mmol) following the deprotection 
procedure given for S4a.  HPLC/MALDI analysis m/z calculated C20H25N6O5S2 (M + 
H)+ 493.1; Gradient 3 (Table 3-1); retention time 32.1 min, found 493.1; retention time 
33.2 min, found 493.1. 
 
(2R,3R,4R,5R)-2-(6-amino-9H-purin-9-yl)-4-hydroxy-5-(hydroxymethyl) 
tetrahydrofuran-3-yl 2-amino-4-((2,2,2-trifluoroethyl)disulfanyl)butanoate 
 (HcTf-A, 5e). 
Trifluoroacetic acid (1 mL), tetrahydrofuran (1 mL) and TIPSH (67.1 mg, 0.087 
mL, 0.421 mmol) were added to 4e (94.9 mg, 0.105 mmol) following the deprotection 
procedure given for S4a.  HPLC/MALDI analysis m/z calculated C16H22F3N6O5S2 (M + 
H)+ 499.1; Gradient 1 at 11 mL/min (Table 3-1); retention time 29.1 min, found 499.1; 
retention time 30.6 min, found 499.1. 
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Figure 3-10.  1H and 13C NMR Characterization of Boc-Met-(DMT)-A (S3a) 
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Figure 3-11.  1H and 13C NMR Characterization of Boc-Cys(Bz)-(DMT)-A (S3b) 
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Figure 3-12.  1H and 13C NMR Characterization of Boc-Csm-OH (7a) 
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Figure 3-13.  1H and 13C NMR Characterization of Boc-Csm-(DMT)-A (9a) 
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Figure 3-14.  1H and 13C NMR Characterization of Boc-Csp-(DMT)-A (9b) 
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Figure 3-15.  1H and 13C NMR Characterization of Boc-Csb-(DMT)-A (9c) 
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Figure 3-16.  1H and 13C NMR Characterization of Boc-Csf-(DMT)-A (9d) 
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Figure 3-17.  1H and 13C NMR Characterization of Boc-CsTf-(DMT)-A (9e) 
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Figure 3-18. 1H and 13C NMR Characterization of Boc-Hcm-OH (2a) 
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Figure 3-19.  1H and 13C NMR Characterization of Hcm-OH, Free Amino Acid 
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Figure 3-20.  1H and 13C NMR Characterization of Boc-Hcm-(DMT)-A (4a) 
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Figure 3-21.  1H and 13C NMR Characterization of Boc-Hcp-OH (2b) 
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Figure 3-22.  1H and 13C NMR Characterization of Boc-Hcp-(DMT)-A (4b) 
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Figure 3-23.  1H and 13C NMR Characterization of Boc-Hcb-OH (2c) 
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Figure 3-24.  1H and 13C NMR Characterization of Boc-Hcb-(DMT)-A (4c) 
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Figure 3-25.  1H and 13C NMR Characterization of Boc-Hcf-OH (2d) 
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Figure 3-26.  1H and 13C NMR Characterization of Boc-Hcf-(DMT)-A (4d) 
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Figure 3-27.  1H and 13C NMR Characterization of Boc-HcTf-(DMT)-A (4e) 
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3.3.3 – Peptide synthesis 
All peptides were synthesized using a manual, Fmoc-solid phase procedure on 2-
chlorotrityl (ClTrt) resin as described previously.173  Protected αS1-4 peptides Ac-
MetAsp(t-Bu)ValPhe-OH (S6) and Ac-McmMetAsp(t-Bu)ValPhe-OH (S7), where Mcm 
is β-(7-methoxy-coumarin-4-yl)-alanine, were cleaved by treatment with acetic acid 
/trifluoroethanol/dichloromethane (1/1/3, v/v) for 1 h.  After the resin was filtered, 
solvent was removed in vacuo.  Ac-MetAspValPheHcsLys (S8) and Ac-
MetAspValPheMetLys (S9) were cleaved with TFA/triisopropylsilane/water (95/2.5/2.5, 
v/v) for 1 h, and purified by C18 reverse phase HPLC using Gradient 4a (S8) and 
Gradient 4b (S9). 
 
3.3.4 – Thioesterification of Ac-MetAspValPhe-SR (11) and Ac-McmMetAspValPhe-
SR (S10) 
100 µmol of protected S6 or S7 was dissolved in 10 mL of DMF in an ice bath.  
10 equiv. each of PyBOP and triethylamine were added to the peptide solution.  Then, 20 
equiv. of methyl mercaptopropionate were added and the solution was allowed to stir 
overnight.  Solvent was removed in vacuo.  Pouring water onto the residue caused 
immediate precipitation of a white solid.  The precipitate was collected by centrifugation, 
and washed again with water.  The crude protected peptide thioester was dissolved in 
TFA/triisopropylsilane/water (95/2.5/2.5, v/v) and allowed to stir for 1 h.  After removal 
of the solvent in vacuo, pouring Et2O onto the residue gave a precipitate that was 
collected by centrifuge, and washed with Et2O (3 times).  Deprotected thioesters 11 or 
S10 (see structure below) were then purified by C18 reverse phase semi-prep HPLC 
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using Gradient 5. 
 
S10 
 
Table 3-1.  Solvent Gradients Used for Peptide Purification and Analysis 
Gradient # Time (min) Buffer A (%) Gradient # Time (min) Buffer A (%) 
1 0:00 99 2 0:00 0 
(rate in text) 10:00 99 15 mL/min 5:00 0 
 40:00 65  35:00 15 
 45:00 0  40:00 100 
 50:00 0  45:00 100 
 55:00 99  50:00 0 
 60:00 99    
3 0:00 99 4a 0:00 71 
12 mL/min 10:00 99 14 mL/min 5:00 71 
 40:00 65  35:00 65 
 50:00 0  40:00 0 
 55:00 0  45:00 0 
 65:00 99  50:00 71 
 70:00 99    
4b 0:00 71 5 0:00 71 
11 mL/min 5:00 71 4 mL/min 5:00 71 
 35:00 65  35:00 65 
 40:00 0  40:00 0 
 45:00 0  45:00 0 
 50:00 71  50:00 71 
      
6 0:00 99 7 0:00 99 
1 mL/min 5:00 99 4 mL/min 5:00 99 
 10:00 70  10:00 85 
 15:00 60  42:00 55 
 20:00 0  46:00 0 
 25:00 0  49:00 0 
 27:00 99  52:00 99 
 30:00 99  55:00 99 
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3.3.5 – MetRS and Met*RS Expression and Purification 
E. coli MetRS and Met*RS were obtained from David Tirell.  Plasmids were 
transformed into E. coli BL21 (DE3) and grown to OD600 0.6 in LB media.  Protein 
expression was induced with 1.0 mM isopropyl β–D–thiogalactoside and grown for 18 h 
at 25 °C.  The cells were harvested at 5000 x g for 15 min and the resulting pellet was 
resuspended in a lysis buffer (300 mM KCl, 50 mM Tris pH 8.0) and included protease 
inhibitor cocktail, 1 mM PMSF, and 10 units/mL DNAse1–Grade II) and sonicated.  
Soluble protein was obtained by centrifugation for 20 minutes at 30,000 x g, 4 °C.  
Collected soluble protein was gently shaken for 1 h on ice with Ni-NTA resin.  Protein 
was purified by rinsing with lysis buffer followed by washing with wash buffer (300 mM 
KCl, 50 mM Tris pH 8.0, and 15 mM imidazole).  Protein was eluted with 4 x 1 mL 
Elution Buffer A (300 mM KCl, 50 mM Tris pH 8.0, and 50 mM imidazole) followed by 
4 x 1 mL Elution Buffer B (300 mM KCl, 50 mM Tris pH 8.0, and 250 mM imidazole).  
SDS-PAGE analysis was performed to analyze the purity of elution fractions.  Collected 
protein fractions were dialyzed against storage buffer (50 mM Tris pH 7.5 in 50 % 
glycerol) at 4 °C.  Protein was stored in 0.5 mL aliquots at -80 °C. 
 
3.3.6 – Chemoenzymatic LysAlaAcm Ligation Assay 
Each ligation reaction, 125 µL total volume, contained the following reagents: 
aminoacyl adenosine donor (1 mM), recombinant His10-tagged E. coli aminoacyl 
transferase (2.26 µM), and LysAlaAcm (100 µM) in the AaT Ligation Buffer (50 mM 
HEPES pH 8.0, 150 mM KCl, 10 mM MgCl2).  The reaction mixtures were incubated at 
37 °C for four hours.  At the second, third, and fourth hour of the reaction, an additional 1 
157 
 
mM dose of aminoacyl adenosine donor was added to the reaction mixture.  The reaction 
was quenched with 1 % acetic acid at 4 h.  One reaction material modification was made 
for Hcm analog only, in which we prepared AaT in transferase buffer without the 
presence of β-mercaptoethanol (50 mM Tris, 30 % glycerol, 120 mM (NH4)2SO4).  The 
proteins were extracted from the reactions via acetone precipitation.  The reactions were 
precipitated using 4X reaction volume of acetone and cooled at - 20 °C for 1 hour.  Next, 
the reactions were centrifuged at 13,200 rpm at 4 °C for 20 min to separate the reaction 
from precipitated protein.  The supernatant was transferred to fresh 1.5 mL centrifuge 
tubes and allowed for acetone evaporation overnight at room temperature for all non-
disulfide analogs.  For all disulfide analogs, the reactions were rotary evaporated 
immediately to remove acetone in order to minimize disulfide reduction due to air 
exposure.  After acetone evaporation, the supernatant was dried in a Speedvac (Savant, 
Thermo Scientific, Fisher Inc.) for 30 min to remove residual acetone.  The resulting 
reaction volume was dissolved up to 1.2 mL using MilliQ water and analyzed by HPLC 
(Gradient 6) to determine ligation yield by integration of separated peak intensities 
monitored at 325 nm.  Collected HPLC fractions were characterized through MALDI MS 
analysis.  Reactions were performed with 3 trials on at least two protein preparations for 
all successful reactions. 
 
3.3.7 – Fully Enzymatic LysAlaAcm Ligation Assay 
 Each ligation reaction, 125 µL total volume, contained the following reagents: 
amino acid (1 mM), ATP (2.5 mM), total E. coli tRNA (2 µg/µL), recombinant His-
tagged E. coli MetRS or Met*RS, recombinant His10-tagged E. coli aminoacyl transferase 
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(2.26 µM), and LysAlaAcm (100 µM) in the AaT Ligation Buffer (50 mM HEPES pH 
8.0, 150 mM KCl, 10 mM MgCl2).  The reaction mixtures were incubated at 37 °C for 30 
minutes and quenched with 1 % acetic acid.  Acetone precipitation and subsequent 
analysis were performed as described for the Chemoenzymatic LysAlaAcm Ligation 
Assay. 
 
3.3.8 – AaT Ligation Reaction Analysis by HPLC 
All HPLC analyses of LysAlaAcm ligations were monitored using a Waters 
Symmetry Shield C18 reversed phase column (Gradient 6).  Peptide retention times 
monitored at 325 nm (Acm absorption) are in Table 3-3 and MALDI MS analyses, 
confirming peptide identity, are in Table 3-2. 
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Table 3-2.  Calculated and Observed Peptide and Protein Masses 
Peptide Calculated 
(M+H)+ 
Observed 
(M+H)+ 
Calculated 
(M+Na)+ 
Observed 
(M+Na)+ 
MetLysAlaAcma 506.243  506.114  528.225 528.1 
CsmLysAlaAcma 524.200 523.892  546.182  545.893 
CbzLysAlaAcma 568.259 --- 590.241 --- 
CspLysAlaAcma 552.231 552.436 574.213 --- 
CsbLysAlaAcma 566.247 566.400 588.229 --- 
CsfLysAlaAcma 586.215 --- 608.198 --- 
CsTfLysAlaAcma 592.187 --- 614.169 --- 
HcsLysAlaAcma* 492.611 --- 514.209 --- 
HcmLysAlaAcma (14) 538.215 538.162 560.197 560.167 
HcpLysAlaAcma 566.247  566.393 588.228 588.357 
HcbLysAlaAcma 580.262 579.923 602.224 601.924 
HcfLysAlaAcma 600.231 --- 622.213 --- 
HcTfLysAlaAcma 606.203 --- 628.185 --- 
Ac-MetAspValPhe-SRa (11) 655.247 --- 677.229 677.302 
Ac-MetAspValPheHcsLysa (S8) 798.352 798.600 820.334 820.591 
Ac-MetAspValPheMetLysa (S9) 812.368 812.449 834.350 834.437 
Ac-McmMetAspValPhe-SRa (S10) 900.31 --- 922.31 922.25 
Ac-MetAspValPheHcsLysAlaAcma (15) 1026.44 1026.59 1048.42 1048.56 
Ac-MetAspValPheMetLysAlaAcma (16) 1040.46 1040.24 1062.44 --- 
αS6-140b (18) 13, 837.3 13, 837.7 13, 859.3 --- 
Hcm-αS6-140b (19) 14, 000.6 14, 001.0 14, 022.6 --- 
AcMcm-αS-Hcs5b (20a) 14, 733.4 14, 735.1 14, 755.4 --- 
AcMcm-αSb (21a) 14, 747.4 14, 748.4 14, 769.4 --- 
Ac-αS-Hcs5b (20b) 14, 489.2 14, 490.0 14, 511.2 --- 
Ac-αSb (21b) 14, 503.2 14, 502.7 14, 525.2 --- 
 
• aExact mass, bMolecular weight 
• HcsLysAlaAcm observed as a byproduct of transfer of 5a, 5b, or 5c in the presence of 
BME. 
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Table 3-3.  HPLC Analysis of LysAlaAcm Transfer Reactions 
Peptide Time (min) Conditions % Yield 
LysAlaAcm 11.3  NA 
PheLysAlaAcm 12.5 S1  99.5 ± 0.1 
PheLysAlaAcm 12.5 S1, 0.05 M Gdn•HCl 96.0 ± 0.1 
PheLysAlaAcm 12.5 S1, 0.10 M Gdn•HCl 93.4 ± 0.1 
PheLysAlaAcm 12.5 S1, 0.20 M Gdn•HCl 79.2 ± 5.0 
PheLysAlaAcm 12.5 S1, 0.30 M Gdn•HCl 71.2 ± 4.0 
PheLysAlaAcm 12.5 S1, 0.40 M Gdn•HCl 62.0 ± 3.8 
PheLysAlaAcm 12.5 S1, 0.50 M Gdn•HCl 54.5 ± 0.4 
PheLysAlaAcm 12.5 S1, 1.00 M Gdn•HCl 25.4 ± 2.4 
PheLysAlaAcm 12.5 S1, 1.50 M Gdn•HCl 10.6 ± 0.4 
PheLysAlaAcm 12.5 S1, 2.00 M Gdn•HCl 3.0 ± 0.2 
PheLysAlaAcm 12.5 S1, 0.1 % Triton 95.0 ± 3.8 
PheLysAlaAcm 12.5 S1, 0.5 % Triton 97.8 ± 0.1 
PheLysAlaAcm 12.5 S1, 1.0 % Triton 96.5 ± 2.4 
PheLysAlaAcm 12.5 S1, 2.0 % Triton 97.4 ± 1.5 
PheLysAlaAcm 12.5 S1, 5.0 % Triton 98.4 ± 0.5 
MetLysAlaAcm 12.1 S4a 74.6 ± 1.3 
MetLysAlaAcm 12.1 Met, MetRS 99.9 ± 0.1 
MetLysAlaAcm 12.1 Met, 1 mg/mL Met*RS, 0.20 M Gdn•HCl 74.2 ± 8.7 
MetLysAlaAcm 12.1 Met, 1 mg/mL Met*RS, 0.50 M Gdn•HCl 30.1 ± 1.3 
MetLysAlaAcm 12.1 Met, 1mg/mL Met*RS, 5.0 % Triton 92.0 ± 9.6 
CbzLysAlaAcm NA S4b 0 
CsmLysAlaAcm 12.3 5*a 20.9 ± 0.5 
CspLysAlaAcm 13.0 5*b 68.4± 0.2 
CsbLysAlaAcm 13.3 5*c 41.3 ± 0.7 
CsfLysAlaAcm NA 5*d 0 
CsTfLysAlaAcm NA 5*e 0 
HcmLysAlaAcm 12.7 5a 21.2 ± 0.7 
HcmLysAlaAcm 12.7 5a, 0 mM BME 36.5 ± 0.1 
HcmLysAlaAcm 12.7 5a, 1 mg/mL MetRS 99.9 ± 0.1 
HcmLysAlaAcm 12.7 5a, 0.1mg/mL MetRS, 30 min 48.8 ± 4.8 
HcmLysAlaAcm 12.7 5a, 1 mg/mL Met*RS 99.9 ± 0.1 
HcmLysAlaAcm 12.7 5a, 0.1mg/mL Met*RS, 30 min 63.8 ± 3.1 
HcmLysAlaAcm 12.7 5a, 0.1mg/mL Met*RS 99.9 ± 0.1 
HcmLysAlaAcm 12.7 5a, 1 mg/mL Met*RS, 5.0 % Triton 99.4 ± 0.1 
HcmLysAlaAcm 12.7 5a, 1 mg/mL Met*RS, 0.20 M Gdn•HCl 76.7 ± 8.1 
HcmLysAlaAcm 12.7 5a, 1 mg/mL Met*RS, 0.50 M Gdn•HCl 15.3 ± 8.3 
HcpLysAlaAcm 13.5 5b 14.6 ± 0.3 
HcbLysAlaAcm 13.7 5c 2.7 ± 0.2 
HcfLysAlaAcm NA 5d 0 
HcTfLysAlaAcm NA 5e 0 
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3.3.9 – Ligation of Ac-MetAspValPhe-SR (11) and HcmLysAlaAcm (14) 
Ligation buffer was prepared as follows: 200 mM sodium phosphate dibasic, 40 
mM TCEP, 1 % v/v thiophenol and 1 % v/v benzylmercaptan, pH 7.2.  Ligation buffer 
was prepared fresh and sparged with argon for 10 – 20 minutes.  50 uL of the ligation 
buffer was added to 50 uL of a 2 mM stock of HcmLysAlaAcm.  The solution was then 
added to 0.33 µmol of Ac-MetAspValPhe-SR and the reaction mixture was sparged for 
an additional 15 minutes.  The reaction was mixed overnight using a micro-stir bar.  The 
reaction was quenched the following day with a 10-fold amount of 0.1 % trifluoroacetic 
acid and analyzed by HPLC (Gradient 7).  Peptide retention times were monitored at 215 
nm (peptide bond absorption) and MALDI MS analyses, confirming peptide identity, are 
in Table 3-2. 
 
3.3.10 – Construction of Recombinant αS6-140 Expression Plasmid 
We have previously described the cloning of the αS gene from a pT7-7 vector into 
the pET-16b prokaryotic expression vector, which contains an N-terminal His tag 
followed by a Factor Xa recognition site (IEGR) (Figure 3-28 Ia).2  QuikChange® 
mutagenesis was used to delete residues H-1 and M1 (Figure 3-28 Ib) followed by a D2K 
mutation (Figure 3-28 Ic) to yield the αS2-140K2 plasmid.  Residues K2-M5 were deleted 
(Figure 3-28 Id) from the αS2-140K2 plasmid using QuickChange® mutagenesis to give 
the αS6-140 plasmid.  All mutagenesis steps were confirmed by DNA sequencing using the 
T7 promoter primer.  Plasmid constructed by John Warner. 
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I.  Construction of αS6-140 Plasmid DNA 
 
II.  DNA Oligomers Used for QuickChange® Mutagenesis 
 
Figure 3-28.  Construction of αS6-140 Plasmid 
 
3.3.11 – Cloning of Calmodulin Expression Constructs 
Quikchange ® mutagenesis was used to generate the following mutant plasmids: 
pET15b-H10-CaM77-149 (C-terminal domain) and pTXB1-CaM1-72 (N-terminal domain).  
All mutagenesis steps were confirmed by DNA sequencing using the T7 promoter 
primer. 
The C-terminal domain of calmodulin (CaM) was cloned from a plasmid 
containing a gene encoding full-length wild-type calmodulin from the chicken genus.  
This plasmid was provided by the Wand Laboratory of the University of Pennsylvania 
School of Medicine.  The CaM gene had been cloned into the pET15b vector (Novagen, 
Gibbstown, NJ) at the NcoI and XhoI restriction enzyme cut sites.  An NdeI site was 
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introduced at K76 of the CaM gene using QuikChange® mutagenesis.  The plasmid was 
digested with PacI/NdeI.  The CaM digested insert was ligated into a pEG6 vector50, 
which contains an N-terminal H10 tag with a factor Xa cleavage site, at cut sites, Nde1 
and XhoI with T4 DNA ligase.  The pEG6 plasmid was a gift from the Muir Lab at 
Princeton University.  To complete the plasmid, an N-terminal lysine was exposed 
through the deletion of HM at the inserted NdeI site resulting in the plasmid pEG6-H10-
FactorXa-(Lys)CaM78-149 (Figure 3-29). 
 
 
Figure 3-29.  Construction of WT CaM78-149 His-Tagged Expression Plasmid 
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The N-terminal domain of calmodulin (CaM) was cloned from a plasmid 
containing a gene encoding wild-type calmodulinS17C, 1-116.  This plasmid was provided by 
the Linse Laboratory of the Department of Biochemistry and Structural Biology at Lund 
University.  The plasmid contained the pTXB1 vector, which encodes a mini-intein GyrA 
from the Mycobacterium xenopi followed by a chitin-binding domain (CBD).  A PacI site 
was introduced at M72 and L117 of the CaM gene using QuikChange® mutagenesis.  With 
the PacI sites encoded, the plasmid was digested with PacI and then the resulting sticky 
ends were ligated using T4 DNA ligase resulting in a pTXB1-CaM1-72-PacI plasmid.  
Next, the PacI site at 72 was mutated back to wild type M72.  To bring the CaM gene 
back to wild-type CaM1-72, the S17C mutation was mutated back to wild type C17S 
(Figure 3-30). 
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Figure 3-30.  Construction of WT CaM1-72 Intein Expression Plasmid with C-Terminal Chitin-
Binding Domain 
 
3.3.12 – Expression and Purification of αS6-140 
The plasmid containing the αS gene was used to transform Escherichia coli 
BL21(DE3) cells.  Transformed cells were selected on the basis of ampicillin resistance.  
Single colonies were used to inoculate 5 mL of LB media supplemented with ampicillin 
(100 µg/mL).  The primary 5 mL culture was incubated at 37 °C with shaking at 250 rpm 
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for 5 hours.  500 mL of LB media supplemented with ampicillin was inoculated with 1 
mL of the primary culture.  The 500 mL culture was incubated at 37 °C with shaking at 
250 rpm until an OD600 of 0.6 was reached.  Expression was induced with the addition of 
1.0 mM isopropyl β-D-thiogalactoside and cells were incubated at 25 °C for 16 hours.  
The cells were harvested at 5000 x g for 15 min and the resulting pellet was resuspended 
in a Factor Xa cleavage buffer (100 mM NaCl, 50 mM Tris pH 8.0, 5 mM CaCl2) and 
included protease inhibitor cocktail, 1 mM PMSF, and 10 units/mL DNAse1–Grade II) 
and sonicated.  Following sonication, the cell lysate was boiled for 20 minutes prior to 
centrifugation for 20 minutes at 30,000 x g, 4 °C.  Collected soluble protein was gently 
shaken for 1 h on ice with Ni-NTA resin.  Protein was purified by rinsing with Factor Xa 
cleavage buffer followed by washing with Factor Xa wash buffer (100 mM NaCl, 50 mM 
Tris pH 8.0, 5 mM CaCl2, and 50 mM imidazole).  Protein was eluted with Factor Xa 
elution buffer 100 mM NaCl, 50 mM Tris pH 8.0, 5 mM CaCl2¸and 250 mM imidazole).  
SDS-PAGE analysis was performed to analyze the purity of αS elution fractions.  
Collected protein fractions were dialyzed against Factor Xa cleavage buffer at 4 °C.  The 
His10 purification tag was removed by incubation of purified αS (0.5 mg/mL) with Factor 
Xa, Restriction Grade, Bovine Plasma (Novagen) (20 Units) overnight at 37 °C.  Factor 
Xa was removed by boiling for 20 minutes and centrifugation for 20 minutes at 30,000 x 
g, 4 °C.  Soluble protein was purified from N-terminal peptide and uncleaved protein by 
1 h incubation with Ni-NTA resin.  Protein concentration was determined by BCA assay 
(Pierce) and adjusted to 1.0 mg/mL, purity was confirmed by SDS-PAGE and MALDI 
mass spectrometry.  Protein was stored at – 80 °C until further use. 
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3.3.13 – Expression and Purification of CaM78-149 
The plasmid containing the CaM78-149 gene was used to transform Escherichia 
coli BL21(DE3) cells.  Transformed cells were selected on the basis of ampicillin 
resistance.  Single colonies were used to inoculate 5 mL of LB media supplemented with 
ampicillin (100 µg/mL).  The primary 5 mL culture was incubated at 37 °C with shaking 
at 250 rpm for ~ 3 hours, until log phase was reached.  One liter of LB media 
supplemented with ampicillin was inoculated with 1 mL of the primary culture.  The 1 
liter culture was incubated at 37 °C with shaking at 250 rpm until an OD600 of 0.6 was 
reached.  Expression was induced with the addition of 1.0 mM isopropyl β-D-
thiogalactoside and cells were incubated at 25 °C for 16 hours.  The cells were harvested 
at 5000 x g for 15 min and the resulting pellet was resuspended in binding buffer (50 mM 
Tris pH 8) and included protease inhibitor cocktail, 1 mM PMSF, and 10 units/mL 
DNAse1–Grade II) and sonicated.  Following resuspension, the cell lysate was sonicated 
for 1 min, 6 times, with a one minute rest between each sonication.  Collected soluble 
protein was gently shaken for 1 h on ice with Ni-NTA resin.  Protein was purified by 
rinsing with Factor Xa cleavage buffer followed by washing with wash buffer (50 mM 
Tris pH 8 and increasing imidazole from 10 mM – 50 mM).  Protein was eluted with 
elution buffer (50 mM Tris pH 8 and 250 mM imidazole).  SDS-PAGE analysis was 
performed to analyze the purity of CaM78-149 elution fractions.  Collected protein 
fractions were dialyzed against Factor Xa cleavage buffer (50 mM Tris, 100 mM NaCl, 5 
mM CaCl2 pH 8) at 4 °C.  The His10 purification tag was removed by incubation of 
purified CaM77-149 with Factor Xa, Restriction Grade, Bovine Plasma (Novagen) (20 
Units) overnight at 37 °C (or until reaction is complete, which can take up to 2 days if 
168 
 
high concentration of protein is used).  Factor Xa cleavage was halted by addition of 1 
mM PMSF, and solution was kept at room temperature for 1 h to ensure PMSF 
degradation.  Protein concentration was determined by BCA assay (Pierce) and adjusted 
to 1.0 mg/mL, purity was confirmed by SDS-PAGE and MALDI mass spectrometry.  
Protein was stored at – 80 °C until further use. 
 
3.3.14 – Expression and Purification of CaM1-72 
The plasmid containing the CaM1-72 gene was used to transform Escherichia coli 
BL21(DE3) cells.  Transformed cells were selected on the basis of ampicillin resistance.  
Single colonies were used to inoculate 5 mL of LB media supplemented with ampicillin 
(100 µg/mL).  The primary 5 mL culture was incubated at 37 °C with shaking at 250 rpm 
for ~ 3 hours, until log phase was reached.  One liter of LB media supplemented with 
ampicillin was inoculated with 1 mL of the primary culture.  The 1 liter culture was 
incubated at 37 °C with shaking at 250 rpm until an OD600 of 0.6 was reached.  
Expression was induced with the addition of 1.0 mM isopropyl β -D-thiogalactoside and 
cells were incubated at 25 °C for 16 hours.  The cells were harvested at 5000 x g for 15 
min and the resulting pellet was resuspended in binding buffer (20 mM Tris, 0.5 M NaCl 
pH 7.5) and included protease inhibitor cocktail, 1 mM PMSF, and 10 units/mL 
DNAse1–Grade II) and sonicated.  Following resuspension, the cell lysate was sonicated 
for 1 min, 6 times, with a one-minute rest between each sonication.  Collected soluble 
protein was incubated with Chitin Beads (pre-equilibrated with binding buffer) and 
gently rotated at 4 °C for 1 - 4 hours (longer incubation enhanced chitin binding to 
protein).  Post incubation, the flow through was collected and the column was washed 
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with 3 x 10 mL binding buffer.  2.5 mL of chitin cleavage buffer was added to the beads 
(20 mM Tris, 0.5 M NaCl, 200 mM MESNA pH 7.5) and incubated at 4 °C with rotation.  
Protein was eluted with elution buffer by collecting incubated flow through and beads 
were washed with 3 x 2 mL chitin cleavage buffer.  SDS-PAGE analysis was performed 
to analyze the purity of CaM1-72 elution fractions.  Collected protein fractions were 
dialyzed against water overnight at 4 °C.  Protein concentration was determined by BCA 
assay (Pierce) and adjusted to 1.0 mg/mL, purity was confirmed by SDS-PAGE and 
MALDI mass spectrometry.  Protein was stored at – 80 °C until further use. 
 
3.3.15 – Full Enzymatic Transfer to αS6-140 and CaM78-149 
For a typical reaction, 4.25 mg αS6-140 in AaT Ligation Buffer pH 8.0 was 
modified with Hcm (1 mM) containing 20 mg E. coli total tRNA, 2.5 mM ATP, 1.0 - 0.1 
mg E. coli Met*RS, and 0.1 mg E. coli AaT.  The reaction was carried out at 37 °C for 4 
h and arrested by boiling for 30 min.  The supernatant was cleared by centrifuging for 20 
min at 30,000 x g.  Hcm-αS6-140 (19) was further purified on the with a HiTrap Q HP 
column (GE Healthcare).  Protein was buffer exchanged into Milli-Q water and stored at 
-80 °C.  The same procedure was used for CaM78-149 except that post-reaction the sample 
was not boiled and instead the reaction was halted by dialysis against 20 mM Tris pH8 
overnight at 4 °C.  FPLC purification and purified protein storage remained the same for 
CaM as with αS. 
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3.3.16 – Ligation of Ac-MetAspValPhe-SR (11) and Ac-McmMetAspValPhe-SR (S10) 
to Hcs-αS6-140 (19) 
Ligation buffer was prepared fresh as follows: 100 mM sodium phosphate dibasic, 
20 mM TCEP, 6 M guanidine hydrochloride and 2 % v/v thiophenol at pH 7.2.  The 
buffer was sparged twice with argon: 20 minutes for a 100 mM sodium phosphate dibasic 
and 6 M guanidine hydrochloride solution and then for an additional 10 min post addition 
of TCEP, thiophenol, and pH adjustment to 7.2.  Sparged ligation buffer (100 uL) was 
added to 0.0404 µmol (1 equivalent) of dried Hcm-αS6-140 protein.  The mixture was 
briefly vortexed and allowed to reduce for 10 min.  Next, the protein solution was added 
to 0.1212 µmol (3 equivalents) of Ac-MetAspValPhe-SR (11).  The reaction was mixed 
overnight at 250 RPM at 37°C.  The reaction was quenched the following day with a 3 
mL addition of MilliQ water and buffer exchanged solvent with six water washes using a 
3 kDa protein concentrator microfuge tube and analyzed by HPLC (Gradient 7).  Protein 
retention times were monitored at 215 nm (and 325 nm for S13).  MALDI MS analyses 
are in Table 3-2.  Example HPLC traces are shown in Figure 3-8. 
 
3.3.17 – Ellman’s Reagent Analysis 
0.8 nmoles of αS-Mcm-Hcs5 (20a) were methylated with 1000 equivalents of 
methyl iodide in 0.1 M sodium bicarbonate pH 8.6 for 5 min at room temperature.  
Following methylation, the reaction was incubated with 150 µM 5,5’-dithiobis-(2-
nitrobenzoic acid (DTNB) for 5 min at room temperature.  UV/Vis measurements were 
taken using a Tecan M1000 plate reader.  Excitation slit width was 5 nm, integration time 
0.02 s, data interval 2.0 nm, flash frequency 400 Hz, 25 flashes, gain set to 100, and z-
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height 20 mm (Figure 3-7).  Section 3.3.17 was performed by John Warner. 
 
3.3.18 - aS-Mcm Fluorescence Readings 
Fluorescence spectra were collected with a Varian Cary Eclipse fluorescence 
spectrophotometer fitted with a Peltier multicell holder.  Fluorescence spectra were 
collected using quartz cells with 1 cm path lengths.  Excitation and emission slit widths 
were 5 nm, scan rate 120 nm/min, averaging time 0.5 s, and data interval 1.0 nm.  Section 
3.3.18 was performed by John Warner. 
 
3.3.19 – Trypsin Digest and MALDI MS Analysis 
Ac-αS 21b (5.4 µg) was buffer-exchanged into 100 µL of freshly prepared 25 mM 
NH4HCO3 (pH 7.6), and digested with 2 µL of sequencing-grade modified trypsin (0.1 
µg/µL).  The digestion was allowed to proceed at 37 °C for 3 h.  An aliquot (1.0 µL) of 
the digest was taken and analyzed by MALDI MS in CHCA matrix (Figure 3-31, Table 
3-4).  MALDI MS data shown in Figure 3-32 confirm that no methylation of His50 took 
place.  To determine the sensitivity of our method for identifying the extent of Hcs 
methylation, we synthesized authentic Ac-MetAspValPheHcsLys (S8) and Ac-
MetAspValPheMetLys (S9).  We mixed them in ratios varying from 1:1 to 1:100 S8/S9 
and spotted these mixtures in CHCA matrix in a manner identical to the analysis of 
trypsinized 21b.  We found that the ionization of Hcs-containing S8 was proportional to 
its ratio in the mixture.  Therefore we feel confident that ratios of Ac-
MetAspValPheHcsLys to Ac-MetAspValPheMetLys observed in the MALDI MS data of 
trypsinized 21b are reflective of the degree of conversion of Hcs5 to Met5.  The 5:95 and 
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1:99 S8/S9 MALDI MS data are shown in Figure 3-31. 
 
Figure 3-31.  MALDI MS Data for Mixtures of Ac-MetAspValPheHcsLys (S8) and Ac-
MetAspValPheMetLys (S9) 
 
Table 3-4.  Trypsin Digest Ac-αS (13b) Sequence Coverage 
m/z Start End Missed Peptide 
798.42 1 6 0 Ac-MDVFXK 
812.37 1 6 0 Ac-MDVFMK 
830.44 24 32 0 QGVAEAAGK 
873.47 13 21 0 EGVVAAAEK 
951.51 35 43 0 EGVLYVGSK 
1295.70 46 58 0 EGVVHGVATVAEK 
1478.78 81 96 0 TVEGAGSIAAATGFVK 
2157.19 59 80 1 TKEQVTNVGGAVVTGVTAVAQK 
4286.73 103 140 0 NEEGAPQEGILEDMPVDPDNEAYEMPSEEGYQDYEPEA 
Underline indicates observed fragment.  Ligation site fragment shown in bold.  X = Homocysteine 
(Hcs). 
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Figure 3-32.  αS Full-Length Sequence and MALDI MS Data for Trypsin Digested Ac-αS6-140 
The fragment corresponds to EGVVHGVATVAEK and the asterisk indicates mass of peptide with 
methylated His50. 
 
3.3.20 – Ligation Motif Prevalence Analysis 
The frequency of XaaMetArg and XaaMetLys motifs (Xaa = any amino acid) in 
protein sequences of the Protein Data Bank (PDB) was assessed using PHI-BLAST.174  
Briefly, a four-letter query, “X1MRX2” or “X1MKX2” (where X1 and X2 were varied to 
cover all 20 natural amino acids), was aligned to the database under the constraints of a 
“X1MR/K” pattern and the PAM30 substitution matrix.  The results were then pooled in a 
spreadsheet, inspected for false hits, and categorized (Table 3-5, 3-6 and 3-7) by Jerri 
Wang. 
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Table 3-5.  Summary of Unique PDB Entries Containing One or More MR or MK Ligation 
Site(s) 
Ligation 
Sites per 
Entry 
# of 
Entries 
Ligation 
Sites per 
Entry 
# of 
Entries 
Ligation Sites per 
Entry 
# of 
Entries 
1 13,550 5 142 9 5 
2 4,842 6 44 11 1 
3 1,554 7 14 14 1 1 
4 543 8 4 17 1 
of unique entries with MetArg or MetLys Ligation site(s) 20,701 
# of unique entries with N-Terminal (≤ 40 aa) MetArg or MetLys Ligation site(s) 5,156 
# of entries in the PDB Database (as of Oct 14, 2012) 60,325 
 
Table 3-6.  Selected Examples of Potential Ligation Targets 
Protein Taxonomy Length Alignment PDB ID 
Human Prion Protein H. sapien 142 19 NMK 21 2LSB 
Ribonuclease S H. sapien 127 6 MMK 8 2K11 
Caspase 2, Chain B H. sapien 105 29 AMR 31 1PYO 
CTerminal Src Kinase H. sapien 278 19 NMK 21 1BYG 
Annexin H. sapien 319 26 AMK 28 2ZOC 
Anti HIV1 Protease Fab, Chain H M. musculus 226 29 FMR 31 1MF2 
Cytochrome P450 B. megaterium 471 29 LMK 31 1FAH 
Myosin P. magellanicus 840 20 MMK 22 2OS8 
BetaAlanine Synthase S. kluyveri 474 34 GMR 36 2VL1 
30S Ribosomal Protein S2 E. coli 241 26 KMK 28 1VS5 
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Table 3-7.  Distribution of Ligation Sites by Thioester Residues and Relative Positions 
Thioester 
Residue 
 
# of Distinct 
Ligation Sites 
 Relative Positions 
  N-Terminal (≤ 40 aa)  Middle  
C-Terminal 
(≤ 40 aa) 
 MR MK  MR MK  MR MK  MR MK 
Very Suitable for Native Chemical Ligation 
G  846 1,158  102 202  644 815  100 141 
A  1,224 1,808  139 354  961 1,177  124 277 
L  1,261 1,691  135 234  945 1,183  181 274 
M  411 524  72 169  242 268  97 87 
F  542 654  78 106  375 455  89 93 
Y  506 590  38 74  401 427  67 89 
Sub-total  11,215  1,703  7,893  1,619 
Suitable  for Native Chemical  Ligation 
K  729 1,109  138 170  481 754  110 185 
R  828 898  125 181  589 579  114 138 
N  529 619  83 122  389 410  57 87 
Q  528 692  115 105  354 509  59 78 
S  932 1,054  266 327  579 551  87 176 
C  202 224  28 30  129 156  45 38 
W  189 197  23 18  139 166  27 13 
Sub-total  8,730  1,731  5,785  1,214 
Mutations Needed to Promote Native Chemical Ligation 
V  1,029 1,155  164 141  706 831  159 183 
I  702 941  80 147  488 684  134 110 
T  784 950  124 150  516 647  144 153 
H  371 761  211 348  137 329  23 84 
D  636 905  59 104  442 663  135 138 
E  907 1,391  131 195  601 952  175 244 
P  396 386  52 65  278 257  66 64 
Sub-total  11,314  1,971  7,531  1,812 
             
Total  31,259  5,405  21,209  4,645 
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CHAPTER 4 
 
EXPANSION OF AMINOACYL TRANSFERASE SUBSTRATE SCOPE 
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Section 4.1 - Introduction 
 An enzyme’s active site is the location in which a chemical reaction occurs, and 
the amino acid residues within the active site convey binding to appropriate substrates.  
Many factors dictate whether a compound will be an enzyme substrate, including 
substrate/enzyme complementarity, active site flexibility, steric matching, and 
noncovalent forces arising from hydrophobicity and charge.131  Some active sites have 
stringent substrate restrictions, which have evolved to make the enzyme highly specific to 
one substrate.  Alternatively, an enzyme can have less specificity, which would allow it 
to accept a variety of substrates; E. coli leucyl/phenylalanyl aminoacyl transferase (AaT) 
falls into this second class.  AaT is an enzyme that can naturally transfer three amino 
acids, leucine, phenylalanine and – to a lesser extent – methionine, from their respective 
aminoacyl tRNAs, to the α-amino group of proteins with an N-terminal lysine or 
arginine.126  The active site of AaT is very hydrophobic and also selective against β-
branched amino acids, such as valine.56  The enzyme delicately balances moderate 
selectivity for its amino acid substrate with high specificity binding for the protein N-
terminus. 
 Using X-ray crystallography, MALDI-TOF MS, amino acid mutagenesis, and 
enzyme kinetics, two groups have proposed mechanisms for the AaT amide bond-
forming reaction.  Suto et al. solved a crystal structure of AaT bound to an aminoacyl-
tRNA analog, puromycin, to help elucidate the key residues that recognize the 
aminoacyl-tRNA substrate. They performed site-directed mutagenesis at residues within 
close proximity to puromycin bound in the enzyme active site.   A hydrophobic pocket 
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containing, M144, F153, L170, F173, and I185, was found to hold the p-methoxybenzyl moiety 
of puromycin, which represented the phenylalanine/leucine portion of the natural 
aminoacyl substrate (Figure 4-1).56  Upon mutation of those residues to alanine, they 
found enzymatic activity to be substantially reduced, indicating the importance of the 
specific size of the hydrophobic amino acids in the active site to correctly fit the Phe/Leu 
aminoacyl tRNA substrates.  Additionally, the hydrophobic residues are well conserved 
within transferases from other eubacteria, giving further proof of their importance in the 
AaT amide bond-forming reaction.56  Additional residues that were proposed to be linked 
to AaT activity included Glu156 and Gln188, which could interact with the positively-
charged N-terminal arginine/lysine of the protein substrate by positioning it for favorable 
reactivity.43 
 
Figure 4-1.  Recognition of Puromycin in AaT 
From X-ray crystal structure by Suto et al.  Hydrophobic pocket: Met144, Phe153, Leu170, Phe173, 
Ile185.56 
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The same group proposed a specific AaT reaction mechanism in a following 
paper in 2007 when they obtained two crystal structures of AaT, one with phenylalanyl 
adenosine, the 3' end of the phenylalanine aminoacyl tRNA natural substrate, and one 
with the product Phe-ligated peptide (PheArgTyrLeuGly).43  Watanabe et al. proposed 
that the AaT ligation reaction of phenylalanine from Phe-tRNA to the N-terminus of an 
Arg/Lys-peptide had a catalytic mechanism similar to the reverse reaction of a serine 
protease (Figure 4-2).43  They determined that nucleophilic attack of the backbone α-
amino group of the N-terminal arginine/lysine on the carbonyl carbon of the 3' ester bond 
of the aminoacyl tRNA is facilitated by several amino acid residues within the active site.  
They proposed that Gln188 acts as a general base, while Asp186 helps place Gln188 in the 
correct reaction orientation, and Asn191 stabilizes the formation of the oxyanion hole that 
is produced in the formation of the tetrahedral intermediate.  When comparing the 
product-bound peptide structure to the starting material Phe-A bound state, they found 
substantial amino acid movement had occurred within the active site, where tryptophan 
residues W49 and W111 rotated and flipped, respectively, to accommodate the product.  As 
they had found before, in addition to the hydrophobic pocket that holds the phenylalanine 
portion of the aminoacyl-tRNA substrate, the specific size of the negatively charged site 
that holds the arginine in place is directly connected to AaT activity, with alanine or 
aspartate mutations abolishing or reducing activity, respectively.  Their research 
determined that the AaT reaction does not act like the peptidyl transfer site of the 
ribosome, which positions residues for substrate-assisted catalysis (below), and instead 
mimics a reverse acylation reaction seen in proteases and esterases. 
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Figure 4-2.  First Proposed AaT Ligation Mechanism 
Adapted from Watanabe et al. 2007.43 
 
 The mechanism proposed by Watanabe et al. was challenged by Fung et al. in 
2011.59  They reevaluated the catalytic mechanism using a quantitative MALDI-TOF 
MS-based assay with radioisotope-enriched peptide standards.  Fung et al. stated that it 
was unconventional for glutamine (Q188) to act as general base and therefore re-analyzed 
the alanine mutations with their MALDI method to determine if the residue mutants were 
indeed catalytically deleterious.59  Using their highly sensitive technique, they determined 
that the previously-determined catalytic residues, D186 and Q188, were not directly 
involved with catalysis, but instead critical for correct orientation of the aminoacyl tRNA 
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and acceptor protein, which react to form a peptide bond without the direct aid of the 
enzyme.  This is similar to the established mechanism of peptide bond formation on the 
ribosome (Figure 4-3).59  An additional argument that they make for a ribosome-like 
active site behavior is the slow reaction rate of AaT, kcat/KM = 8.02 x 103 M-1s-1.43, 59  The 
substrate-assisted catalysis mechanism is still a proposal, however, and the exact 
influence of AaT on peptide bond catalysis is currently unconfirmed.  While the two 
proposed mechanisms suggest differing means of enzyme catalysis, both include 
nucleophilic attack on the aminoacyl tRNA carbonyl by the α-amino group arginine. 
 
Figure 4-3.  Second Proposed AaT Ligation Mechanism 
Adapted from Fung et al. 2011.  The reaction takes place via the 2'-hydroxyl in “substrate-
assisted catalysis.”  The AaT-bound aminoacyl tRNA acts similarly to the P-site in the ribosome, 
and the Arg-peptide is analogous to the A-site.59 
 
The AaT crystal structures with bound substrate Phe-A and product Phe-peptide, 
give evidence that the AaT active site has flexibility upon substrate binding; however, we 
had determined that the WT AaT, while accommodating a variety of unnatural amino 
acid residues, has a steric limit.  In the aforementioned discussion of the AaT catalysis 
mechanism, mutagenesis was used to help determine key residues involved in substrate 
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recognition and influence in enzyme activity.  For our purposes, we used alanine 
mutagenesis to expose space within the AaT active site to accommodate larger amino 
acid residues.  We synthesized several aminoacyl adenosine analogs with residues that 
could not transfer to the N-terminus of our model peptide, LysAlaAcm, using WT AaT 
(Figure 4-4).  We determined that we would need space within the active site to allow for 
extension in areas that around the aminoacyl adenosine α-amino group and sidechain R-
group.  By inspection of the crystal structures, we chose several amino acids that could 
“open up” the active site to accommodate the larger unnatural amino acids: M144A, 
M158A, L170A, F173A, F177A, I185A, C187A.  We made individual and double amino acid 
substitution combinations but had difficulty with expressed protein stability.  We 
obtained several expression-stable single alanine mutants, M144A, L170A, I185A, and 
C187A, which we assayed for enzymatic activity with a natural aminoacyl substrate 
mimic, Phe-A, and corresponding donors with the unnatural amino acids, Mef, Azf, Nap, 
Nbd, Mcm, 1, 8-naphthalimide (Npt1,8), and 2, 3-Naphthalenedicarboximide (Npt2,3) 
(Figure 4-4).  Phe-A and Nap-A had lower peptide bond-forming efficiency than WT and 
none of the unnatural residues larger than napthylalanine were compatible with our 
mutant enzymes. 
We next established a collaboration with the Saven group to attempt to find an 
AaT mutant that, through predictions from computer-aided protein design, would be 
more active for one particular type of unnatural aminoacyl adenosine substrate, 
homocysteine or cysteine disulfide-protected analogs.  An improved enzyme for these 
specific substrates would enhance our efficiency in forming native chemical ligation-
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ready precursor proteins.  Along with our studies of the AaT active site, we explored the 
possibility of utilizing another aminoacyl transferase, Bpt from V. vulnificus, by 
examining its ability to accept a minimized substrate, leucyl adenosine, similarly to AaT. 
 
Figure 4-4.  Amino Acids Not Utilized by WT AaT 
 
Section 4.2 - Results and Discussion 
In our previous work, we determined that WT AaT could use a variety of 
substrates with bulky sidechain R-groups such as naphthylalanine, and reactive handles 
residues such as p-azido-phenylalanine.  However, we determined that the active site has 
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polar and steric restrictions; therefore, a phase of this project has been to create active site 
mutations to open space for more bulky and/or more polar R-groups in order to expand 
substrate scope.  We chose a several amino acids that could “open up” the active site to 
accommodate the larger unnatural amino acids: M144A, M158A, L170A, F173A, F177A, 
I185A, C187A (Figure 4-5).  We were careful not to choose amino acids that were directly 
involved with substrate binding in an attempt to avoid issues of enzyme catalysis 
inactivation.  We made individual amino acid substitutions and additionally made all the 
respective combinations of double mutants of the listed residues, resulting in a total of 27 
mutants.  All of the residues chosen for alanine mutagenesis are located around the 
aminoacyl R-group recognition site.  Phe173 and Phe177 are the farthest from the substrate 
phenylalanyl moiety, seen in Figure 4-5, but could possibly open a “slot” to fit planar 
fluorescent molecules such as Npt1,8 and Npt2,3. 
 
Figure 4-5.  AaT Residues Selected for Mutagenesis 
Residues to be mutagenized (green spheres) and Phe-A (grey spheres) bound to active site. 
PDB ID: 2Z3K43 
185 
 
Of the mutants, few could be expressed successfully.  Most of the mutants had 
problems of folding stability, and while could be expressed, would fall out of solution 
upon cellular extraction mixed with the cellular debris and likely stuck in inclusion 
bodies (Figures 4-6 and 4-7).  Additionally, with the mutants that expressed poorly, we 
tended to see an increase in a higher molecular weight band, which approximately 
corresponded to dimerization of AaT (Figure 4-7, beige arrow).  Of the 27 mutant 
enzymes, enzymes that expressed to a degree comparable to wild type included both 
double mutants and single mutants.  One double mutant in particular, L170A M158A, had 
the best expression of the mutants (Figures 4-8 and 4-9).  However, even with this case, a 
substantial amount of protein precipitated from solution during lysis and removal of 
cellular debris through centrifugation to obtain the soluble protein in the supernatant. 
 
Figure 4-6.  SDS PAGE Gel Production Analysis of F177A AaT 
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Figure 4-7.  SDS PAGE Gel Expression Analysis of F177A AaT 
 
 
Figure 4-8.  SDS PAGE Gel Production Analysis of L170A/M158A AaT 
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Figure 4-9.  SDS PAGE Gel Expression Analysis of Double Mutant L170A/M158A AaT 
 
 We attempted to keep the protein more soluble by altering lysis buffer conditions 
through changing the salt composition (Figure 4-10).  We had noticed that we lost some 
protein into the insoluble fraction during overexpression; therefore, due to the expression 
variability of each mutant we did this lysis analysis on WT AaT.  The standard 
resuspension lysis buffer conditions consist of 50 mM Tris, 10 mM imidazole, 300 mM 
potassium chloride, and 5 mM β-mercaptoethanol.  For each altered condition, DNAse, 
PMSF, and His-Tag protease inhibitor concentrations were kept the same as for standard 
WT AaT overexpression.  The conditions varied with salt concentration ranging from 300 
– 600 mM of ammonium sulfate or potassium chloride.  Additionally, one condition 
maintained standard lysis buffer conditions with the addition of 10 % glycerol.  None of 
these changes increased the percentage of soluble AaT retained in the supernatant. 
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Figure 4-10.  Soluble Fraction Analysis of Salt Concentration Lysis Conditions for WT AaT 
L = lysis, S = Supernatant.  Conditions (1) 50 mM Tris, 10 mM imidazole, 300 mM ammonium 
sulfate, 5 mM β-mercaptoethanol, (2) 50 mM Tris, 10 mM imidazole, 600 mM ammonium sulfate, 
5 mM β mercaptoethanol, (3) 50 mM Tris, 10 mM imidazole, 600 mM potassium chloride, 5 mM 
β-mercaptoethanol, (4) 50 mM Tris, 10 mM imidazole, 300 mM potassium chloride, 300 mM 
ammonium sulfate, 5 mM β-mercaptoethanol, (5) 50 mM Tris, 10 mM imidazole, 300 mM 
potassium chloride, 5 mM β-mercaptoethanol, 10 % glycerol, (6) Standard resuspension lysis 
buffer conditions:  50 mM Tris, 10 mM imidazole, 300 mM potassium chloride, 5 mM β-
mercaptoethanol. 
 
After the first trial of lysis buffers, we changed other possible variables that could 
affect AaT solubility, including the duration and type of cell lysis, higher percentages of 
glycerol in the lysis buffer, and different buffer compositions used in published AaT 
overexpression protocols.  We tested seven different conditions for cell lysis (Figure 4-
11).  The trials that yielded the greater soluble protein over wild type conditions included 
increased waiting time between 1 min sonications, addition of 30 % glycerol to the 
standard lysis buffer, or use of lysozyme instead of sonication to break open the cells.  
However, it is important to note that in all of the higher yielding AaT protein 
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supernatants, a substantial amount of AaT was still lost between the lysis and supernatant 
removal steps. 
 
 
Figure 4-11.  Soluble Fraction Analysis of Alternate AaT Lysis Conditions 
Lysis buffer conditions are as follows:  (1) decreased sonication to three iterations of 1 min 
sonication at 30 %, (2) Increased waiting time between standard six sonications from 1 min to 2 
min, (3) included 20 % glycerol in lysis buffer, (4) included 30 % glycerol in lysis buffer, (5) new 
lysis buffer = 50 mM Tris, 1 mM imidazole, 100 mM KCl130 (6) new lysis buffer = 20 mM Tris, 500 
mM NaCl175 (7) used lysozyme for cell lysis instead of sonication.  Unless otherwise specified, all 
resuspended cells were lysed by sonication as described in 4.3 materials and methods section for 
WT AaT. 
 
Given that the aforementioned buffer and lysis conditions did not substantially 
decrease the amount of AaT lost into the cell debris pellet, we decided to take another 
approach, and completely change the cell overexpression conditions.  The overexpression 
protocol was adapted from Graciet et al.50  The major changes of this protocol were a one 
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hour pre-IPTG cell growth stage at 42 °C and a post IPTG-induced cell growth phase for 
a shortened period, 5 h instead of 16 h (Figures 4-12 and 4-13).  We found that our new 
overexpression protocol had better retention of soluble protein compared to previous 
mutant protein expressions. However, again, much of the overexpressed AaT was lost in 
the cell pellet again during cell debris removal.  Therefore, despite our best efforts, we 
decided to continue our analysis of larger unnatural aminoacyl adenosine analogs 
substrates with AaT mutants that had previously expressed to a high enough 
concentration to be tested by our LysAlaAcm peptide bond formation analysis assay (see 
4.3 Materials and Methods). 
 
Figure 4-12.  SDS PAGE Gel Overexpression Conditions of I185A AaT 
Protein was overexpressed and purified from E. coli using IPTG overexpression and Nickel Bead 
purification.  Protocol adapted from Graciet et al.50 
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Figure 4-13.  SDS PAGE Gel Expression Analysis of Mutant I185A Elution Fractions 
 
Several expression-stable mutants (M144A, L170A, I185A, and C187A) were assayed 
for enzymatic activity with Phe-A and LysAlaAcm to determine a standard of peptide 
bond-formation activity compared to wild type.  For additional comparison, we tested 
other unnatural aminoacyl adenosine analogs that could be transferred by WT AaT with 
varying degree: Nap, Azf, and Mef.  To complete our assay, we analyzed several of our 
unnatural amino acids that could not be transferred with WT AaT (Nbd, Mcm, Npt1,8, 
and Npt2,3) to determine if the mutants could use them as substrates with the “space” 
made from the amino acid replacements with alanine.  Unfortunately, we found that none 
of the mutants were more active than the WT enzyme toward the substrates that could 
already be transferred by wild-type, and none could utilize substrates with an R-group 
larger than napthylalanine (Figure 4-14, Table 4-1). 
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Figure 4-14.  Transfer Efficiencies of Phenylalanine by AaT Mutants 
Phenylalanine adenosine was ligated onto peptidyl substrate LysAlaAcm via AaT and percent 
ligation was determined by HPLC analysis of peak integration.  All reactions were standardized 
according to the Materials and Methods.  The ligation reactions were monitored at 325 nm, the 
absorption maximum of Acm (aminomethylcoumarin). 
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Table 4-1.  Percent LysAlaAcm Ligation of Analogs Using Mutant AaT 
Enzyme Analog R-Group % AA-LysAlaAcma 
WT AaT None 0 
L170A Phe 58.6 
M158A Phe 68.0 
M144A Phe 6.2 
C187A Phe 36.4 
WT AaT Phe 98.0 
L170A Nap 74.6 
M158A Nap 32.7 
M144A Nap 27.7 
C187A Nap 3.6 
L170A AzF 41.3 
M158A AzF 35.2 
M144A AzF 18.4 
C187A AzF 4.7 
L170A Nbd 0 
M158A Nbd 0 
M144A Nbd 0 
C187A Nbd 0 
WT AaT Nbd 0 
L170A, buffer pH 6 Nbd 0 
M158A, buffer pH 6 Nbd 0 
WT AaT, buffer pH 6 Nbd 0 
L170A Mef 0 
M158A Mef 0 
M144A Mef 0 
C187A Mef 0 
L170A Mcm 0 
M158A Mcm 0 
WT AaT Mcm 0 
L170A Npt1,8 0b 
M158A Npt1,8 0b 
WT AaT Npt1,8 0b 
L170A Npt2,3 0 
M158A Npt2,3 0 
M144A Npt2,3 10.3b 
C187A Npt2,3 0 
a AA corresponds to the amino acid transferred to the LysAlaAcm peptide N-terminus. 
b Additional peaks appear in the HPLC spectra but none correspond to product formation. 
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Additionally, we had some problems in resolving the signal from the fluorescent 
analogs from the LysAlaAcm product peptide on the HPLC chromatogram (Figure 4-15). 
Nbd, Npt1,8, Npt2,3, and Mcm all absorb in 325 nm, the wavelength used to monitor 
Acm.  For Nbd, we observed a peak in the HPLC analysis of the LysAlalAcm reaction at 
10.9 min, corresponding to the analog.  Npt2,3 had the greatest “bleed-through” 
absorption at 325 nm with a total of three visible peaks.  The co-absorptions at 325 nm 
made for difficult analysis via HPLC, but product formation could generally be resolved 
by MALDI MS analysis of HPLC fractions. 
 
Figure 4-15.  Co-absorption of Analogs at 325 nm for LysAlaAcm Ligation HPLCs 
 
We concluded that despite our attempts, the mutants were not as enzymatically 
efficient or structurally stable as the respective WT AaT.  Therefore, we collaborated 
with the Saven group to design an AaT mutant that, through predictions from computer-
aided protein design, would be mutated to become more specific for an unnatural 
aminoacyl adenosine substrate.  Enhanced substrate specificity for a cysteine or 
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homocysteine disulfide analog would be advantageous because currently our best analog 
is only at 68 % product formation for S-isopropyl cysteine (Csp).  Structural changes and 
amino acid interactions must take place for the accommodation of the disulfide analogs, 
which have increased polarity and length compared to the natural residue substrates of 
AaT, phenylalanine and leucine (Figure 4-16).  To help understand the unnatural amino 
acid fit into the AaT active site, the Saven group determined which locations and residue 
mutations would favorably interact with the respective aminoacyl adenosine analog of 
interest (Table 4-2).  Currently, we have focused our efforts on making a more specific 
and stable AaT for a variety of substrates, in particular, cysteine disulfides. We have 
designed primers for the following mutants: L67M, F173L, T194A, and T194I.  With the help 
of Haviva Garrett, we have successfully made the following mutants, L67M and T194A, 
and have also overexpressed the T194I mutant.  Our efforts are ongoing to make a better 
mutant AaT that can maintain solubility. 
     
Figure 4-16.  Csp-A Docking in WT AaT Active Site 
Image was produced using Spartan and the AaT crystal structure (PDB ID: 2Z3K), which had 
Phe-A docked in the active site.43 
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Table 4-2.  Mutagenesis Determined by Computational Modeling 
WT E. coli 
AaT* L67 L72 M144 M158 L170 F173 I185 C187 T194 L197 
Leu L67M L72 M144 M158 L170 F173L I185 C187 T194A L197 
Met L67M L72 M144 M158 L170 F173L I185 C187 T194I L197 
Csm L67M L72 M144 M158 L170 F173L I185 C187 T194I L197 
Csp L67M L72 M144 M158L L170V F173M I185 C187 T194I L197 
Csb L67M L72 M144 M158L L170V F173M I185 C187 T194I L197 
Trp L67M L72 M144L M158 L170 F173L I185M C187 T194I L197 
 
• Modeling completed by L. Lu. 
• *This sequence is for WT AaT E. coli active site amino acids.  The following rows are 
mutations predicted to aid in the specificity of binding to a particular aminoacyl adenosine 
 
 In addition to our studies of the AaT active site, we also investigated the 
possibility of using an alternate transferase, Bpt from V. vulnificus.  This transferase has a 
different N-terminal specificity than AaT.  Bpt ligates leucine onto proteins with an N-
terminal aspartate or glutamate (Scheme 4-1).50  We found that Bpt is not as efficient an 
enzyme as AaT, and even with Leu-tRNA and a leucyl tRNA synthetase, the highest 
yielding product formation of LeuAspAlaAcm was only 44.5 % compared to WT AaT 
and Phe-tRNA/PheRS going to completion after 4 h (Figure 4-17).  We also investigated 
the use of a Leu-A analog with Bpt and found that its product yield was even worse, 1.6 
% LeuAspAlaAcm.  Both ligations, enzymatic or chemoenzymatic, had lower percent 
ligation when used with an N-terminal glutamate peptide, GluAlaAcm.  We hypothesized 
that Bpt might need a molecular chaperone to enhance its enzymatic activity.  We have 
not rigorously tested this hypothesis, but because we noted that AaT and Bpt are 
expressed in a gene cluster in V. vulnificus, we have carried out Bpt reactions in the 
presence of AaT.  No enhancement of Bpt activity was observed. 
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Scheme 4-1.  Peptide Analysis of Bpt Reaction 
(A) fully enzymatic and (B) chemoenzymatic with methylcoumarin reporter peptides.  The 
Asp/GluAlaAcm peptides were synthesized by I. Medina. 
 
 
Figure 4-17.  HPLC Analysis of Bpt Reaction 
Bpt was tested as fully enzymatic (non-analog based) and chemoenzymatic (Leu-A analog used) 
with two methylcoumarin reporter peptides, AspAlaAcm and GluAlaAcm, monitored at 325 nm. 
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 Through our analysis of AaT, we have concluded that active site mutagenesis is a 
delicate task.  Even one amino acid mutation can make the enzyme insoluble.  Therefore, 
we are hopeful that with the aid of L. Lu of the Saven group that we can rationally-design 
a more efficient and stable transferase.  It is also possible that we will additionally 
investigate Bpt with in silico design to help understand its low degree of enzymatic 
catalysis in vitro.  We are continuing our efforts to better understand the mode of 
enzymatic catalysis and importance of active site residues in AaT. 
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Section 4.3 – Materials and Methods 
4.3.1 – Materials 
General Information. Chloroacetonitrile, N,N-diisopropylethylamine (DIPEA), 5′-
O-(4,4′-Dimethoxytrityl) adenosine ((DMT)-A), 4-Chloro-7-nitrobenzofurazan, 
tetrabutylammonium acetate (TBAAc), trifluoroacetic acid (TFA), and triisopropyl silane 
(TIPSH) were purchased from Sigma-Aldrich (St. Louis, MO).  (DMT)-A production 
was discontinued by Sigma-Aldrich, after which it was purchased as a custom order from 
ChemGenes Corporation (Wilmington, MA) and was additionally synthesized in-house 
following the protocol outlined by Ogilvie et al.139  Lysylalanyl-aminomethylcoumarin 
(LysAlaAcm) was purchased from Bachem (Torrance, CA).  N-Boc-L-phenylalanine 
(Boc-Phe-OH), 1, 8-naphthalic anhydride and all solvents were purchased from Fisher 
Scientific (Pittsburgh, PA).  2, 3-naphthalic anhydride was purchased from TCI America 
(Portland, OR).  All deuterated solvents were purchased from Cambridge Isotopes 
Laboratories, Inc. (Andover, MA).  E. coli BL21(DE3) cells were purchased from 
Stratagene (La Jolla, CA).  The pEG6 plasmid, containing His10-tagged E. coli AaT, was 
a gift from Alexander Varshavsky (California Institute of Technology).  All other 
reagents were purchased from Fisher Scientific (Pittsburgh, PA). N-Boc-L-leucine (Boc-
Leu-OH), N-Boc-L-p-azidophenylalanine (Boc-Azf-OH), N-Boc-L-naphthylalanine 
(Boc-Nap-OH), N-Me-L-phenylalanine (Boc-Mef-OH), and N-Fmoc-
methoxycoumarinylalanine (Fmoc-Mcm-OH) were purchased from Bachem (Torrence, 
CA).  All solvents were purchased from Fisher Scientific (Pittsburgh, PA).  
QuikChange® site-directed mutagenesis kits were purchased from Stratagene (La Jolla, 
CA).  DNA oligomers were purchased from Integrated DNA Technologies, Inc 
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(Coralville, IA).  Bradford reagent assay kits and protease inhibitor cocktail was 
purchased from Sigma-Aldrich (St. Louis, MO).  All other reagents were purchased from 
Fisher Scientific (Pittsburgh, PA).  Milli-Q filtered (18 MΩ) water was used for all 
aqueous solutions (Millipore; Billerica, MA).  Matrix-assisted laser desorption ionization 
(MALDI) mass spectra were collected using a Bruker Ultraflex III MALDI-TOF-TOF 
mass spectrometer (Billerica, MA).  UV absorbance spectra were obtained with a 
Hewlett-Packard 8452A diode array spectrophotometer (currently Agilent Technologies; 
Santa Clara, CA).  Donor molecule purification was conducted on a BioCad Sprint FPLC 
(GMI Inc.; Ramsey, MN; originally from Perseptive Biosystems) and Varian HPLC with 
a Waters Sunfire Prep C18-prep OBD column, 5 µm, 17 - 150 mm (Milford, MA).  
Analytical HPLC assays were performed on an Agilent 1100 HPLC using a Waters 
Symmetry Shield C18 column.  NMR spectra, 1H and 13C, were collected with a Bruker 
DRX 500 MHz instrument.  “Low resolution” electrospray ionization (ESI) mass spectra 
(LRMS) were obtained on a Waters Acquity Ultra Performance LC connected to a single 
quadrupole detector (SQD) mass spectrometer.  DNA sequencing was performed at the 
University of Pennsylvania DNA sequencing facility. 
 
4.3.2 – Aminoacyl adenosine cyanomethyl ester precursors 
 The respective aminoacyl adenosine cyanomethyl ester precursors, 2A-D, were 
synthesized and characterized by Mark Fegley (Scheme 4-2).  Information describing 
their synthesis and characterization can be found in his Master’s degree thesis, M. Fegley, 
University of Pennsylvania 2007. 
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Scheme 4-2.  Synthesis of Xaa-A Analogs from Cyanomethylester Precursors 
 
 (S)-(2R,3R,4R,5R)-2-(6-amino-9H-purin-9-yl)-5-((bis(4-
methoxyphenyl)(phenyl)methoxy)methyl)-4-hydroxytetrahydrofuran-3-yl 2-((tert-
butoxycarbonyl)amino)-3-((7-nitrobenzo[c][1,2,5]oxadiazol-4-yl)amino)propanoate 
(Boc-Nbd-(DMT)-A, 3A). 
Tetrahydrofuran (5 mL) was added to Boc-Nbd-OCH2CN (288.6 mg, 0.710 
mmol), (DMT)-A (99.8 mg, 0.175 mmol), and NBu4Ac (13 mg,) and stirred for 24 h.  
The solvent was removed under reduced pressure and silica chromatography (100 % 
ethyl acetate, 2.5 % - 10 % methanol in ethyl acetate), afforded 23.3 mg of an orange 
solid in 14.5 % yield.  Rf 0.5 in 5 % methanol in ethyl acetate; 1H and 13C NMR shown 
below in Figure 4-18; LRMS (ESI) m/z calculated for C45H47N10O12 (M + H)+ 919.3, 
found 919.5. 
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(S)-(2R,3R,4R,5R)-2-(6-amino-9H-purin-9-yl)-4-hydroxy-5-
(hydroxymethyl)tetrahydrofuran-3-yl 2-amino-3-((7-nitrobenzo[c][1,2,5]oxadiazol-
4-yl)amino)propanoate (Nbd-A, 4A). 
Trifluoroacetic acid (1 mL tetrahydrofuran (1 mL) and TIPSH (16.1 mg, 0.021 
mL, 0.101 mmol) were added to 3A (23.3 mg, 0.0254 mmol).  The reaction mixture was 
reduced to dryness by rotary evaporation and extracted using 1 mL dichloromethane and 
1 mL water twice with a final 1 mL water back-extraction against the dichloromethane 
layer.  The water-soluble layer containing 4A was then HPLC-purified on a C18-prep 
column using Gradient 1 (Table 4-3).  HPLC/MALDI analysis m/z calculated 
C19H21N10O8 (M + H)+ 517.2; product was found in four separate peaks (17.5 min, 18.3 
min, 18.5 min, and 19.3 min), and in all four peaks found 517.1. 
 
 (S)-(2R,3R,4R,5R)-2-(6-amino-9H-purin-9-yl)-5-((bis(4-
methoxyphenyl)(phenyl)methoxy)methyl)-4-hydroxytetrahydrofuran-3-yl 2-((tert-
butoxycarbonyl)amino)-3-(7-methoxy-2-oxo-2H-chromen-4-yl)propanoate (Boc-
Mcm-(DMT)-A, 3B). 
Tetrahydrofuran (5 mL) was added to Boc-Mcm-OCH2CN (26 mg, 0.0646 
mmol), (DMT)-A (35.5 mg, 0.0623 mmol), and NBu4Ac (4.8 mg,) and stirred for 24 h.  
The solvent was removed under reduced pressure and preparative thin-layer 
chromatography (5 % methanol in ethyl acetate, eluted in 10 % methanol in chloroform), 
afforded 26.5 mg of a white solid in 44.8 % yield.  Rf 0.3 in 5 % methanol in ethyl 
acetate; 1H and 13C NMR shown below in Figure 4-19; LRMS (ESI) m/z calculated for 
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C49H51N6O12 (M + H)+ 915.4, found 915.5. 
 
(S)-(2R,3R,4R,5R)-2-(6-amino-9H-purin-9-yl)-4-hydroxy-5-
(hydroxymethyl)tetrahydrofuran-3-yl 2-amino-3-(7-methoxy-2-oxo-2H-chromen-4-
yl)propanoate (Mcm-A, 4B). 
Trifluoroacetic acid (1 mL tetrahydrofuran (1 mL) and TIPSH (18.3 mg, 0.024 
mL, 0.116 mmol) were added to 3B (26.5 mg, 0.0290 mmol).  The reaction mixture was 
reduced to dryness by rotary evaporation and extracted using 1 mL dichloromethane and 
1 mL water twice with a final 1 mL water back-extraction against the dichloromethane 
layer.  The water-soluble layer containing 4B was then HPLC-purified on a C18-prep 
column using Gradient 1 (Table 4-3).  HPLC/MALDI analysis m/z calculated 
C23H25N6O8 (M + H)+ 513.2; retention time 19.9 min, found 513.1; retention time 21 min, 
found 513.1. 
 
 (S)-(2R,3R,4R,5R)-2-(6-amino-9H-purin-9-yl)-5-((bis(4-
methoxyphenyl)(phenyl)methoxy)methyl)-4-hydroxytetrahydrofuran-3-yl 2-((tert-
butoxycarbonyl)amino)-3-(1,3-dioxo-1H-benzo[f]isoindol-2(3H)-yl)propanoate (Boc-
Npt2,3-(DMT)-A, 3C). 
Tetrahydrofuran (5 mL) was added to Boc-Npt2,3-OCH2CN (350.4 mg, 0.828 
mmol), (DMT)-A (118.9 mg, 0.207 mmol), and NBu4Ac (20.9 mg,) and stirred for 24 h.  
The solvent was removed under reduced pressure and silica chromatography (100 % 
ethyl acetate, 2.5 % - 10 % methanol in ethyl acetate), afforded 31 mg of an orange solid 
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in 16 % yield.  Rf 0.75 in 5 % methanol in ethyl acetate; 1H and 13C NMR shown below 
in Figure 4-20; LRMS (ESI) m/z calculated for C51H50N7O11 (M + H)+ 936.4, found 
936.5. 
 
(S)-(2R,3R,4R,5R)-2-(6-amino-9H-purin-9-yl)-4-hydroxy-5-
(hydroxymethyl)tetrahydrofuran-3-yl 2-amino-3-(1,3-dioxo-1H-benzo[f]isoindol-
2(3H)-yl)propanoate (Npt2,3-A, 4C). 
Trifluoroacetic acid (1 mL tetrahydrofuran (1 mL) were added to 3C (31 mg, 
0.0331 mmol).  The reaction mixture was reduced to dryness by rotary evaporation and 
extracted using 1 mL dichloromethane and 1 mL water twice with a final 1 mL water 
back-extraction against the dichloromethane layer.  The water-soluble layer containing 
4C was then HPLC-purified on a C18-prep column using Gradient 1 (Table 4-3).  
HPLC/MALDI analysis m/z calculated C25H23N7O7 (M + H)+ 534.2; retention time 23.7 
min, found 534.2; retention time 25 min, found 534.3. 
 
 (S)-(2R,3R,4R,5R)-2-(6-amino-9H-purin-9-yl)-5-((bis(4-
methoxyphenyl)(phenyl)methoxy)methyl)-4-hydroxytetrahydrofuran-3-yl 2-((tert-
butoxycarbonyl)amino)-3-(1,3-dioxo-1H-benzo[de]isoquinolin-2(3H)-yl)propanoate 
(Boc-Npt1,8-(DMT)-A, 3D). 
Tetrahydrofuran (5 mL) was added to Boc-Npt1,8-OCH2CN (26.5 mg, 0.0283 
mmol), (DMT)-A (15.6 mg, 0.0274 mmol), and NBu4Ac (2.1 mg,) and stirred for 24 h.  
The solvent was removed under reduced pressure and preparative thin-layer 
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chromatography (5 % methanol in ethyl acetate, eluted in 10 % methanol in 
dichloromethane), afforded 17.2 mg of a white solid in 67.2 % yield.  Rf 0.5 in 100 % 
ethyl acetate; 1H and 13C NMR shown below in Figure 4-21; LRMS (ESI) m/z calculated 
for C51H50N7O11 (M + H)+ 936.4, found 936.5. 
 
(S)-(2R,3R,4R,5R)-2-(6-amino-9H-purin-9-yl)-4-hydroxy-5-
(hydroxymethyl)tetrahydrofuran-3-yl 2-amino-3-(1,3-dioxo-1H-
benzo[de]isoquinolin-2(3H)-yl)propanoate (Npt2,3-A, 4D). 
Trifluoroacetic acid (1 mL tetrahydrofuran (1 mL) and TIPSH (11.7 mg, 0.015 
mL, 0.074 mmol) were added to 3D (17.2 mg, 0.0184 mmol).  The reaction mixture was 
reduced to dryness by rotary evaporation and extracted using 1 mL dichloromethane and 
1 mL water twice with a final 1 mL water back-extraction against the dichloromethane 
layer.  The water-soluble layer containing 4D was then HPLC-purified on a C18-prep 
column using Gradient 1 (Table 4-3).  HPLC/MALDI analysis m/z calculated 
C25H24N7O7 (M + H)+ 534.2; retention time 20.5 min, found 534.2; retention time 22 min, 
found 534.2. 
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Figure 4-18.  1H and 13C NMR Characterization of Boc-Nbd-(DMT)-A (3A) 
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Figure 4-19.  1H and 13C NMR Characterization of Boc-Mcm-(DMT)-A (3B) 
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Figure 4-20.  1H and 13C NMR Characterization of Boc-Npt2,3-(DMT)-A (3C) 
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Figure 4-21.  1H and 13C NMR Characterization of Boc-Npt1,8-(DMT)-A (3D) 
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Table 4-3.  Gradients Used for HPLC Purification of Small Molecules and Peptides 
Gradient # Time (min) Buffer A (%) Gradient # Time (min) Buffer A (%) 
1 0:00 99 2 0:00 99 
15 mL/min 10:00 99 1 mL/min 5:00 99 
 40:00 65  10:00 70 
 45:00 0  15:00 60 
 50:00 0  20:00 0 
 55:00 99  25:00 0 
 60:00 99  27:00 99 
    30:00 99 
 
4.3.3 – Aminoacyl Transferase Expression and Purification 
E. coli AaT was expressed from the pEG6 plasmid in E. coli BL21-Gold (DE3) 
cells using a procedure adapted from Graciet et al.50  E. coli were grown in a primary 
culture of 5 mL LB at 37 °C to OD600 of 0.5 and then were rediluted into a secondary 
culture of 500 mL LB and grown to OD600 of 0.6.  AaT expression was induced using 0.1 
mM isopropyl β-D-thiogalactoside and cells were grown at 25 °C for ~16 h.  Cells were 
pelleted at 6, 000 RPM using a GS3 rotor and Sorvall RC-5 centrifuge.  Cell pellets were 
resuspended in the Ni-NTA binding buffer (50 mM Tris, 10 mM imidazole, 300 mM 
KCl, and 5 mM β-mercaptoethanol, pH 8.0) and included protease inhibitor cocktail, 1 
mM PMSF, and 10 units/mL DNAse1–Grade II.  Following resuspension, the cells were 
lysed using sonication.  Soluble proteins were collected via centrifugation at 13,200 RPM 
for 15 min.  Collected soluble protein was gently shaken for 1 h on ice with Ni-NTA 
resin.  The resin was prepared by rinsing with Ni-NTA binding buffer and then washed 
with four volumes of Ni-NTA wash buffer (50 mM Tris, 50 mM imidazole, 300 mM 
KCl, and 5 mM β-mercaptoethanol, pH 8.0).  The proteins were eluted with elution buffer 
(50 mM Tris, 250 mM imidazole, 300 mM KCl, and 5 mM β-mercaptoethanol, pH 8.0).  
Pure elution fractions of E. coli AaT were dialyzed overnight in transferase buffer (50 
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mM Tris, 30 % glycerol, 120 mM (NH4)2SO4, 5 mM β-mercaptoethanol, pH 8.0).  The 
dialyzed enzymes were stored at – 80 °C.  Protein concentrations were determined using 
the Bradford assay and a bovine serum albumin standard curve according to the 
manufacturer’s instructions (Figure 4-22). (Sigma Aldrich; St. Louis, MO) 
 
Figure 4-22.  SDS PAGE Gel Analysis of AaT Expression and Purification 
Lanes (left to right): 1) Molecular weight markers (Masses in kDa: 16, 25, 32, 47, 80, 100, 210); 2) 
Pre-induction; 3) Post-induction; 4) Crude cell lysate; 5) Supernatant after centrifugation; 6) Ni-
NTA column flow-through; 7) Column wash 1; 8) Column wash 3; 9) Elution fraction 1; 10) 
Combined elution fractions 3-5 after overnight dialysis.  Figure reprinted with permission from 
(Anne M. Wagner, Mark W. Fegley, John B. Warner, Christina L. J. Grindley, Nicholas P. Marotta, 
and E. James Petersson. J. Am. Chem. Soc. 2011, 133, 15139–15147.).  Copyright (2011) 
American Chemical Society. 
 
4.3.4 – Bpt Transferase Expression and Purification 
V. vulnificus Bpt, 29.7 kDa, was expressed from the pEG6 plasmid in E. coli 
BL21-Gold (DE3) cells using the same procedure as discussed above for AaT, which was 
adapted from Graciet et al.50  The enzyme preparation only differed from AaT in the 
dialysis buffer.  Pure elution fractions of V. vulnificus Bpt were dialyzed overnight in 1X 
Bpt buffer (50 mM Tris, 300 mM potassium chloride, 10 % glycerol, and 15 mM β-
mercaptoethanol, pH 8.0).  Overexpression of Bpt can be found in Figure 4-23. 
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Figure 4-23.  SDS PAGE Gel Analysis of Bpt Expression and Purification 
Lanes (left to right): 1) Molecular weight markers (Masses in kDa: 16, 25, 32, 47, 80, 100, 210); 2) 
Pre-induction; 3) Post-induction; 4) Crude cell lysate; 5) Supernatant after centrifugation; 6) Ni-
NTA column binding wash flow-through; 7) Column wash 1; 8) Column wash 2; 9) Column wash 
3; 10) Combined elution fractions after overnight dialysis. 
 
4.3.5 – Chemoenzymatic LysAlaAcm Ligation Assay 
Each ligation reaction, 125 µL total volume, contained the following reagents: 
aminoacyl adenosine donor (1 mM), recombinant His10-tagged E. coli aminoacyl 
transferase (2.26 µM), and LysAlaAcm (100 µM) in the AaT Ligation Buffer (50 mM 
HEPES pH 8.0, 150 mM KCl, 10 mM MgCl2).  The reaction mixtures were incubated at 
37 °C for four hours.  At the second, third, and fourth hour of the reaction, an additional 1 
mM dose of aminoacyl adenosine donor was added to the reaction mixture.  The reaction 
was quenched with 1 % acetic acid at 4 h.  One reaction material modification was made 
for Hcm analog only, in which we prepared AaT in transferase buffer without the 
presence of β-mercaptoethanol (50 mM Tris, 30 % glycerol, 120 mM (NH4)2SO4).  The 
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proteins were extracted from the reactions via acetone precipitation.  The reactions were 
precipitated using 4X reaction volume of acetone and cooled at – 20 °C for 1 h.  Next, the 
reactions were centrifuged at 13,200 rpm at 4 °C for 20 min to separate the reaction from 
precipitated protein.  The supernatant was transferred to fresh 1.5 mL centrifuge tubes 
and allowed for acetone evaporation overnight at room temperature for all non-disulfide 
analogs.  For all disulfide analogs, the reactions were rotary evaporated immediately to 
remove acetone in order to minimize disulfide reduction due to air exposure.  After 
acetone evaporation, the supernatant was dried in a Speedvac (Savant, Thermo Scientific, 
Fisher Inc.) for 30 min to remove residual acetone.  The resulting reaction volume was 
dissolved up to 1.2 mL using MilliQ water and analyzed by HPLC (gradient 1) to 
determine ligation yield by integration of separated peak intensities monitored at 325 nm 
(Table 4-4).  Collected HPLC fractions were characterized through MALDI MS analysis. 
 
4.3.6 – Fully Enzymatic LysAlaAcm Ligation Assay 
 Each ligation reaction, 125 µL total volume, contained the following reagents: 
amino acid (1 mM), ATP (2.5 mM), total E. coli tRNA (2 µg/µL), recombinant His-
tagged E. coli LeuRS, recombinant His10-tagged E. coli aminoacyl transferase (2.26 µM), 
and LysAlaAcm (100 µM) in the AaT Ligation Buffer (50 mM HEPES pH 8.0, 150 mM 
KCl, 10 mM MgCl2).  The reaction mixtures were incubated at 37 °C for 4 h and 
quenched with 1 % acetic acid.  Acetone precipitation and subsequent analysis were 
performed as described for the Chemoenzymatic LysAlaAcm Ligation Assay. 
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4.3.7 – AaT Ligation Reaction Analysis by HPLC 
All HPLC analyses of LysAlaAcm ligations were monitored on an Agilent HPLC 
using a Waters C18 column (Milford, MA).  The solvents used for peptide purification 
were the following: 0.1 % trifluoroacetic acid in water (Solvent A) and 0.1 % 
trifluoroacetic acid in acetonitrile (Solvent B).  The HPLC method had the following 
solvent gradient 1 (Table 4-4).  Peptides were monitored at two absorption wavelengths 
during HPLC analysis, 215 nm for peptide absorption, and 325 nm for Acm absorption.  
MALDI MS analyses confirmed identity N-terminally modified peptide products (Table 
4-5). 
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Table 4-4.  Calculated and Observed masses for LysAlaAcm assay Using Mutant AaT 
Product Peptide Enzyme 
M+H+ M+Na+ 
Calc’d Obs. Calc’d Obs. 
PheLysAlaAcm L170A 522.271 522.083 544.254 544.048 
PheLysAlaAcm M158A 522.271 522.098 544.254 544.063 
PheLysAlaAcm M144A 522.271 522.290 544.254 --- 
PheLysAlaAcm C187A 522.271 522.328 544.254 544.299 
PheLysAlaAcm WT AaT 522.271 522.096 544.254 544.062 
NapLysAlaAcm L170A 572.287 572.110 594.269 594.065 
NapLysAlaAcm M158A 572.287 572.135 594.269 594.079 
NapLysAlaAcm M144A 572.287 572.302 594.269 594.302 
NapLysAlaAcm C187A 572.287 572.270 594.269 --- 
AzfLysAlaAcm L170A 563.272 563.062 585.255 --- 
AzfLysAlaAcm M158A 563.272 537.089a 585.255 --- 
AzfLysAlaAcm M144A 563.272 563.307 585.255 --- 
AzfLysAlaAcm C187A 563.272 563.288 585.255 --- 
NbdLysAlaAcm L170A 624.252 --- 646.235 --- 
NbdLysAlaAcm M158A 624.252 --- 646.235 --- 
NbdLysAlaAcm M144A 624.252 --- 646.235 --- 
NbdLysAlaAcm C187A 624.252 --- 646.235 --- 
NbdLysAlaAcm WT AaT 624.252 --- 646.235 --- 
NbdLysAlaAcm L170A, pH6 624.252 --- 646.235 --- 
NbdLysAlaAcm M158A, pH 6 624.252 --- 646.235 --- 
NbdLysAlaAcm WT AaT, pH 6 624.252 --- 646.235 --- 
MefLysAlaAcm L170A 536.287 --- 558.269 --- 
MefLysAlaAcm M158A 536.287 --- 558.269 --- 
MefLysAlaAcm M144A 536.287 --- 558.269 --- 
MefLysAlaAcm C187A 536.287 --- 558.269 --- 
McmLysAlaAcm L170A 620.271 --- 642.254 --- 
McmLysAlaAcm M158A 620.271 --- 642.254 --- 
McmLysAlaAcm WT AaT 620.271 --- 642.254 --- 
Npt1,8LysAlaAcm L170A 641.272 --- 663.254 --- 
Npt1,8LysAlaAcm M158A 641.272 --- 663.254 --- 
Npt1,8LysAlaAcm WT AaT 641.272 --- 663.254 --- 
Npt2,3LysAlaAcm L170A 641.272 --- 663.254 --- 
Npt2,3LysAlaAcm M158A 641.272 --- 663.254 --- 
Npt2,3LysAlaAcm M144A 641.272 641.283 663.254 --- 
Npt2,3LysAlaAcm C187A 641.272 --- 663.254 --- 
a Loss of N2 in MALDI analysis.  This has been seen in many Azf-peptide samples. 
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Table 4-5.  Elution Times for LysAlaAcm Ligation Reactions 
Enzyme Analog R-Group KACm (min) Product (min) 
WT AaT None 11.03 --- 
L170A Phe 11.92 13.13 
M158A Phe 11.92 13.13 
M144A Phe 12.06 13.28 
C187A Phe 12.06 13.28 
WT AaT Phe 11.93 13.14 
L170A Nap 11.93 14.22 
M158A Nap 11.91 14.20 
M144A Nap 11.90 14.19 
C187A Nap 11.90 14.20 
L170A AzF 11.91 13.76 
M158A AzF 11.90 13.75 
M144A AzF 11.89 13.76 
C187A AzF 11.88 13.76 
L170A Nbd 11.91 --- 
M158A Nbd 11.92 --- 
M144A Nbd 12.06 --- 
C187A Nbd 12.06 --- 
WT AaT Nbd 11.92 --- 
L170A, buffer pH 6 Nbd 11.91 --- 
M158A, buffer pH 6 Nbd 11.90 --- 
WT AaT, buffer pH 6 Nbd 11.91 --- 
L170A Mef 11.90 --- 
M158A Mef 11.90 --- 
M144A Mef 11.91 --- 
C187A Mef 11.91 --- 
L170A Mcm 11.97 --- 
M158A Mcm 11.96 --- 
WT AaT Mcm 11.95 --- 
L170A Npt1,8 11.90 --- 
M158A Npt1,8 11.90 --- 
WT AaT Npt1,8 11.91 --- 
L170A Npt2,3 11.88 --- 
M158A Npt2,3 11.88 --- 
M144A Npt2,3 11.90 12.95* 
C187A Npt2,3 11.89 --- 
* See co-absorption of analog at this time point, but there is also a small MALDI hit for product. 
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4.3.8 – Design of an AaT Mutant Library 
Quikchange ® mutagenesis was used to generate the following alanine mutations. 
E. coli AaTH10, from the pEG6 plasmid, was mutated at specific residues listed in Tables 
4-6 and 4-7.  For the double alanine mutants, if the residues were close, we opted to make 
a double mutant primer, Table 4-7.  For all other double mutant combinations, we 
performed two Quikchange ® mutagenesis steps.  The primers used for the collaboration 
with the Saven group can be found in Table 4-8.  All mutagenesis steps were confirmed 
by DNA sequencing using the T7 promoter primer. 
 
Table 4-6.  Single Codon Reassignment Primers for AaT Alanine Mutations 
 
  
I185A 
L170A 
(A) M144A Forward 5' – GCTTGTCGGCGGTGCGTACGGCGTGGCC – 3' 
Reverse 5' – GGCCACGCCGTACGCACCGCCGACAAGC – 3' 
(B) M158A Forward 5' – GTGGCGAGTCCGCGTTCAGCCGGATGGAAAATG – 3' 
Reverse 5' – CATTTTCCATCCGGCTGAACGCGGACTCGCCAC  – 3' 
(C) L170A Forward 5' – GAAAATGCGTCTAAAACGGCGGCGCTGGTATTCTGTGAGG – 3' 
Reverse 5' – CCTCACAGAATACCAGCGCCGCCGTTTTAGACGCATTTTC  – 3' 
(D) L173A Forward 5' – GCTTCTGGTAGCGTGTGAGGAATTTATCGGTCATGG – 3' 
Reverse 5' – CCATGACCGATAAATTCCTCACACGCTACCAGAAGC – 3' 
(E) L177A Forward 5' – CTGGTATTCTGTGAGGAAGCGATCGGTCATGGCGGTAAG – 3' 
Reverse 5' – CTTACCGCCATGACCGATCGCTTCCTCACAGAATACCAG  – 3' 
(F) I185A Forward 5' – CATGGCGGTAAGCTTGCGGACTGCCAGGTCCTTAAC – 3' 
Reverse 5' – GTTAAGGACCTGGCAGTCCGCAAGCTTACCGCCATG – 3' 
(G) C187A Forward 5' – GCGGTAAGCTTATCGACGCGCAGGTCCTTAACGATCACAC – 3' 
Reverse 5' – GTGTGATCGTTAAGGACCTGCGCGTCGATAAGCTTACCGC – 3' 
M144A 
M158A 
F173A 
F177A 
C187A 
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Table 4-7.  Double Codon Reassignment Primers for AaT Alanine Mutations 
 
 
Table 4-8.  Codon Reassignment Primers for AaT Mutations for Saven Collaboration 
 
  
I185A 
L170A 
(A) L170A F173A Forward 5' – GCGTCTAAAACGGCGGCGCTGGTAGCGTGTGAGGAATTTATCGG – 3' 
Reverse 5' – CCGATAAATTCCTCACACGCTACCAGCGCCGCCGTTTTAGACGC  – 3' 
(B) L170A F177A Forward 5' – CGTCTAAAACGGCGGCGCTGGTATTCTGTGAGGAAGCGATCGGTCATGGC – 3' 
Reverse 5' – GCCATGACCGATCGCTTCCTCACAGAATACCAGCGCCGCCGTTTTAGACG  – 3' 
(C) F173A F177A Forward 5' – GCGCTTCTGGTAGCGTGTGAGGAAGCGATCGGTCATGGCGGTAAGC – 3' 
Reverse 5' – GCTTACCGCCATGACCGATCGCTTCCTCACACGCTACCAGAAGCGC  – 3' 
(D) I185A C187A Forward 5' – CGGTCATGGCGGTAAGCTTGCGGACGCGCAGGTCCTTAACGATCAC – 3' 
Reverse 5' – GTGATCGTTAAGGACCTGCGCGTCCGCAAGCTTACCGCCATGACCG – 3' 
F173A 
C187A 
L170A 
F173A 
F177A 
F177A 
(A) L67M Forward 5' – GATCCCCGCGCGGTGATGTGGCCAGAATCACTG – 3' 
Reverse 5' – CTAGGGGCGCGCCACTACACCGGTCTTAGTGAC – 3' 
(B) F173L Forward 5' – CTAAAACGGCGCTTCTGGTACTGTGTGAGGAATTTATCGGT – 3' 
Reverse 5' – GATTTTGCCGCGAAGACCATGACACACTCCTTAAATAGCCA – 3' 
(C) T194A Forward 5' – GGTCCTTAACGATCACGCAGCATCGCTTGGTGC – 3' 
Reverse 5' – CCAGGAATTGCTAGTGCGTCGTAGCGAACCACG – 3' 
(D) T194I Forward 5' – CTGCCAGGTCCTTAACGATCACATTGCATCGCTTGGT – 3' 
Reverse 5' – CCATGACCGATAAATTCCTCACACGCTACCAGAAGC – 3' 
T194A 
F173L 
L67M 
T194I 
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ATTEMPTED APPLICATIONS OF LEUCYL/PHENYLALANYL AMINOACYL 
TRANSFERASE 
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Section 5.1 – Introduction 
 Alternate routes for the utilization of AaT were attempted over the course of our 
research in the Petersson Laboratory.  We have developed two collaborations with the 
Bode Laboratory in the Laboratorium für Organische Chemie at the Eidgenössische 
Technische Hochschule (ETH) in Zürich, Switzerland and the Kashina Laboratory in the 
University of Pennsylvania Veterinary Medicine School.  In both areas, we made 
progress in the usage at AaT in different ligation reactions and peptide substrates. 
With the Bode group, we investigated the possibility of AaT utilization of N-
hydroxylamine-phenylalanyl adenosine (HONH-Phe-A).  Bode et al. determined that an 
α-hydroxylamine can act as a reactive moiety in the amide bond-forming ligation with an 
α-ketoacid, called the KAHA ligation.30  If AaT could transfer an amino acid bearing an 
α-hydroxylamine, it could be possible to bring this ligation from peptides to the protein 
domain ligation scale.  We envisioned using the hydroxylamine as an orthogonal reactive 
handle in a three-piece protein ligation strategy that could be prepared in a one-pot 
synthesis (Figure 5-1).  Generation of semi-synthetic proteins would take place in a one-
pot, chemically-specific dual ligation reaction allowing insertion of synthetic fragments 
into proteins while taking maximal advantage of cellular biosynthesis. 
 
Figure 5-1.  KAHA Ligation of a Hydroxylamine and keto-Acid 
This reaction, developed by Bode et al., can be done in aqueous conditions with and without 
substitution at the hydroxylamine oxygen.30 
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Figure 5-2.  KAHA Ligation and NCL Ligation in a One-Pot Protein Dual Ligation Strategy 
The reactive handles of each ligation, NCL and KAHA, will only react with their respective partner.  
The orthogonality and high specificity of these ligations will allow for the reactions to take place in 
one pot without cross-reactivity between handles. 
 
 The Kashina Laboratory is interested in Ate1, a mammalian arginyl transferase.  
Ate1 is an enzyme that arginylates proteins and is essential for cardiovascular 
development, actin development and the mammalian N-end protein degradation 
pathway.176  The destabilizing residue signals are different for the mammalian pathway, 
but Ate1 essentially serves the same function as AaT, it ligates a primary destabilizing 
residue (Arg) onto a secondary destabilizing residue (Asp/Glu) (Figures 5-3, 5-4).  One 
difference from AaT, according to Wang et al, is MALDI evidence that Ate1 can also 
ligate an arginine residue onto aspartates and glutamates that are located internally in 
addition to the N-terminus.177  The N-end pathway is only a portion of Ate1 function and 
the biological function of arginylation is still being elucidated.  One way in which the 
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Kashina lab has learned more about Ate1 arginylation is through a global analysis of 
mammalian protein substrates that become arginylated using 2D gels and MALDI 
analysis of Ate1-/- and Ate1+/+ knockout and wild type mouse strains.178  In conjunction 
with our research in the Petersson laboratory, we aimed to explore the possibility of using 
AaT to tag Ate1-arginylated proteins.  The goal was to tag N-terminally arginylated 
proteins with p-azidophenylalanine via AaT, and then use a click reaction-mediated pull 
down assay to determine the identity of the arginylated proteins.  AaT could possibly 
identify arginylated proteins that were not found through previous methods. 
 
 
Figure 5-3.  Ate1 and AaT Involvement in N-Degradation of Proteins 
In the E. coli N-End rule a secondary residue, Lys/Arg, is exposed via peptidase or exogenous 
activities (A).  In B, AaT transfers a primary residue, Leu/Phe, to the protein N-terminus.  ClpS is 
a molecular chaperone that recognizes the destabilizing residues (C) and brings the protein to the 
ATP-mediated protein degradation machinery, ClpA/P (D).  In the mammalian N-End rule, a 
tertiary destabilizing residues is converted to a secondary destabilizing residue, Asp/Glu/Oxidized 
Cys, is exposed (A).  In B, Ate1 transfers a primary destabilizing residue, Arg, to the protein N-
terminus.  E2 and E3 recognize the N-terminal sequence and poly-ubiquitin is transferred to the 
protein N-terminus (C), which signals the protein to be degraded by the 26S proteosome (D).39 
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Figure 5-4.  Ate1 Reaction Specificity 
Ate1 uses arginyl-tRNA as a substrate and transfers arginine onto Asp/Glu at the N-terminus and 
has been implicated as possibly arginylating at internal Asp/Glu residues.177 
 
 In this chapter, I will discuss the progress we have made with the Bode and 
Kashina laboratory collaborations.  With the Bode group, our greatest difficulty was the 
instability of the hydroxylamine, even in its protected form as the phenylnitrone.  We 
thought that we observed transfer of an α-hydroxylamine to the N-terminus of a model 
peptide, LysAlaAcm, using the analog, N-hydroxylamine-phenylalanyl adenosine 
(HONH-Phe-A); however, we found that we had substantial loss of the hydroxylamine on 
the product peptide to the α-amine.  The instability of the hydroxylamine and the 
concurrent inability to demonstrate the KAHA ligation on the protein scale (data not 
shown, determined by I. Medina of the Bode Lab) caused us to abandon this project.  For 
the Kashina laboratory collaboration, the efforts are ongoing, but we have determined 
that AaT can utilize Ate1-arginylated peptides as substrates.  We believe that it will be 
feasible to bring this multi-enzyme reactivity into cell lysates and possibly to fixed cells. 
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Section 5.2 – Results and Discussion 
 For the KAHA ligation, we synthesized two possible substrates for AaT ligation 
of a hydroxylamine onto the N-terminus of peptides, N-hydroxylamine-leucine (HONH-
Leu) and HONH-Phe-A (Figure 5-5).  We planned to use the HONH-Leu as a free amino 
substrate that we could use with total synthetase and AaT in a solely enzymatic reaction.  
The HONH-Phe-A was going to be used as an adenylate small-molecule substrate to be 
used with AaT without any synthetases present in the reaction.  One of the major 
obstacles of using the HONH-Leu was its insolubility in water requiring it to be dissolved 
in dimethylsulfoxide.  When using this HONH-Leu in a LysAlaAcm transferase reaction, 
the best product formation was about 52 %; however, according to MALDI, only leucine 
was transferred to the peptide N-terminus, not leucyl hydroxylamine.  Additionally, we 
attempted to reduce hydroxylamine instability by lowing the pH of the AaT reaction to 
pH 6.5 and reducing the β-meracaptoethanol concentration in the AaT storage buffer to 5 
mM.  However, with both changes, again only leucine was ligated to the peptide.  We 
changed our approach to use an adenosyl analog to transfer the α-amino hydroxylamine 
to avoid the use of a synthetase that could be preferentially selecting the leucine amino 
acid degraded from the hydroxylamine substrate.  One of the issues that we found with 
the HONH-Phe-A analog again stemmed from hydroxylamine instability again but in the 
form of its protected precursor N-phenylnitrone-Phe-A (See section 5.3, Scheme 2, 10).  
The N-phenylnitrone-Phe-A degraded while being purified on the HPLC to the 
hydroxylamine and oxime forms.  This degradation effectively negated the last step of the 
synthesis, deprotection of the hydroxylamine.  We used the HPLC purified 
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hydroxylamine-Phe-A in AaT reactions.  Again, we found the same problem observed 
with the HONH-Leu substrate.  The HONH-Phe that was ligated onto the peptide also 
contained a substantial portion of PheLysAlaAcm peptide, which could not be used as a 
substrate in the KAHA ligation (Figure 5-6).  The 53.1 % product yield was a 
combination of PheLysAlaAcm peptide with and without the hydroxyl at the α-amine.  
At the time, the Bode group was unable to perform KAHA ligations under suitable 
aqueous conditions for subsequent elongation of the transferred HONH-Phe; therefore we 
decided to halt our research until a more stable hydroxylamine precursor could be 
synthesized. 
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Figure 5-5.  AaT Ligation of Hydroxylamine Substrates Onto LysAlaAcm Model Peptide 
A.  Structures of HONH-Leu and HONH-Phe-A.  B.  Reactions of hydroxylamine analogs with 
LysAlaAcm.  HONH-Leu could not be used as a substrate for AaT and E. coli synthetases.  
HONH-Phe-A analog could not be transferred without degradation product formation. 
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Figure 5-6.  HPLC Analysis of AaT ligation of HONH-Phe-A Onto LysAlaAcm Peptide 
LysAlaAcm elutes at 12.6 min and HONH-PheLysAlaAcm/PheLysAlaAcm co-elutes at 13.8 min.  
MALDI confirmation of all HPLC peaks.  Co-product percent yield = 53.1 %. 
 
 For the Kashina collaboration, we started on the peptide level, and Junling Wang 
from the Kashina laboratory argninylated two model peptides, AspAlaAcm and 
GluAlaAcm, synthesized by I. Medina.  We found that AaT can use Ate1-arginylated 
peptides as substrates (Figure 5-7).  Using HPLC analysis, we found that the Ate1 
reaction produced 63 % ligated product (Figure 5-8).  The AaT reaction produced 75 % 
phenylalanine ligated to the ArgGluAlaAcm peptide.  Additionally, we attempted to 
determine whether Ate1, like AaT, could use minimalist substrates in order to bypass the 
use of synthetases and arginyl-tRNA substrates.  However, Ate1 could not use Arg-A as a 
substrate.  More investigation into minimalist substrates will be required.  This research 
is ongoing and we are investigating the possibility of using this tagging method with p-
azidophenylalanine in cell lysates. 
Time/min!
Ab
so
rb
an
ce
 a
t 3
25
 n
m
!
LysAlaAcm!
HONH-PheLysAlaAcm,!
PheLysAlaAcm!
228 
 
 
Figure 5-7.  Ate1 and AaT Ligation of Peptides 
A.  Two step N-terminal ligation strategy using Ate1 and AaT.  Ligation 1.  (Asp/Glu)AlaAcm 
peptides are ligated via Ate1 (including synthetase, arginyl tRNA, and ATP) with arginine.  
Ligation 2.  Phe-A and arginylated peptides are used as substrates by AaT to form 
PheArg(Asp/Glu)AlaAcm peptides.  B.  Arg-A was synthesized but could not be used as a 
substrate by Ate1. 
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Figure 5-8.  HPLC Analysis of Ate1 and AaT Ligation Onto Model Peptides 
GluAlaAcm elutes at 24.4 min, ArgGluAlaAcm elutes at 23.5 min, and PheArgGluAlaAcm elutes 
at 28.8 min.  The percent yield of ArgGluAlaAcm was 61 %.  The percent yield of 
PheArgGluAlaAcm was 75 %. 
 
Section 5.3 – Materials and Methods 
5.3.1 – Materials 
General Information.  Chloroacetonitrile, N,N-diisopropylethylamine (DIPEA), 
5′-O-(4,4′-Dimethoxytrityl) adenosine ((DMT)-A), tetrabutylammonium acetate 
(TBAAc), trifluoroacetic acid (TFA), and triisopropyl silane (TIPSH) were purchased 
from Sigma-Aldrich (St. Louis, MO).  Note: (DMT)-A production was discontinued by 
Sigma-Aldrich, after which it was purchased as a custom order from ChemGenes 
Corporation (Wilmington, MA) and was additionally synthesized in-house following the 
protocol outlined by Ogilvie et al.139  Lysylalanylaminomethylcoumarin (LysAlaAcm) 
and N-Boc-p-azidophenylalanine (Boc-Azf-OH) were purchased from Bachem 
(Torrance, CA).  All solvents were purchased from Fisher Scientific (Pittsburgh, PA).  
All deuterated solvents were purchased from Cambridge Isotopes Laboratories, Inc. 
Ab
so
rb
an
ce
 a
t 3
25
 n
m
!
Time/min!
20 22 24 26 28 30
A!
!
!
!
B!
!
!
C!
! ! !       GluAlaAcm ! ! ! ! !!
!
!
!
!
ArgGluAlaAcm     GluAlaAcm!
!
!
!
!
!
!
!
ArgGluAlaAcm!         GluAlaAcm                              PheArgGluAlaAcm
! !
AaT can use ATE1-arginylated peptides as 
substrates!
230 
 
(Andover, MA).  E. coli BL21(DE3) cells were purchased from Stratagene (La Jolla, 
CA).  The pEG6 plasmid, containing His10-tagged E. coli AaT, was a gift from Alexander 
Varshavsky (California Institute of Technology).  All other reagents were purchased from 
Fisher Scientific (Pittsburgh, PA).  Bradford reagent assay kits were purchased from 
BioRAD (Hercules, CA).  Protease inhibitor cocktail was purchased from Sigma-Aldrich 
(St. Louis, MO).  All other reagents were purchased from Fisher Scientific (Pittsburgh, 
PA).  Milli-Q filtered (18 MΩ) water was used for all aqueous solutions (Millipore; 
Billerica, MA).  Matrix-assisted laser desorption/ionization (MALDI) mass spectra were 
collected with a Bruker Ultraflex III MALDI-TOFTOF mass spectrometer (Billerica, 
MA).  Electrospray ionization (ESI) mass spectra were collected with a Waters LCT 
Premier XE liquid chromatograph/mass spectrometer (Milford, MA).  UV/Vis 
absorbance spectra were obtained with a Hewlett-Packard 8452A diode array 
spectrophotometer (Agilent Technologies, Santa Clara, CA). 
 
5.3.2 – Leucyl hydroxylamine (Lha) (6) Synthesis 
The synthesis of hydroxylamine donor 6 is given as a general procedure, starting 
from commercially available Leu-OH (Scheme 1).  The carboxy-terminus of the amino 
acid was first protected with a t-butyl group to form 2.  Next, the amino group was 
activated as a cyanomethyl ester using chloroacetonitrile or bromoacetonitrile to give 3.  
Then, the amino group was oxidized using meta-Chloroperoxybenzoic acid (mCPBA), 
forming 4.  Then the nitrone hydroxylamine precursor, 4, was converted to the 
hydroxylamine, 5, using hydroxylamine hydrochloride.  The carboxyl group was 
deprotected with trifluoroacetic acid to form the final leucyl hydroxylamine product, 6. 
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Scheme 5-1.  Hydroxylamine HONH-Leu Synthesis 
 
 
 (S)-tert-butyl 2-amino-4-methylpentanoate (Leu-OtBu, 2). 
Leu-OH (13.12 g, 0.1 mol) was dissolved in 200 mL dioxane in a three-arm round 
bottom flask.  3.7 equivalents of sulfuric acid (20 mL, 0.37 mol) were added to the 
reaction dropwise.  After dissolution of materials, the round bottom flask was placed in 
an ice bath with stirring.  The reaction was kept under nitrogen and a cold finger and gas 
condenser were attached to keep the isobutylene cold and liquefied.  The gas condenser 
was filled with 100 mL of isobutylene and released into the round bottom flask; this step 
was repeated a second time to add a total of 21.4 equivalents (200 mL, 2.14 mols).  
Reaction was mixed overnight on ice.  The reaction was worked up by first neutralizing 
the acidic conditions with NaOH and then was extracted with ether.  The combined 
organic layers were dried with sodium sulfate (anhydrous).  The extract was crystallized 
as the hydrochloride salt using dry hydrochloric acid (11.6 equiv., 10 mL, 1.6 moles) and 
afforded 9.96 g, 44.3 %.  Product was characterized using NMR: 1H NMR (500 MHz, 
MeOD) δ 3.91 – 3.88 (m, 1H), 1.82 – 1.76 (m, 2H), 1.68 – 1.62 (m, 1H), 1.54 (s, 9H), 
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1.04 –1.01 (m, 6H); 13C NMR (125 MHz, CDCl3) δ 167.3, 82.2, 50.3, 38.1, 25.5, 23.0, 
19.8.  Product does not ionize well on ESI-MS. 
 
(S)-tert-butyl 2-((cyanomethyl)amino)-4-methylpentanoate (N-CH2CN-Leu-OtBu, 3). 
Leu-OtBu, 2, (1 g, 4.45 mmol) was dissolved in 9 mL of dry acetonitrile in an 
oven-dried 25 mL round bottom flask.  1.1 equivalents of bromoacetonitrile (0.34 mL, 
4.9 mmol) and 2 equivalents of diisopropylethylamine (DIPEA) (1.55 mL, 8.9 mmol) 
were added to the reaction mixture under nitrogen via syringe.  The reaction was mixed at 
room temperature overnight.  After evaporation of solvent, the product was purified on 
silica gel (gradient solvent system: 10 – 20 % ethyl acetate in hexanes to give 0.5 g (49.4 
%).  Rf 0.5 in 20 % EtOAc in hexanes.  1H NMR (500 MHz, CDCl3) δ 3.72 – 3.58 (m, 
2H), 3.28 – 3.23 (m, 1H), 1.80 – 1.75 (m, 2H), 1.50 (s, 9H), 0.94 (t, J = 6.25, 6 H); 13C 
NMR (125 MHz, CDCl3) δ 173.9, 117.8, 82.0, 59.6, 42.5, 36.1, 28.2, 24.9, 22.9, 22.2.  
Product does not ionize well on ESI-MS. 
 
 (S,Z)-1-(tert-butoxy)-N-(cyanomethylene)-4-methyl-1-oxopentan-2-amine oxide (N-
CH2CN-nitrone-Leu-OtBu, 4). 
N-CH2CN-Leu-OtBu, 3, (0.5 g, 2.2 mmol) was dissolved in 5.5 mL of 
dichloromethane under nitrogen in an ice bath.  Two equivalents of mCPBA (759 mg, 4.4 
mmol) were added in small scoops over 30 minutes.  After addition of mCPBA, the 
reaction was mixed for 30 min at room temperature.  The reaction was monitored via 
TLC and worked up upon reaction completion, Rf product = 0.5 in 20 % ethyl acetate in 
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hexanes. To quench the reaction, 5 mL saturated aqueous sodium thiosulfate and 15 mL 
saturated sodium bicarbonate were added.  Slurry was mixed for 15 minutes until all 
white solid dissolved.  Product was extracted with dichloromethane and dried with 
anhydrous sodium sulfate.  The product was characterized using NMR: 1H NMR (500 
MHz, CDCl3) δ 6.81 (s, 1H), 4.61 – 4.58 (m, 1H), 2.11 – 2.05 (m, 1H), 1.85 – 1.79 (m, 
2H), 1.48 (s, 18.3H), 0.98 – 0.92 (m, 9H).  Product was assumed to go to 100% 
completion and taken directly to the next synthetic step to form the hydroxylamine. 
 
(S)-tert-butyl 2-(hydroxyamino)-4-methylpentanoate (Lha-OtBu, 5). 
N-CH2CN-nitrone-Leu-OtBu, 4, (0.53 g, 2.2 mmol) was dissolved in 5.5 mL of 
methanol.  Five equivalents of hydroxylamine hydrochloride (0.76 g, 11 mmol) were 
added and the reaction was mixed overnight at 60 ºC.  Rf = 0.4 in 20 % ethyl acetate in 
hexanes.  Unreacted hydroxylamine hydrochloride was precipitated from the reaction 
using excess dichloromethane.  Aqueous sodium bicarbonate was added and the product 
was extracted using dichloromethane.  Collected organic layers were dried with 
anhydrous sodium sulfate.  2 equivalents of oxalic acid (0.4 g, 4.4 mmol) dissolved in 2 
mL methanol were added to dried extract product.  The product was crashed out as a salt 
using excess ether.  No further purification was needed.  1H NMR (500 MHz, DMSO) δ 
3.71 (s, 2 H), 3.49 (s, 1 H), 1.42 (s, 9 H), 0.87 (s, 6 H); 13C NMR (125 MHz, CDCl3) δ 
162.3, 64.3, 37.9, 28.3, 25.2, 23.1, 22.7.  NMR had poor resolution.  MALDI MS calcd 
m/z for C10H22NO3 (M + H)+ 204.16, found 203.8. 
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(S)-2-(hydroxyamino)-4-methylpentanoic acid (Lha, 6). 
Lha-OtBu, 5, was deprotected with the addition of  1 mL 50 % trifluoroacetic acid 
and 50 % dichloromethane.  0.5 mL acetonitrile was added to the reaction to help 
solubilize Lha-OtBu.  The reaction was monitored via TLC every 30 min until complete 
in 1.5 hr.  Rf = baseline in 50% ethyl acetate in hexanes.  No further purification was 
needed.  ESI MS calcd m/z for C6H13NO3 (M + H)+ 148.1, found 148.6.  NMR had poor 
resolution and not all peaks were accounted for, but there is a loss of t-butyl peak.  1H 
NMR (500 MHz, DMSO) δ 2.52 – 2.49 (m, 3), 1.73 – 1.46 (m, 6), 0.92 – 0.87 (m, 6 H). 
 
5.3.3 – Phenylalanyl hydroxylamine adenosine (HONH-Phe-A) (11) Synthesis 
The synthesis of Phenylalanyl hydroxylamine adenosine 11 is given as a general 
procedure, starting from the phenyl nitrone cyanomethyl ester synthesized by I. Medina 
according to Bode et al. (Scheme 2).30  The protected amino acid was attached to one of 
the available hydroxyls (2′ OH or 3′ OH) of (DMT)-A, which is commercially available, 
without preference using a catalytic amount of TBAC.  The resulting protected adenylate 
(9) was deprotected using a 50/50 mixture of TFA and THF with TIPSH present as a 
scavenger, producing 10.  The final product 11 containing the N-hydroxylamine, HONH-
Phe-A, was formed by addition of hydroxylamine hydrochloride. 
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Scheme 5-2.  Hydroxylamine HONH-Phe-A Analog Synthesis 
 
 
 (S,Z)-1-(((2R,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-2-((bis(4-
methoxyphenyl)(phenyl)methoxy)methyl)-4-hydroxytetrahydrofuran-3-yl)oxy)-N-
benzylidene-1-oxo-3-phenylpropan-2-amine oxide (N-phenylnitrone-Phe-(DMT)-A, 
9). 
(DMT)-A (26.2 mg, 0.0460 mmol) was dissolved in 5 mL of tetrahydrofuran 
(dried with 4 Å molecular sieves) in an oven-dried 4 dram reaction vessel.  Twenty 
equivalents of 7 (267.7 mg, 0.878 mmol) were added to the reaction mixture.  TBAAc 
(27.6 mg, 92 µmol), the catalyst, was added last to the reaction mixture.  The reaction 
was stirred under argon overnight at room temperature overnight.  After evaporation of 
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solvent, the product was purified on silica gel (gradient solvent system: 20 – 0 % 
petroleum ether in EtOAc, 5 % methanol in EtOAc) to give 24.4 mg (65 %) after 
evaporation.  Rf 0.5 in 5 % methanol in EtOAc.  LRMS (ESI) calcd m/z for  
C47H45N6O8 (M + H)+ 821.3, C47H44N6O8Na (M + Na)+ 843.3, found 821.3, 843.3. 
 
(S,Z)-1-(((2R,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-4-hydroxy-2-
(hydroxymethyl)tetrahydrofuran-3-yl)oxy)-N-benzylidene-1-oxo-3-phenylpropan-2-
amine oxide (N-phenylnitrone-Phe-A, 10). 
9 (12.2 mg) was dissolved in 1 mL of THF and 1 mL trifluoroacetic acid (TFA) 
and 2.3 mg oxalic acid and reacted for 30 min.  The reaction mixture was reduced to 
dryness by rotary evaporation and extracted using 1 mL dichloromethane and 1 mL water 
twice with a 1 mL water final back-extraction against the dichloromethane layer.  The 
water-soluble layer containing 10 was then HPLC-purified on a C18-prep column using 
an increasing acetonitrile gradient (gradient 1 used for Phe-A discussed in Chapter 2 
section 2.3).  NMR analysis of 10 can be found in Figure 5-9.  HPLC/MALDI analysis 
m/z calcd C26H27N6O6 (M + H)+ 519.2; retention time 23 - 25 min, found 519.3; retention 
time 38.1-38.5 min, found 519.3.  During the process of HPLC purification, additional 
side products were found, (1) loss of phenyl nitrone producing hydroxylamine at 
retention time 21.5 – 25 min ((M + H)+ m/z = 431.2) and (2) formation of oxime at 40.6 
min ((M + H)+  m/z = 429.1).  Over time in water, product 10 converted into 11. 
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 (S)-(2R,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-4-hydroxy-2-
(hydroxymethyl)tetrahydrofuran-3-yl 2-(hydroxyamino)-3-phenylpropanoate 
(HONH-Phe-A, 11). 
10 (11 mg) was dissolved in to a 0.2 M concentration in methanol (104 µL).  5 
equivalents of hydroxylamine hydrochloride was added (7.9 mg, 0.114 mmol) and 
reacted for 4 h at 60 ºC, monitoring via MALDI.  At the end of the reaction, mixture was 
diluted with water and lyophilized to remove solvents.  MALDI analysis m/z calcd 
C19H23N6O6 (M + H)+ 431.2, found 430.9. 
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Figure 5-9.  1H and 13C NMR Characterization N-phenylnitrone-Phe-A (10) 
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5.3.4 – Ate1 and AaT Expression and Purification 
E. coli AaT was expressed from the pEG6 plasmid in E. coli BL21-Gold (DE3) 
cells using a procedure adapted from Graciet et al and explained in detail in section 2.3.6 
of Chapter 2.50  Ate1 was overexpressed and purified by the Kashina Laboratory. 
 
5.3.5 – Model Peptide Assays for AaT and Ate1 
For the AaT peptide ligations, they were performed the same as previously 
described in Ch. 2 section 2.3.7.  All of the AaT ligation reactions using hydroxylamine 
substrates were purified by HPLC using the same method as described in Chapter 2 
section 2.3.10.  Ate1 arginylation reactions of peptides Asp/GluAlaAcm were performed 
by the Kashina laboratory according to standard published procedures.177  All HPLCs for 
Asp/GluAlaAcm peptides and ligations were purified using the method outlined in Table 
5-1.  Collected HPLC fractions were characterized through MALDI MS analysis (Table 
5-2). 
 
Table 5-1.  Gradient Used for HPLC Purification of Asp/GluAlaAcm Peptides and Ligations 
Gradient # Time (min) Buffer A (%) 
1 mL/min 0:00 99 
 5:00 99 
 30:00 74 
 35:00 0 
 40:00 0 
 45:00 99 
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Table 5-2.  HPLC Analysis of (Asp/Glu)AlaAcm Transfer Reactions 
Product Peptide Retention Time (min) 
M+H+ M+Na+ 
Calc’d Obs. Calc’d Obs. 
AspAlaAcm 24.0 362.135 362.395 384.117 --- 
ArgAspAlaAcm 22.9 518.236 518.462 540.218 540.418 
PheArgAspAlaAcm ** 665.305 665.515 687.287 687.495 
GluAlaAcm 24.4 376.151 376.429 398.133 398.398 
ArgGluAlaAcm 23.5 532.252 532.487 554.234 554.480 
PheArgGluAlaAcm 28.8 679.320 679.482 701.302 701.458 
**This reaction was not HPLC purified. 
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CHAPTER 6 
 
CONCLUSIONS 
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 Current research has shown that there are a variety of ways to modify proteins, 
depending on your reaction restrictions.  We have found a new and versatile 
chemoenzymatic way to modify proteins that fulfills a wide variety of constraints: site-
specificity, amide bond formation at the ligation site, amino acid substrate variety for 
both peptide and small molecule substrates, aqueous conditions, near physiological pH, 
high salt concentrations, in the presence of denaturants, and with high reproducibility.  
The AaT amide bond forming reaction is slow, but the native N-terminal specificity 
outweighs its unfavorable kinetics.  We have manipulated a natural enzyme to accept and 
ligate a variety of small molecule substrates that range from p-azido-phenylalanine to 
protected disulfides without the need for mutagenesis.  We hope through the aid of in 
silico studies with the Saven group, we will be able to target an aminoacyl adenosine 
substrate and enhance ligation efficiency for our lower yielding substrates. 
Ligation of synthetic molecules has proven very useful in the study of protein 
function, localization, and folding.  We plan on using the AaT ligation technique to 
access protein folding studies that have yet to be achieved without significant peptide 
synthesis.  For example, through the demonstrations of model proteins α-synuclein and 
calmodulin, we have shown that it is possible to incorporate a small synthetic moiety 
while maximizing the use of expressed protein fragments.  AaT N-terminal modifications 
allow for the accessibility of click reactions at sidechain R-groups and NCL reactions at 
new residue locations, arginine and lysine, instead of cysteine.  Additionally, AaT-ligated 
homocysteine can be masked, under mild conditions, again allowing for an even greater 
number of possible ligation sites within proteins.  With the increased number of 
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allowable ligation sites for AaT, small synthetic moieties to study protein structure and 
function can be inserted into the structure using AaT, with minimal perturbation since the 
ligation site results in a natural amide bond.  The AaT ligation will expand the 
accessibility of protein structure and folding analysis by incorporating small FRET–based 
probes such as a thioamide and p-cyanophenylalanine pair.  The AaT ligation has 
expanded the opportunities for scientists as a new tool for studying proteins and 
designing new proteins through protein engineering. 
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